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Abstract 
 
 
Decreasing signalling through the Insulin and Insulin-like Signalling (IIS) cascade by 
genetic and pharmacological means can increase the lifespan and healthspan of many 
organisms. Crucially, when long-lived animals are crossed with animal models of 
neurodegenerative disorders, the onset of pathology is slowed. Pharmacological 
inhibitors of the IIS cascade have also shown neurodegeneration delaying and 
neuroprotective properties. Furthermore, IIS is changed in neurodegenerative 
disorders; with increased astrocyte IGF1, localised increased ERK1/2 phosphorylation 
(p-ERK), and brain insulin and IGF1 resistance observed. The IIS cascade therefore 
seems critically implicated in neurodegeneration, and crucially via pharmacological 
means could yield disease-modifying interventions. 
 
To investigate pharmacological IIS manipulation for therapeutic gain in 
neurodegeneration, I firstly characterised changes in IIS in human Alzheimer’s 
Disease patient brain samples, and in brain samples of mice modelling rising amyloid 
beta and plaque levels, or rising hyperphosphorylated tau and tangle levels; finding 
increased IIS at early ages in these models. I subsequently designed a bilaminar 
neuron and astrocyte co-culture model of acute neurodegeneration, whereby I 
identified that increased astrocyte Igf1 expression following a noxious stimulus is 
dependent on the presence of neurons during stress. I then manipulated IIS during the 
noxious stimulus by either knocking down increased Igf1 expression, inhibiting p-
ERK with the drug Trametinib, or both. I identified that increased astrocyte Igf1 
expression contributes to neuronal cell death, and that Trametinib was protective 
against neuronal cell death, but the mechanism of Igf1 induced neuronal cell death 
was not due to increase p-ERK. This confirms IIS as a viable pharmacological target 
for intervening in neurodegeneration.  
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Chapter 1 
 
 
Introduction 
 
 
 
Neurodegenerative Diseases and their growing burden on humanity 
 
 
 
Through the endeavours of biomedical research human life expectancy has been 
greatly increased. The success in limiting death from early and midlife causes of 
mortality has lead to diseases that were previously rare, as they mainly afflicted the 
old, now being the leading causes of death. Not only is the global prevalence of 
neurodegenerative diseases increasing rapidly, but also there are insufficient 
therapeutic options for treating them. In this thesis we address the urgent need for 
improved therapeutics for a family of diseases that are increasing in prevalence at a 
particularly rapid rate – the neurodegenerative diseases.  
 
One molecular pathway seems uniquely poised to offer us the possibility of 
intervening in the neurodegenerative process. Signalling levels through the Insulin 
and Insulin-like Signalling (IIS) cascade have been shown to modulate the rate of 
ageing in organisms from worms to man, but also be able to modulate the rate of 
neurodegenerative disease development in experimental animal models of 
neurodegenerative disease. Furthermore, changes in the IIS cascade have been 
implicated as neuronal cell death signals, and endogenous alterations in IIS have been 
reported in a variety of neurodegenerative diseases. All of these features together 
implicate the IIS cascade as playing a central role in neuronal health and diseases, and 
therefore offer an alternative route to modulating neurodegeneration. Our overall aim 
therefore is to examine IIS in neurodegenerative disease, and investigate the 
possibility of modulating this cascade as a means of providing novel therapeutic 
approaches to ameliorating neuronal cell death.  
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Suitable neurodegenerative diseases for IIS therapeutic intervention 
 
 
Neurodegenerative diseases are a wide and varied group, but all have the common 
feature of a progressive permanent loss of neurons. With adult neurogenesis being 
limited (Altman and Das, 1965; Lois et al., 1996), and with the overwhelming 
majority of adult neurons being made during embryogenesis, the neuronal cell loss in 
neurodegenerative diseases cannot be repaired and is therefore permanent. 
Considering that the oldest know living mammal, the bowhead whale, is estimated to 
have a lifespan of over 200 years, this means that individual neurons are capable of 
surviving for hundreds of years (Keane et al., 2015). Furthermore it seems that the 
host species limits the length of time that a neuron can survive for, not the neurons 
themselves (Magrassi et al., 2013). Given the potential lifespan of these neurons 
therefore, it seems sensible to view neurodegeneration as the premature death of 
neurons, with neurons having an extraordinary capacity to survive.  
 
For such a prevalent group of diseases, the therapeutic interventions available are 
extremely limited. Most therapeutic interventions are disease pathology specific, with 
only Riluzole attempting to target a mechanism of neurodegeneration, in this case by 
preventing glutamate educed excitotoxicity (Doble, 1996). With many recent phase 
III trials for novel neurodegenerative therapies failing, and the burden of these 
diseases on society growing with the ageing population, the need for more effective 
therapies is great. With neuronal death being permanent, and being a ubiquitous 
feature in these diseases, it seems clear that therapies that target neuronal death itself 
have not been fully utilised in the attempted treatment of neurodegenerative diseases.  
 
Neurodegenerative diseases can be demarcated into two groups based upon the length 
of time that neuronal cell death occurs over; with chronic neurodegenerative diseases 
experiencing neuronal loss over the duration of months and years, and acute 
neurodegenerative diseases showing neuronal loss over the duration of days to weeks. 
Typically the term neurodegenerative disease has only been applied to diseases which 
in this thesis I classify as chronic neurodegeneration, but I think the progressive loss 
of neurons also observed in acute neurodegenerative diseases, albeit over a shorter 
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time frame, makes grouping these diseases together useful. The reason behind this is 
that I think it seems more likely that the molecular underpinnings of neuronal cell 
death in these diseases will overlap, rather than there being distinct mechanisms of 
neurodegeneration for each disease.  
 
We have focused our attentions in this thesis on the chronic neurodegenerative 
disease Alzheimer’s disease (AD), and more generally acute neurodegenerative 
diseases such as stroke and traumatic brain injury (TBI). These diseases are the most 
prevalent neurodegenerative diseases, with both sets having insufficient therapies 
currently available, and therefore are the neurodegenerative diseases in most dire need 
to investigation with regards to unearthing new therapeutics. Most importantly, both 
have been shown to be susceptible to possible therapeutic intervention by IIS 
modulation (Ashabi et al., 2013; Cohen et al., 2009; Gladbach et al., 2014). 
 
 
Alzheimer’s disease  
 
 
Dementia is a family of diseases primarily affecting people over the age of 60, 
clinically defined as a gradual decline in cognitive function and memory loss over the 
space of years. Progressive gradual memory loss is the most distinctive characteristic, 
but as the disease progresses cognitive ability reduces, with language and behavioural 
changes common (World Health Organisation, 1992). Dementias are estimated to 
have a global cost of US$ 818 billion, which equates to 1.09% of global GDP 
(Alzheimer's Disease International, 2015). This figure is expected to top US$ 2 
trillion by 2030. 
 
ADis the most common subtype of dementia, followed by vascular dementia, Lewy 
body dementia, and frontotemporal dementia (FTD). Whilst each type of dementia 
has distinct pathological hallmarks, the extent of an overlap of pathology between 
these types of dementia is substantial. Distinct from acute neurodegenerative diseases 
there is often not one clear initiating factor for dementia in patients, with the 
exception of autosomal dominantly inherited forms of dementia with high penetrance 
(>95%) such as familial Alzheimer’s disease (fAD), or frontotemporal dementia with 
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a MAPT mutation (Bekris et al., 2010; Hutton et al., 1998). These inherited forms of 
dementia are by far in the minority however, with the vast majority of dementias 
being sporadic in nature. In these sporadic cases, whilst genetic contributing factors 
may be apparent, this does not solely dictate the emergence of the disease phenotype 
in a patient.  
 
Sporadic AD (sAD) patients present with symptoms typically from 60 years, with the 
average disease duration from diagnosis being 8-10 years. Prior to this clinical stage 
is a long prodromal period however, with cognitive decline present for years before 
diagnosis (Amieva et al., 2008; Lim et al., 2013). When a patient presents with the 
early phenotype of mild amnesia, they are diagnosed with Mild Cognitive Impairment 
(MCI), with a distinguishable clinical phenotype from dementia (Petersen et al., 
1999). MCI often progresses to dementia, with a conversion rate between 6-15% of 
MCI patients per year, of which 90% progress to sAD (Farias et al., 2009; Fischer et 
al., 2007; Solfrizzi et al., 2004). Therefore the neuronal loss present in the dementias 
and sAD takes place over decades, rather than weeks as in acute neurodegenerative 
diseases.  
 
The neuropathological hallmarks of AD are the presence of extracellular protein 
accumulations in the form of senile plaques composed of aberrantly folded amyloid 
beta 42 (Aβ42) and intracellular neurofibrillary tangles (NFT’s) of 
hyperphosphorylated microtubule associated protein tau, combined with a reduction 
in volume of the frontal and parietal cortices and increased ventricle size. Due to the 
defining properties of these hallmarks when separating AD from other dementias, 
they have justifiably attracted much attention as a source of potential therapeutic 
target.  
 
With the causative factor of sAD being hard to ascertain, focus was placed on 
identifying what caused the emergence of fAD, and thereby involved characterisation 
of the genetic mutations that give rise to a patients developing fAD. This identified 
various mutations in the amyloid-processing pathway (Goate et al., 1991), which 
results in altered processing of amyloid precursor protein (APP) into Aβ fragments 
(figure 1.1, (Crews et al., 2010; Haass et al., 2012)). Usually APP is overwhelmingly 
sequentially cleaved by α-secretase and γ-secretase (a complex containing presenilin  
Figure 1.1. The amyloid processing pathway and position of APP mutations. Simplified 
diagrammatic representation of the processing of membrane bound APP, and the location of some 
APP mutations on the APP protein. (A) APP is cleaved either by α or β-secretase before being 
processed by γ-secretase. In the amyloidogenic pathway the sequential cleavage by β-secretase then 
γ-secretase produces amyloidogenic Aβ fragments. (B) The location of 3 APP fAD mutations. APP 
– amyloid precursor protein, α-sec – alpha secretase, β-sec – beta secretase, γ-sec – gamma 
secretase, CTF – carboxy-terminal fragment, AICD – APP intracellular domain, Swe – Swedish, 
Bey/Ibe - Beyreuther/Iberian, Arc – Arctic.  
A Anti-amyloidogenic pathway Amyloidogenic pathway 
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Modified from Haass et al,. 2012  
Modified from Crews et al,. 2010  
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1), producing non-amyloidogenic components, but in fAD mutations at various points 
in the APP processing pathway lead to preferential cleavage of APP by β-secretase 
(BACE) leading to amyloidogenic Aβ fragments being produced. These mutations not 
only result in a higher ratio of Aβ42 to Aβ40, but also an increase in total Aβ level, 
with Aβ42 fragments forming oligomers and eventually plaques (Burdick et al., 1992; 
Chen and Glabe, 2006; Scheuner et al., 1996). This combined with the 
cerebrovascular amyloid protein accumulations present in late life dementia in people 
with Down’s syndrome being very similar to beta amyloid in fAD, lead to the 
establishment of the Amyloid Hypothesis (Glenner and Wong, 1984; Hardy and 
Higgins, 1992), which puts amyloid accumulation as the central pathogenic 
mechanism of AD development, with all subsequent neurodegeneration and 
neurological changes a result of this.  
 
Despite studies showing the deleterious effects of accumulated Aβ to various cells of 
the brain and their normal functioning, the Aβ toxicity observed seemed to be 
dependant on and facilitated by tau (Ittner et al., 2010; Jin et al., 2011; Rapoport et al., 
2002; Roberson et al., 2007; Shipton et al., 2011). Furthermore, cognitive decline 
shown in AD patients did not correlate well with the increase in Aβ plaques, but did 
correlate well with NFT increase, neuronal loss, and synaptic loss (Arriagada et al., 
1992; Giannakopoulos et al., 2003; Gomez-Isla et al., 1997; Gomez-Isla et al., 1996; 
Terry et al., 1991). Despite this correlation, whether these large insoluble NFT’s or 
indeed Aβ plaques, represent a toxic species in themselves, or whether they represent 
a protective accumulation of smaller more toxic constituents, has recently come under 
fierce scrutiny. 
 
It is becoming apparent that Aβ plaques are not the harmful species, but in fact the 
soluble oligomers cause a range of alterations in normal neuron physiology (Lambert 
et al., 1998; Shankar et al., 2007). It appears that this is also the case with NFT’s, with 
small constituent oligomers the toxic species rather than the NFT itself (Lasagna-
Reeves et al., 2011; Patterson et al., 2011). This is supported by human tauopathy 
patients showing high levels of neurodegeneration accompanied by high levels of tau 
phosphorylation, but only mild NFT formation (Bird et al., 1999). With the 
identification of what appears to be the specific species that give rise to toxicity in the 
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brains of dementia patients, efforts are now being undertaken to pharmacologically 
target these to elicit therapeutic gain. 
 
 
Current therapeutics for Alzheimer’s disease 
 
 
Presently the extent of therapeutic intervention in AD is limited to symptomatic 
treatments that temporarily stem the decline in cognitive function in patients. 
Cholinesterase inhibitors (Donepezil, Galantamine, and Rivastigmine) are prescribed 
to mild and moderate AD patients to target the early degeneration and loss of long 
projecting cholinergic neurons in the forebrain, temporarily amplifying the dwindling 
signals from these pathways that contribute to memory and attention (Bird et al., 
1983; Birks, 2006; Davies and Maloney, 1976; National Institute for Health and 
Clinical Excellence, 2011). Memantine, a NMDA receptor antagonist, is also 
prescribed for moderate and severe AD with limited clinical efficacy (McShane et al., 
2006; National Institute for Health and Clinical Excellence, 2011). The effects of 
these drugs are short lived however, and make no attempt to target the cause of the 
disease or ameliorate the neurodegeneration present.  
 
To disturb the accumulation of amyloid plaques, the drugs semagacestat and 
avagacestat were designed to inhibit the gamma secretase component of the amyloid-
processing pathway. This branch is responsible for preferentially cleaving the amyloid 
precursor protein into the amyloidogenic Aβ42 rather than the non-amyloidogenic 
Aβ40 (Haass et al., 2012). These drugs showed little clinical efficacy however, with 
limited prevention of cognitive decline and side effects from the inhibition of the non-
pathogenic functions of gamma secretase (Coric et al., 2012; De Strooper et al., 1999; 
Haapasalo and Kovacs, 2011). To bypass this, inhibitors of another member of the 
amyloidogenic branch of the APP processing pathway, BACE1, have been designed 
and show far more promising results in early clinical trials, although other protein 
targets of BACE1 mean off target effects are similarly a concern (Eisai, 2012; Forman 
et al., 2012).  
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Trials directly attempting to remove rather than prevent the build up of Aβ have also 
been attempted with the development of the passive Aβ immunotherapy drugs 
Bapineuzemab and Solineuzemab, both targeting the removal of Aβ oligomers from 
the central nervous system. Whilst the removal of Aβ was apparently achieved in 
these trials as measured by Pittsburg compound B imaging and peripheral Aβ 
oligomer levels, cognitive decline was not slowed in the Bapineuzemab trials, and 
was only slowed in the mild AD patients in the Solineuzemab trails (Doody et al., 
2014; Farlow et al., 2012; Rinne et al., 2010; Salloway et al., 2014; Sperling et al., 
2012). This positive result in the Solineuzemab trials has lead to on-going trials 
targeting patients earlier in the disease, either when they are likely to develop fAD as 
they have familial mutations in the DIAN trial, or in cognitively normal adults who 
show increased brain amyloid accumulation in the A4 trial (Alzheimer's Association, 
2015; ClinicalTrials.gov, 2016a, b). Other Aβ clearance methods have also been 
employed in an attempt to stimulate the supposed natural clearance of Aβ, but with 
limited success at phase II trials for Crenezumab, or phase III trials for Gammagard 
(Adolfsson et al., 2012; Roche, 2014). Similarly to the Solineizemab trials, the 
Alzheimer’s Prevention Initiative Trial using Crenezumab is currently underway, 
focusing on pre-emptively treating those likely to develop AD before the onset of 
symptoms, in this case in people with dominant presenillin mutations (Genentech, 
2012). 
 
Directly targeting tau species for therapeutic gain has not been a pharmaceutical 
priority given the predominance of amyloid processing mutations that give rise to 
fAD, and limited genetic indications of tau being an upstream factor in the 
pathogenesis of AD (Kauwe et al., 2008). Two main areas are now being explored 
however to try and treat AD by reducing the impact of toxic tau on the brain; either by 
reducing tau hyperphosphorylation, or by stopping the aggregation of tau tangles.  
 
Very few tau kinase inhibitors have moved past preclinical trails. This is due to the 
vast number of phosphorylation sites on the tau protein and the promiscuity of the 
kinases that phosphorylate these sites (Pierre and Nunez, 1983), leading to off target 
effects when inhibiting these kinases. Even therapies that have progressed, for 
example the GSK3 inhibitors lithium and tideglusib, have failed to show sufficient 
benefit, or in doses where cognitive decline is slowed, have frequently shown off 
	 25	
target side effects (del Ser et al., 2013; Dominguez et al., 2012; Forlenza et al., 2011; 
Grogan, 2012; Hampel et al., 2009; Nunes et al., 2013).  
 
Increasing the activity of phosphatases that dephosphorylate tau has also been 
explored as a pharmacological target. One of the mechanisms of action of selenium 
salts and the anti-diabetic drug metformin, is to potentiate the activity of protein 
phosphatase 2A (PP2A), which dephosphorylated many proteins including tau 
(Yamamoto et al., 1988). Despite potentially contradictory roles on metformin 
(dephosphorylating tau by PP2A activation, but potentially increasing tau 
phosphorylation via activating AMPK), positive preclinical data has been published, 
with a phase II trial treating patients with amnesic mild cognitive impairment 
completed in 2012 but awaiting publication, and a preliminary trial looking at 
cognition, imaging, and cerebrospinal fluid biomarker outcomes from metformin 
treatment in MCI and AD (ClinicalTrials.gov, 2016c, d; Mairet-Coello et al., 2013; 
Vingtdeux et al., 2010; Wang et al., 2012). Selenium salts also showed promising 
preclinical results, and a phase III trial looking to prevent AD development by 
selenium supplementation has recently been completed (ClinicalTrials.gov, 2016e; 
Corcoran et al., 2010; van Eersel et al., 2010).  
 
The inhibition of tau aggregation has also been attempted using TRx0237, a 
methylene blue derivative, which has now completed various phase III trails. 
TRx0237’s actions are not limited to disturbing tau aggregation, having been shown 
to inhibit Aβ fibrilisation, promoting tau degradation, and be neuroprotective by 
increasing cerebral blood flow and reducing reactive oxygen species (Lin et al., 2012; 
Taniguchi et al., 2005; Wischik et al., 1996). The clinical use of methyl blue is 
already well established for the treatment of malaria and methemoglobinemia, but 
despite positive results from phase II trials in AD patients, higher dosing having no 
effects, as well as an unorthodox use of control groups, means the phase III results are 
difficult to predict (Schirmer et al., 2011; Wischik et al., 2008).  
 
Presently patients diagnosed with sAD can expect to receive treatment which 
temporarily ameliorates their symptoms and aims to temporarily slow their 
deteriorating quality of life. 
 
	 26	
Acute neurodegenerative diseases  
 
 
Acute neurodegenerative diseases include ischaemic and haemorrhagic stroke, TBI, 
and cerebral hypoxia/ischemia. Although all of these disorders have an initial starting 
insult, neuronal loss not only occurs directly at the time of the said incident, but also 
is accompanied by a progressive further loss of neurons over the following period of 
weeks.  
 
The most common acute neurodegenerative disorder is stroke, of which around 80% 
are ischaemic, and 20% are haemorrhagic. Cerebrovascular disease, of which stroke is 
the most common, accounts for approximately 10% of worldwide deaths, 85% of 
deaths due to neurological disorders, and 3.5% of Disability Adjusted Life Years (a 
measurement of the combined effect of disability and death on reducing the number 
of years of healthy life of an individual) lost worldwide ((Aarli, 2006) chapter 3). The 
incidence of stroke increases with age, with the risk of stroke roughly doubling every 
decade over 55. Whilst stroke incidence has dropped in recent decades in developed 
nations, there has been a remarkable leap in yearly incidence in middle and lower 
income nations (Feigin et al., 2009).  
 
A stroke is defined as a rapid onset of focal or global cerebral deficit with no apparent 
cause other than a vascular one. Ischaemic stroke is the decrease in blood supply to an 
area or areas of the brain because of an occlusion to a blood vessel, or decrease in 
blood supply. This local ischemia leads to the area of brain deprived of oxygen and 
nutrients to die if blood flow is not re-established within minutes. The area 
surrounding this ischaemic area will also experience a decrease in blood flow, but 
may still be receiving partial blood flow from other vessels; this area is called the 
penumbra. Due to only the partial loss of blood flow to penumbra tissue, the death of 
these brain areas is not immediate, but depends upon the speed at which the blockage 
is rectified, the treatment the patient received, and the location and duration of the 
ischaemic incident. The subsequent delayed cell death occurs over the space of weeks 
following the ischaemic incident, but every further minute of ischemia without 
treatment essentially increased the amount of brain, and crucially neurons, that are 
lost as a consequence (Saver, 2006).  
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Haemorrhagic stroke is somewhat different in its neuronal cell death pattern, whereby 
it is often fatal to the patient, but if the ictus is survived the hematoma leads to 
progressive neuronal cell death radiating from the site of injury, for various proposed 
pathophysiological reasons, over the space of days to weeks (Aronowski and Zhao, 
2011). Nonetheless, both variants of stroke have an immediate period of injury, 
followed by a more prolonged loss of neurons and brain tissue.  
 
TBI is an externally generated impact to the head that results in injury to the brain and 
subsequent neuronal cell death. Although comprehensive data is lacking of the global 
burden of TBI’s, it is estimated that 10 million people are affected annually, and it is 
often cited as the leading cause of disability in children and young adults in the world 
(Aarli, 2006; Hyder et al., 2007). Similarly to stroke, there is immediate cell death 
followed by delayed secondary cell death, with a variety of mechanisms proposed 
(Raghupathi, 2004).  
 
Sharing this primary and secondary loss of neurons is cerebral hypoxia/ischemia 
(Huang and Castillo, 2008). Its cause overlaps greatly with ischaemic stroke insofar 
as it is a reduction in either oxygenated blood or blood in general that is received by 
the brain, but the fact that cerebral hypoxia affects the whole brain, rather than local 
areas distinguishes the two. The cause of cerebral hypoxia is a sudden decrease in 
oxygenation of the blood, most frequently caused by an obstruction of breathing, and 
cerebral ischaemia is the sudden decrease in blood in general to the brain, often due to 
the reduced blood flow to the brain.  
 
 
Current therapeutic options for acute neurodegenerative diseases 
 
 
In all of these acute neurodegenerative diseases the immediate therapeutic course of 
action is to identifying the exact cause of the incident, and immediately combat the 
acute source of pathology, with the speed of correct therapeutic intervention being of 
paramount importance (Fan et al., 2012; Marler et al., 2000). This intervention can be 
by removing the source of ischemia with thrombolytic and anticoagulant medication 
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or surgical intervention for ischaemic stroke (Gupta et al., 2003; The National 
Institute of Neurological Disorders and Stroke rt-PAStroke Study Group, 1995), or 
reducing the intracranial pressure following a bleed and removing the haemorrhage in 
some instances of haemorrhagic stroke (Hemphill et al., 2015). Once the acute 
incident has been treated, appropriate medication is then used to mitigate the 
redevelopment of pathology, and then the long-term neuropathological treatment of 
the patient essentially involves leaving the brain to recover on its own. The prevention 
of the reoccurrence of ischaemic stroke is achieved by prescribing anticoagulants and 
thrombolytics to prevent the reoccurrence of vessel occlusion, however this may 
increase the short-term incidence of haemorrhagic stroke (Adams et al., 2007).  
 
The mitigation of long-term pathology in all of these acute diseases is done with 
secondary therapies such as physiotherapy to try and preserve motor function, or 
speech therapy to try and preserve speech. Crucially, in all of these cases, whilst 
patients can generally expect excellent and swift treatment, no current therapeutic 
interventions are available to try and stop the progressive neurodegeneration 
following the incident that results in such profound disability in these diseases. The 
prognosis of these diseases varies from patient to patient therefore, but if therapies 
could be devised to mitigate the post-incident neuronal loss, a novel and crucial new 
therapeutic strategy may be possible for treating acute neurodegenerative disease. 
 
 
 
Insulin and insulin-like signalling in neurodegenerative disorders – a potential 
therapeutic target 
 
 
 
Whilst there are substantial differences in neuropathology between the different 
neurodegenerative diseases, one molecular pathway has been repeatedly shown to be 
endogenously altered in its signalling level in neurodegenerative disorders, and seems 
uniquely poised to impact on the general health and survival of neurons. This pathway 
is of substantial interest to us because it is implicated in the ageing process itself, and 
is therefore directly involved in the longevity and healthspan of organisms and 
tissues, as well as directly being implicated in neuronal cell death mechanisms. All  
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Figure 1.2. The canonical insulin and insulin-like growth factor signaling pathway. Simplified 
diagrammatic representation of the canonical IIS cascade. The soluble ligands IGF1 and insulin 
bind and activate IGF1R and IR respectively, as well as IR and IGF1R with less affinity. This 
causes autophosphorylation of the receptor tyrosine kinases IGF1R and IR, and the subsequent 
downstream signaling through the PI3K-AKT and RAS-MAPK pathways. Crosstalk between 
pathways, and input onto these pathways from other signaling cascades is apparent. Common 
protein names used; see key in appendix for official/alternate protein and gene names. 
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these factors make the IIS cascade an ideal candidate for the type of pro-health 
interventions that we desire.  
 
 
The IIS cascade in the brain in health and disease 
 
 
 
The IIS cascade is an ancient and well-conserved molecular signalling pathway, 
which in essence is a nutrient sensing pathway, implicated in a multitude of key 
cellular processes in nearly all tissues in the human body. The signalling pathway can 
be seen in figure 1.2, and is activated in its signalling via three hormone ligands; 
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insulin, insulin-like growth factor 1 (IGF1) and insulin-like growth factor 2 (IGF2). 
Whilst the effects of insulin and IGF2 are undoubtedly very important in human brain 
physiology, it is the signalling of IGF1 specifically that we are interested in this 
thesis. IGF1 predominantly signals through the IGF1 receptor (IGF1R), although 
IGF1R is still receptive to both IGF2 and insulin, albeit with 10 and 100 fold lower 
affinity (Czech, 1989). Similarly IGF1 can activate both the insulin receptor (IR), and 
IGF2 receptor (IGF2R), but with less affinity than their namesake ligands (Czech, 
1989). With IGF1R and IR both being comprised of two subunits forming a 
heterodimer (Hubbard, 1999), and sharing great homology (Ullrich et al., 1986), it is 
also the case that IGF1R/IR heterodimer can form with a high affinity for IGF1 and 
low for insulin (Soos et al., 1993), but the exact significance and prevalence of these 
hybrid receptors, especially in the brain, are yet to be fully determined.  
 
The downstream effects of receptor activation are mainly conveyed via the Insulin 
Receptor Substrates 1 and 2 (IRS1 and IRS2) and Shc, whereby activation of IGF1R 
and IR directly phosphorylates these proteins and thereby allows the binding of SH2 
domain proteins to these large receptor substrates. This leads to the activation of two 
molecular pathways; the phosphatidylinositol 3-kinase (PI3K)–AKT pathway, and the 
Ras–mitogen-activated protein kinase (MAPK) pathway (Avruch, 1998). It is highly 
likely that there is tissue specific signalling through these cascades, and therefore we 
must specifically examine IIS signalling in the brain.  
 
By adding IGF1 and insulin to post-mortem brain tissue and then measuring the 
changes in phosphorylation levels in downstream components of the IIS cascade, 
Talbot et al showed that insulin signalled predominantly through IRS1 to the PI3K 
branch of the IIS cascade, whereas IGF1 signalled predominantly through IGF1R and 
IRS2 through the MAPK (ERK1/2) branch in the brain (Talbot et al., 2012).  This 
therefore represents the two divergent yet interacting signalling cascades that make up 
canonical IIS: the PI3K, and MAPK branches. These two branches go on to signal to 
various transcription factors such as the ELK1 and FOXO families. These signalling 
cascades seem to have distinct functions in the brain that is only now beginning to be 
fully elucidated (Broughton and Partridge, 2009).  
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So far this is only a simplistic overview of the canonical IIS cascade. Other non-
canonical branches of IR/IGF1R signalling do exist, for example there is evidence to 
suggest that IR/IGF1R phosphorylates proteins such as Gabs (Nishida and Hirano, 
2003) and DOKS (Mashima et al., 2009). Also IGF1 and insulin have been shown to 
be activators of other non-receptor kinases such as the Janus kinases (Gual et al., 
1998), and c-Abl kinase (Genua et al., 2009). These associations are yet to be 
thoroughly investigated however, and how they may impact on IIS specifically in the 
brain is far from known.  
 
In the periphery the most significant action of IGF1 is via the mediation of the growth 
promoting effects of growth hormone by acting as a growth and differentiation factor 
on many tissue types (Laron, 2001). This is achieved by growth hormone being 
released into the blood from the pituitary gland where it stimulates the synthesis and 
release of IGF1 into the blood from the liver (Daughaday et al., 1972). Therefore 
IGF1, by being a trophic factor in the periphery, is seen overwhelmingly as a pro-
growth factor. Indeed, it is this pro-growth property that is implicated in some 
cancers, leading to IGF1R inhibitor development as chemotherapy agents (Weroha 
and Haluska, 2008).  
 
The bioavilability of IGF1 in the blood is regulated by its high affinity binding to IGF 
binding proteins (IGFBPs), with various IGFBPs having differing affinities for IGF1 
(Duan, 2002). Whilst the pro-growth effects of IGF1 in the periphery are well 
defined, cell types in the periphery are mitotic and therefore capable of undergoing 
cell division and replication. The brain is a unique organ containing neurons that are 
post mitotic and extremely long lived, and also astrocytes which are likely long lived 
with a low cell turnover, as well as containing cell types capable of proliferation such 
as microglia. Therefore the effects that IGF1 has in the brain are worthy of special 
consideration, as abundant evidence suggests atypical properties for what is 
classically assumed to be a proliferative pathway. 
 
IIS signaling is integral in brain development, with IGF1 and IGF1R mutations 
causing microcephaly (Netchine et al., 2009; Walenkamp et al., 2005), and the lack of 
humans with a total genetic loss of IGF1R implies its lethality. Insulin and IGF1 are 
expressed abundantly in the periphery, with increased levels in the blood causing an 
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increase in levels in the brain (Baura et al., 1993). The work of Liu et al showed that 
the liver was not the only organ capable of expressing IGF1 (Liu et al., 2000), and 
although IGF1 and insulin are actively transported into the brain from the periphery, 
cells in the brain also express IGF1.  
Developmental studies show that under healthy conditions this IGF1 expression is 
predominantly in neurons (Bondy, 1991; Bondy et al., 1990), and this pattern is 
confirmed in online expression databases (Zhang et al., 2014)(figure 1.3). The 
expression of IGF1 and the IGF1 receptor (IGF1R) in the brain is highest during 
development, with IGF1 expression decreasing significantly in the adult brain (Bondy 
and Lee, 1993; Han et al., 1988; Sandberg et al., 1988). IGF1 acts during all the major 
phases of brain development, with IGF1R’s expressed as early as the formation of the 
ventral floor plate, as well as in major brain regions such as the hippocampus, 
neocortex and cerebellum during later stages of development, acting to promote the 
proliferation of neuronal precursor cells and the differentiation of neurons to form 
complex networks (Bondy et al., 1992; Bondy et al., 1990; Ozdinler and Macklis, 
2006; Sosa et al., 2006).  
These patterns of expression change profoundly during injury however, with 
increased IGF1 production in astrocytes observed in TBI, hypoxia, and sAD (Beilharz 
et al., 1998; Connor et al., 1997; Madathil et al., 2013), although a reduction has been 
observed when IGF1 expression is measured in the AD brain via RT-qPCR (Steen et 
al., 2005). The increase in IGF1 expression in such a wide variety of diseases suggests 
that it is a response to damage in the brain, with the proximity of IGF1 expressing 
astrocytes to the site of head injury in TBI supporting this. What is of interest here is 
that the IGF1R is expressed in nearly all cells of the brain, but crucially in neurons 
and astrocytes (figure 1.3, B). Given the non-mitotic properties of astrocytes and 
neurons, and the pro-growth and differentiation signals that IGF1 usually conveys, it 
is clear that increased IGF1 signaling in these cells must have different cellular effects 
to those characterized in the periphery. 
It is possible that this increase in IGF1 production in glial cells is stimulating growth 
not in terms of cell division, but in terms of synapses and neuronal processes to 
compensate for damage, as IGF1 has been shown to affect neuronal transmission and 
promote synapse formation (Gazit et al., 2016; Shcheglovitov et al., 2013). With  
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Figure 1.3. Expression levels of IGF1 and IGF1R in the mouse and human brain. (A) IGF1 in 
the adult human and mouse brain is nearly exclusively expressed in neurons, but also to a lesser 
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synaptic loss proximal to the damaged area of the brain well documented, this is a 
distinct possibility.  
 
Another more worrying possibility is that increased IGF1 levels cause an increase in 
signaling downstream of IRS2, and in particular at ERK1/2. Neuronal cell death has 
been associated with ERK1/2 activation, and in multiple experiments neuronal cell 
death in neuronal cultures has been reduced using the specific inhibitors of MEK1 and 
MEK2 U0126 and PD98059 (Bhat and Zhang, 1999; Canals et al., 2003; de Bernardo 
et al., 2004; Lesuisse and Martin, 2002; Stanciu et al., 2000). PD98059 was also 
shown to be neuroprotective in vivo, by reducing hippocampal neuronal loss 
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following TBI in rats (Lu et al., 2008). It seems though that the duration of ERK1/2 
activation is relevant as to whether the signal is protective or indicative of neuronal 
cell death, with prolonged ERK1/2 activation proving neurodegenerative, and 
transient increases being neuroprotective (Almeida et al., 2005; Luo and DeFranco, 
2006; Subramaniam et al., 2005). Crucially Subramaniam et al showed that 
exogenous IGF1 application to a cell culture model of neuronal cell death showed a 
transient increase in ERK1/2 and neuroprotection. How this translates to the 
endogenous IGF1 increase in neurodegenerative disorders however is unclear, 
especially in the chronic neurodegenerative disease sAD, where presumably the IGF1 
increase is for a far longer time. 
 
Changes in IIS with regards to ERK1/2 phosphorylation levels in disease states have 
also been shown, with ERK1/2 activity being directly attributed to key pathological 
changes in AD. In AD patients, increased phosphorylated ERK1/2 has been shown to 
co-localise with tau tangle containing hippocampal neurons, with the sequential 
presence of phosphorylated and therefore activated forms of ERK1/2 and its kinase 
MEK in pretangle neurons in parallel with Braak staging (Pei et al., 2002; Perry et al., 
1999). The sizes of cytosolic granular accumulations of these activated kinases in this 
sequential progression increased with the accumulation of hyperphosphorylated tau 
within the neurons (Pei et al., 2002). One of the many substrates of ERK1/2 is tau, 
implying that ERK1/2 signalling increase could contribute to tau 
hyperphosphorylation (Guise et al., 2001; Harris et al., 2004). Considering that Aβ 
accumulation precedes tau phosphorylation, and tau phosphorylation increase seems 
to be increasingly implicated as the source of neurotoxicity in AD, the direct action of 
Aβ in inducing prolonged activation of ERK1/2 resulting in tau phosphorylation in 
neuronal cell cultures provides a possible crucial link between these two pathological 
hallmarks of AD (Rapoport and Ferreira, 2000).   
 
Increased ERK1/2 activation is not unique to AD however, with neurons containing 
Lewy bodies in the substantia nigra of Parkinson’s disease patients being shown to 
contain the same granular accumulations of phosphorylated ERK1/2 as those apparent 
in tau tangle containing neurons in AD patients (Zhu et al., 2002). Similarly alpha 
synuclein itself increases p-ERK levels in microglia, inducing the release of pro-
inflammatory cytokines (Klegeris et al., 2008). Furthermore the gradual loss of 
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neurons in the weeks following an ischaemic event has been shown to be dependent 
of increased ERK1/2 phosphorylation, with increased phosphorylated ERK1/2 
observed in middle cerebral artery occlusion (MCAO) models of ischemia, permanent 
MCAO models, and in other hypoxia ischemia and pure ischemia animal models of 
stroke (Alessandrini et al., 1999; Irving et al., 2000; Kitagawa et al., 1999; Lennmyr 
et al., 2002; Namura et al., 2001; Wang et al., 2003). Therefore with the above 
mentioned changes in ERK1/2 phosphorylation in multiple neurodegenerative 
diseases, and its implications in neuronal cell death, it would seem that not only is IIS 
clearly implicated in pathogenesis in neurodegeneration, but ERK1/2 represents a 
focal point of signalling through which neuronal cell death signalling is present.   
 
ERK1/2 is not the only part of the IIS cascade that is endogenously changed in 
neurodegenerative diseases however. Substantial IIS resistance, whilst normally 
associated with peripheral disorders such as diabetes mellitus and polycystic ovary 
disease, has been observed in the brains of sAD patients, with the level of resistance 
correlating with the cognitive decline of these patients (Talbot et al., 2012). This 
resistance has been shown to occur as a decrease in expression of proteins in the IIS 
cascade (Steen et al., 2005), and also at the phosphorylation level. This resistance 
importantly is most profound in the hippocampus (Talbot et al., 2012), with the 
hippocampus being one of the brain regions most profoundly degenerated in AD 
(West et al., 1994). As with the p-ERK change detailed above, this change in IIS 
signaling is not apparent in all cell types of the hippocampus, with histological 
staining of a phosphorylation site on IRS1 that reduces IIS (pS616 IRS1) highlighting 
pyramidal neurons of the CA1 region (Talbot et al., 2012). The correlation between 
AD progression, cognitive decline, and the development of IIS resistance all 
coinciding in the hippocampus of AD patients, has inevitably led to many inferring 
that IIS resistance in AD is a contributing factor to the development of pathology and 
neurodegeneration in the disease. This has led to an abundance of research into 
treatments to prevent or alleviate the IIS resistance seen in AD (Bomfim et al., 2012; 
Long-Smith et al., 2013; Talbot and Wang, 2014). It is possible to interpret this 
resistance in another way however, with decreases in signaling through the IIS 
cascade having been shown to have very different effects on diseases pathology.  
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Ageing and neurodegeneration 
 
 
 
Ageing can be defined as the deterioration of the physiological functions of an 
organism in a time dependant manner that affects the correct functioning and 
ultimately survival of that organism. This is a distinguishable process from age-
related diseases, and it is this deterioration of physiological function that is one of the 
theories of how ageing affects the probability of developing age-related diseases. 
Although long thought of as an unregulated natural stochastic process in an 
organism’s life, the regulatory pathways that determine the rate of ageing in 
organisms have begun to be defined. By far the most thoroughly researched of these 
regulatory pathways is the IIS cascade.  It has been shown that by altering the level of 
signalling through this pathway, the rate of ageing of an organism can be modulated. 
By systemically decreasing signalling through the IIS pathway, a lifespan of over 
double what is normally seen can be achieved in daf-2 (a hormone receptor similar to 
that of insulin and IGF1) mutants in Caenorhabditis elegans (C. elegans) (Kenyon et 
al., 1993). This has been demonstrated robustly in many experimental animals with 
increasing supportive evidence in higher organisms, including humans (Barbieri et al., 
2010; Holzenberger et al., 2003; Kojima et al., 2004; Milman et al., 2014; Suh et al., 
2008; Tatar et al., 2001).  
 
The most remarkable aspect of this lifespan extension is not just that these animals 
live longer, but that they live healthier for longer. The amount of time that an 
organism spends in a healthy non-diseased state is termed its healthspan, and it is the 
increase in healthspan that makes this lifespan extension very relevant for 
understanding the affects of ageing on the increased risk of neurodegenerative disease 
development. It has been shown that decreasing IIS signalling in animal models of 
AD can prolong the healthspan of these animals, and slow the onset of the AD 
phenotype when compared to non-IIS reduced AD mutant mice, as well as crucially 
decreasing neuronal cell death (Cohen et al., 2009). Processes known to lower 
systemic IGF1 levels such as fasting have also been shown to delay the onset of AD 
in AD model mice (Halagappa et al., 2007).  
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This ability to manipulate an ageing regulatory pathway and show delays in the 
development of neurodegenerative disease pathology, therefore represents tangible 
proof that neurodegeneration can be delayed by ageing delaying therapies. Precisely 
how the onset of these diseases is delayed by slowing ageing, and how this change is 
manifest at a cellular level, is currently the focus of rigorous research, with pathways 
and molecules downstream of the IGF1 receptor and its orthologs being scrutinised 
(Baird et al., 2014; Pierce et al., 2013). If this link can be better understood then there 
would be potential to develop therapies that would manipulate this process for 
therapeutic gain. Whilst genetic manipulation to lower signalling through the IIS 
cascade does not seem plausible, the identification of drugs that inhibit this pathway 
opens up the possibility of pharmacological manipulation of this pathway. This is a 
far more clinically applicable concept. 
 
 
 
Modulating IIS in the brain as a therapeutic target – our aims 
 
 
 
With the IIS cascade appearing to be a pharmacologically modifiable molecular 
pathway capable of influencing neuronal cell death and brain health, we have 
identified an approach to directly target neuronal cell death in neurodegenerative 
diseases that is yet to be fully explored. Attempts have already been made to utilise 
the IIS pathway in the brain for therapeutic gain, with varying success.  
 
 
Therapeutically targeting chronic neurodegeneration 
 
 
 
The window for neuroprotective therapeutic intervention in acute neurodegenerative 
disorders is fairly straightforward, neuronal cell death occurs in the weeks following 
the initial noxious insult, so therapeutically opposing neuronal cell death in this time 
period seems the obvious intervention strategy. For chronic neurodegenerative 
diseases the picture is far more complex.  
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Certain aspects of AD pathology make designing IIS based therapeutics for this 
disease very difficult. The first difficulty is the substantial prodromal period and 
extent of neuronal loss and disease development before clinical presentation of AD 
symptoms, with substantial hippocampal atrophy present by diagnosis (Fox et al., 
1996). Ideally disease intervention would be before substantial neuronal loss and 
cognitive impairment has occurred, and indeed substantial effort is being put into 
devising improved pre-cognitive impairment diagnostic tests (Humpel, 2011). Due to 
this concerted effort to diagnose AD earlier in the disease progression, the search for 
improved therapeutics should not limit itself to post-diagnosis interventions, and 
therefore our search for optimal IIS modulating therapy intervention will include pre 
and post-diagnosis AD stages. 
 
The second difficulty in IIS modulating therapies being considered for disease 
intervention in AD is that endogenous IIS changes have been reported in the AD brain 
(Steen et al., 2005; Talbot et al., 2012). These changes could undermine our proposed 
interventions. For example, the profound IIS resistance in the diagnosable AD brain 
could limit the efficacy of both inhibitors and stimulators of the IIS pathway. IIS 
inhibitors would have reduced effect as the pathway is already lessened in its 
signalling, and the efficacy of applications of stimulators such as IGF1 would be 
lessened as the extent to which it can stimulate signalling would be reduced by the 
resistance. Understanding the endogenous changes in IIS at different points in AD 
progression is therefore essential in order to aid the appropriate timing of our 
proposed IIS based interventions.  
 
In order to identify the most appropriate time point for disease intervention in 
the chronic neurodegenerative disease AD via IIS modulation, the first aim in 
this thesis was to examine how IIS changes at different time points during 
disease pathogenesis in AD.  
 
To examine IIS changes at earlier disease stages in the AD brain we chose from the 
wide range of mouse models available that model different pathological components 
of AD. Given the heritability of fAD, animal models have been made by 
incorporating fAD mutations such as those in the PSEN1 and APP genes into the 
genomes of the model animal of choice (Goate et al., 1991; Sherrington et al., 1995).  
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With a profound overlap in the clinical and neuropathological presentation of fAD 
and sAD, these fAD models of AD can be used as a means to study sAD and AD in 
general. These models lead to animals with increasing levels of Aβ pathology and 
plaque formation, but lacked the complete tau pathology seen in clinical AD, with 
hyperphosphorylated tau occasionally observed but never producing tau tangles 
(Howlett et al., 2008; Kurt et al., 2003; Sturchler-Pierrat et al., 1997).  
 
To be able to model hyperphosphorylated tau and tau tangles, mutations in the MAPT 
gene were incorporated into animal genomes (Santacruz et al., 2005; Terwel et al., 
2005). These are not mutations found in AD patients however, but mutations that give 
rise to frontotemporal dementia (FTD), thereby utilising the overlap in tau pathology 
between these diseases to form a mouse model of tau pathology, and thereby examine 
the effects of tau pathology on the brain. Animal models of AD that only contain Aβ 
pathology or tau models are not accurate portrayals of AD in humans however, and 
therefore should not be viewed as “models of AD” as they only model one 
pathological component of the disease. Whilst this is often seen as a downside to 
animal models of AD, it provides the opportunity to tease apart the effect of these two 
neuropathological components on IIS signalling.  
 
 
Mouse models of amyloid and tau pathology in AD 
 
The amyloid pathology mouse model that was chosen was the APP knock-in model 
developed by Saito and Saido (Saito et al., 2014). Both strains developed by this 
group are an improvement on previous APP based amyloid transgenic mouse models, 
as they avoid the problems of APP overexpression common in other models. This was 
achieved by using a humanised Aβ sequence in the mouse APP gene; meaning human 
Aβ is produced in mouse neurons at a physiologically correct level. This 
improvement on previous overexpression transgenic APP models was the main reason 
why the APP knock-in model was used for our experiments, as this will allow a far 
more physiological response to misfolded Aβ to be studied. This is in sharp contrast 
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to overexpression models, where the variable of increased protein load was also 
present.  
 
With these mice having a human Aβ sequence, the addition of specific fAD mutations 
therefore produces misfolded aggregating Aβ, with the two APP-KI strains differing 
in the number of fAD mutations present. The NL-F/NL-F strain harbours only the 
Spanish Beyreuther/Iberian mutations, whereas the NL-F-G/NL-F-G strain also 
contain the Arctic mutation (Saito et al., 2014). The Swedish KM670/671NL 
mutation increases Aβ40 and Aβ42 creation, the Beyreuther/Iberian I716F mutation 
increases the Aβ42 to Aβ40 ratio, and the Arctic mutation caused the mice to exhibit 
greater neuroinflammation and a swifter pathology (Citron et al., 1992; Guardia-
Laguarta et al., 2010; Saito et al., 2014; Tsubuki et al., 2003).  
 
Whilst both strains show progressive amyloid pathology, the addition of the arctic 
mutation greatly increases the speed of its development. In the APP-KINL-G-F/NL-G-F 
mouse model, there is an age dependant development of Aβ pathology beginning at 2 
months of age in the cortex hippocampus and subcortex, with Aβ accumulation 
saturating by 7 to 9 months (Saito et al., 2014). This is accompanied by extensive 
neuroinflammation with increased astrogliosis and microgliosis by 9 months. Memory 
impairment was observable by 6 months of age as measured by deficits in the Y-maze 
test. Crucially this model also has no distinguishable neuronal cell loss. In the APP-
KINL-F/NL-F strain however, Aβ deposition only began at around 6 months, progressing 
to around 8% cortical plaque coverage by 20 months – a plaque burden observed by 7 
months when the Arctic mutation is present (Saito et al., 2014). Furthermore 
comparatively less neuroinflammation is observed in APP-KINL-F/NL-F mice.  
 
Due to our APP-KINL-F/NL-F colony only being young at the time of my experiments, 
all my experiments were performed on the more aggressive APP-KINL-G-F/NL-G-F  strain 
using tissue sent from our collaborators Saito and Saido (see chapter 2). Based upon 
this pathology development in the APP-KINL-G-F/NL-G-F mice, we examined IIS 
signalling at 2, 4, and 8 months of age, which corresponds to the very beginning of 
amyloid pathology at 2 months, midrange amyloidosis at 4 months, and maximal 
amyloid deposition at 8 months.  
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The rising tau model that was chosen is the TG4510 model (Santacruz et al., 2005). 
This model expresses human tau containing a P301L mutation which in humans leads 
to a type of familial FTD called frontotemporal dementia and parkinsonism linked to 
chromosome 17 (FTDP-17)(Hutton et al., 1998). In this model pretangles develop by 
2.5 months and progressed rapidly with full tangles observable by 4 month in the 
cortex and 5.5 months in the hippocampus (Santacruz et al., 2005). This was 
accompanied by extensive neuronal cell loss, with substantial brain weight reduction, 
and a 60% reduction in hippocampal CA1 pyramidal neurons by 5.5 months. This 
profound neurodegeneration continue with only 23% of these neurons still present in 
8.5-month-old mice. Whilst this model is very aggressive, we wanted a model that 
showed pretangle pathology, tangle pathology, and also showed extensive neuronal 
cell loss. This aggressive pathology development can also be seen as a disadvantage 
however, as more subtle changes in IIS may be lost given the speed of progression. 
However, as neuronal cell loss defines neurodegenerative diseases, the presence of a 
substantial level of neurodegeneration in this model was seen as an advantage given 
our aims.  
 
With such a rapidly progressing pathological progression, we chose to examine the 
IIS cascade in 2-month-old animals to see how the development of pretangle 
pathology affected IIS in the brain, and 8-month-old animals to see how IIS is 
changed in the brain during neurodegeneration. This model therefore allowed us to 
examine very early AD events, and also very late, post diagnosis events, in relation to 
the level of IIS.  
 
As human AD contains both amyloid and tau pathology, to gain insight into how our 
IIS characterisations in just amyloid and tau containing mice compared with the IIS 
changes in the AD brain, we also carried out a preliminary investigation into IIS 
levels in a small number of human brain samples from the UCL Queen Square brain 
bank. These samples were from fAD and sAD patients, as well as from non-demented 
controls for comparison. Depending on this initial human brain tissue study, more 
samples can be requested for further analysis.  
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Using these two mouse models, we can therefore assess changes in IIS signalling at a 
range of time points during AD pathology development that is not possible in human 
brains.  
 
 
IGF1 and neurodegeneration 
 
 
 
There is evidence to suggest that exogenous insulin and IGF1 administration in 
various forms has positive effects on cognition and proteostasis in animal models of 
AD. Infusions of IGF1 have been shown to improve Aβ clearance from the brain in 
aging rats, and decrease behavioral impairments seen in AD mouse models (Carro et 
al., 2006; Carro et al., 2002). This combined with evidence showing that intranasal 
administration of insulin improves memory in healthy humans, has lead to 
considerable attention being given to the prospect of insulin administration being a 
viable therapy for treating, or at least providing alternative symptomatic relief for 
sAD patients (Benedict et al., 2004; Benedict et al., 2007; Wadman, 2012).  
 
IGF1 administration or increasing IGF1 has had positive effects in animal models of 
motor neuron disease (MND) and stroke. Following ischemia and stroke IGF1 has 
proven to be neuroprotective in rats and sheep, but has yet to be translated into 
clinical benefit. In these models both administering, and genetically overexpressing 
astrocyte IGF1 was neuroprotective following hypoxia ischemia, albeit in a dose 
response relationship, with only higher levels providing neuroprotection (Bergstedt 
and Wieloch, 1993; Carro et al., 2006; Guan et al., 2000; Guan et al., 1993; Johnston 
et al., 1996; Li et al., 2010; Madathil et al., 2013). Overexpressing IGF1 in the brains 
of MND model mice has also proved beneficial for disease symptoms in those 
animals (Dodge et al., 2008). These studies all suggest a neuroprotective role for 
IGF1 in neurodegenerative conditions.  
 
As mentioned above, endogenous IGF1 increase has been observed in astrocytes in 
traumatic head injury, hypoxia, and sAD (Beilharz et al., 1998; Connor et al., 1997; 
Madathil et al., 2013). Based on the neuroprotective findings of IGF1 administration, 
this endogenous increase would appear to be a neuroprotective response to damage in 
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the brain. However, as described earlier a reduction in IIS signaling by genetic and 
pharmacological means has shown to be able to postpone neurodegenerative disease 
progression and be neuroprotective. With IGF1 being a potent activating factor of 
signalling through the IIS cascade (Laviola et al., 2007), there are directly opposing 
views as to the role IIS signaling plays in the pathogenesis of neurodegenerative 
disease. Furthermore, with a dose-response relationship shown in the IGF1 
neuroprotection papers (Bergstedt and Wieloch, 1993; Johnston et al., 1996), where 
low levels of IGF1 administration elicited no neuroprotection against injury, the role 
of endogenously changed IGF1 levels in neurodegenerative diseases is difficult to 
predict.  
 
With the complications of IIS intervention timing in chronic neurodegenerative 
disease, and the identification of a brain resistant state in sAD (Talbot et al., 2012), 
we cannot assume that the effect of endogenous IGF1 increase is the same in chronic 
and acute neurodegenerative diseases. We therefore focused only on the effects of 
endogenously increased IGF1 in acute neurodegenerative disease. 
 
The second aim in this thesis was to clarify the role of endogenously increased 
IGF1 in acute neurodegenerative diseases, especially with regards to neuronal 
cell loss.  
 
To investigate this, we chose to develop an in vitro model of acute neurodegeneration, 
which showed neuronal cell loss accompanied by increased astrocyte Igf1 levels. Our 
model was based on the bilaminar co-culture protocol of Shimizu et al, where primary 
astrocyte and neuron cultures from mice are generated, and then combined in a single 
well by suspending a coverslip with primary neurons attached above an astrocyte 
culture grown in the bottom of the well (Shimizu et al., 2011). This allowed the 
sharing of the medium between these cultures, but the separation of each cell type for 
separate analysis. To induce neurodegeneration we applied a short-term hypoxic 
insult.  
 
 
 
 
 
	 44	
Inhibiting the IIS pathway as a therapeutic target 
 
 
 
Probably the strongest support for using IIS inhibitors to treat neurodegenerative 
diseases in mammals comes from the separate work of Echeverria et al, Gladbach et 
al, and Ashabi et al. Whilst recent further supportive evidence for the therapeutic 
benefit of inhibiting IIS to slow neurodegenerative disease progression has been 
shown using Caenorhabditis elegans (El-Ami et al., 2014), the work of the above 
groups is closer to progression to the clinic in virtue of being carried out in intact 
mammalian systems. Echeverria et al  showed that by administering the clinically 
approved c-Raf inhibitor Sorafenib, neuronal cell death was ameliorated in culture, 
and successfully rescued memory deficits in a mouse model of AD (Echeverria et al., 
2008; Echeverria et al., 2009). What was lacking from this was a direct quantification 
of whether this c-Raf inhibitor prevented neuronal cell death, or had more general 
effects on the disease pathology, such as rescuing alterations in neuronal plasticity. 
Direct evidence of neuronal cell protection in a neurodegenerative disease animal 
model treated with an IIS inhibitor was shown in studies that administered the MEK 
inhibitors U0126 and PD169316 to mice following an ischemic incident, or mice 
injected with Aβ fibrils into their brains (Ashabi et al., 2013; Gladbach et al., 2014). 
In both of these studies neuronal cell loss was substantially reduced by IIS inhibitor 
administration. The progress of IIS inhibitors to the clinic to treat neurodegeneration 
is yet to happen however.  
 
On a mechanistic level as mentioned above, a prolonged increase in signalling 
through this cascade specifically at ERK1/2, has been shown to be indicative of a 
neuronal cell death cascade, and this increased ERK1/2 signalling has been shown in 
multiple neurodegenerative disorders specifically in the areas of brain that are 
undergoing neurodegeneration (Alessandrini et al., 1999; Almeida et al., 2005; Lu et 
al., 2008; Luo and DeFranco, 2006; Pei et al., 2002; Perry et al., 1999; Subramaniam 
et al., 2005; Zhu et al., 2002). With neuronal cell death such an integral feature of 
neurodegenerative disorders, the neuroprotective effects of IIS inhibitor 
administration could be through interference in these increased ERK1/2 neuronal cell 
death signals.  
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Whilst most work using IIS inhibitors to modulate neuronal cell death has focused on 
experimental inhibitors such as U0126 and PD169316, or novel preclinical inhibitors 
such as NT219 (El-Ami et al., 2014), many inhibitors of the IIS cascade have already 
been approved for human use to treat many forms of cancer.  
 
The third and final aim of this thesis is therefore to investigate the possible 
repurposing of clinically approved IIS inhibitors to ameliorate 
neurodegeneration in acute neurodegenerative diseases.  
 
Whilst there is undoubtedly use in trialing novel inhibitors of this pathway, the 
abundance of already clinically approved inhibitors, albeit for different diseases, 
could greatly facilitate the transition of our hypothesis to the clinic. For this reason 
already clinically approved inhibitors, or inhibitors in late stage clinical trials, were 
prioritized over preclinical compounds. Furthermore, with the impressive mammalian 
work of Echeverria et al, Gladbach et al, and Ashabi et al, focusing at the Ras and 
ERK1/2 stage of the IIS, we chose to focus at specifically this level of the pathway 
rather than higher or lower. This also provided a wide range of clinically approved 
inhibitors to choose from.   
Once more acute neurodegenerative diseases were chosen in preference over chronic 
neurodegeneration, this time due to the time frame of the possible drug 
administration, and the common side effects of IIS inhibitors.  
Figure 1.4 lists inhibitors of the IIS cascade that are already approved for use in 
humans or are in later stages of clinical trials, the diseases they target, and the 
pharmaceutical companies that own them. Clinically approved inhibitors with low 
IC50’s were preferred, with inhibitors of MEK and Ras specifically being a focus as 
discussed above. Priority was given to investigating the MEK inhibitor Trametinib 
(Mekinist), with the B-Raf inhibitor Dabrafenib (Tafinlar) chosen as an alternative 
option. The work by Slack et al established Trametinib as a pharmacological 
intervention that decreased signalling in the IIS pathway leading to lifespan extension 
in Drosophila (Slack et al., 2015). With reduced pathology in animal models of 
neurodegeneration when crossed with animal models of lifespan extension or treated 
with experimental IIS inhibitors, and Trametinib administration leading to lifespan 
extension, this drug was chosen over others that lacked this direct link.   
Official 
name 
Trade name Stage Disease 
prescribed/ in 
testing for 
Daily dose IC50 Company 
IGF1R inhibitors 
Picropodophyll
in (AXL1717) 
Phase I/II 
(NCT01721577) 
Astrocytoma 300-520mg 
twice daily 
orally 
1nM1 Axelar AB 
BMS-754807 Phase I/II 
(NCT01225172) 
(NCT00898716) 
Breast cancer; 
neoplasms 
100mg daily 
orally 
1.8nM2 Bristol-Myers 
Squibb 
Linsitinib 
(OSI-906) 
PhaseII/III 
(NCT00924989)
(NCT02546544) 
(NCT02057380) 
Adrenocortical 
Carcinoma; 
Erwing 
sarcoma; 
Advanced 
solid tumours 
35nM3 Astellas 
Pharma Inc 
Raf inhibtors 
Vemurafenib  
(PLX4032) 
Zelboraf Approved V600E 
melanoma 
960mg twice 
daily orally 
100nM4 Roche 
Sorafenib Nexavar Approved Renal cell 
carcinoma; 
Hepatocellular 
carcinoma; 
Thyroid cancer 
400mg twice 
daily orally 
6nM5 Bayer/Onyx 
Pharmaceutica
ls 
Dabrafenib Tafinlar Approved V600E 
melanoma 
150mg twice 
daily orally 
3.2nM6 GlaxoSmithKli
ne 
Raf265 
(Chir265) 
Phase I/II 
(NCT00304525) 
(NCT01352273) 
Metastatic 
melanoma; 
Solid tumours 
83.6mg daily 60nM7 Novartis 
RXDX-105 
(CEP-32496) 
Phase I/II 
(NCT01877811) 
Solid tumours 275mg once 
daily orally 
36nM8 Ignyta Inc. 
Encorafenib 
(LGX818) 
Phase III 
(NCT02109653) 
V600E 
melanoma 
300mg daily 
orally 
N/A9 Array 
BioPharma 
LY3009120 Phase I 
(NCT02014116) 
Neoplasms; 
Melanoma 
47nM10 Eli Lilly 
RO5126766 
(CH5126766) 
Phase I 
(NCT02407509) 
(NCT00773526) 
Solid tumours; 
Multiple 
myeloma; 
Neoplasms 
19nM11 Roche 
MEK inhibitors 
Selumetinib 
(AZD6244) 
Phase III 
(NCT01974752) 
(NCT01843062) 
(NCT01933932) 
Metastatic 
melanoma; 
Thyroid 
cancer; Non 
small cell lung 
cancer 
75mg twice 
daily orally 
14nM12 AstraZeneca 
PD0325901 Phase I/II 
(NCT02022982) 
(NCT02096471) 
KRAS mutant 
non small cell 
lung cancer; 
Neurofibramat
osis 
4mg twice 
daily orally 
0.33nM13 Pfizer 
Trametinib 
(GSK1120212) 
Mekinist Approved V600E 
melanoma 
2mg once 
daily orally 
1.8nM14 GlaxoSmithKli
ne 
PD184352 
(CI-1040) 
Phase II 
(NCT00033384) 
Breast cancer; 
Colorectal 
Twice daily 
orally 
17nM15 Pfizer 
Pimasertib 
(AS-703026) 
Phase II 
(NCT01936363) 
(NCT01693068) 
Ovarian 
cancer; 
Cutaneous 
melanoma 
60mg once 
daily orally 
20nM16 Merck Serono 
Binimetinib 
(MEK162) 
Phase III 
(NCT01763164) 
(NCT01849874) 
Cutaneous 
melanoma; 
Ovarian cancer 
45mg twice 
daily orally 
12nM17 Array 
BioPharma 
Refametinib 
(RDEA119) 
Phase II 
(NCT02168777) 
(NCT01915589) 
Neoplasms; 
Carcinoma 
50mg twice 
daily orally 
19nM18 Bayer 
GDC-0623 Phase I 
(NCT01106599) 
Solid cancers 0.13nM19 Genentech 
Cobimetinib Cotellic Approved V600E 
melanoma 
60mg once 
daily orally 
4.2nM20 Genentech 
ERK1/2 inhibitors 
Ulixertinib 
(BVD-523, 
VRT752271) 
Phase I/II 
(NCT02608229) 
(NCT02296242) 
Pancreatic 
cancer; 
Leukemia 
0.3nM21 BioMed 
Valleys 
Discoveries 
GDC-0994 Phase I 
(NCT01875705) 
Solid cancers 0.3nM22 Genentech 
Figure 1.4. Inhibitors of the IIS signalling pathway that are currently approved for human 
use, or currently in Phase trials. ClinicalTrails.gov identifier numbers are given for on-going 
trials.  IC50 figures refer to inhibition of wild type protein only, and can be far more sensitive 
for specific mutated versions of the proteins. (1- (Girnita et al., 2004), 2- (Carboni et al., 2009), 
3- (Mulvihill et al., 2009), 4- (Bollag et al., 2010), 5- (Wilhelm et al., 2004), 6- (Laquerre et al., 
2009), 7- (Mordant et al., 2010), 8- (Rowbottom et al., 2012), 9 - (Stuart et al., 2012), 10- 
(Henry et al., 2015), 11- (Ishii et al., 2013), 12- (Huynh et al., 2007), 13- (Barrett et al., 2008), 
14- (Yamaguchi et al., 2011), 15- (Sebolt-Leopold et al., 1999), 16- (Kim et al., 2010), 17- 
(Pheneger et al., 2006), 18- (Iverson et al., 2009), 19- (Hatzivassiliou et al., 2013), 20- 
(Hoeflich et al., 2012), 21- (Ward et al., 2015), 22- (Robarge et al., 2014)). 
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Trametinib is currently approved for use in terminal metastatic melanoma with a 
V600E B-Raf mutation, but these patients have a high chance of developing 
secondary metastases in the brain (Amer et al., 1978; Infante et al., 2012). Inhibitors 
showing specificity for mutated B-raf rather than wild-type B-raf, such as Dabrafenib 
and Vemurafenib, have shown efficacy in inhibiting secondary brain metastases in 
clinical trials, whilst no evidence exists of clinical efficacy of Trametinib treating 
brain metastases (Dummer et al., 2014; Long et al., 2012). Experiments in mice 
further suggest poor brain bioavailability of Trametinib (Vaidhyanathan et al., 2014). 
With this being the organ we are aimed to target, this could severely limit 
Trametinib’s effectiveness as an IIS inhibitor for diseases of the brain.  
 
Several limitations of Dabrafenib as a sole agent for treating melanoma, including 
acquired resistance to Dabrafenib and the increased incidence of squamous cell 
carcinoma with treatment, which was reduced when paired with a MEK inhibitor, 
lead to Trametinib being paired with Dabrafenib as a combination therapy for treating 
metastatic melanoma with a B-Raf V600E mutation (Anforth et al., 2012; King et al., 
2013; Robert et al., 2015; Solit and Rosen, 2011). Whilst many neurodegenerative 
disorders are accompanied by damage to the blood brain barrier and neurovasculature 
that may well increase the brain bioavailability of Trametinib (Obermeier et al., 
2013), it seems prudent to also examine Dabrafenib as a secondary pharmacological 
option given its apparent brain bioavailability (Mittapalli et al., 2013). It is for this 
reason that Dabrafenib has been chosen as a secondary agent in our investigations.  
 
To establish the susceptibility of brain cells to inhibition by Trametinib and 
Dabrafenib, we first considered expression levels of the proteins being targeted in 
these cell types in the brains of humans and mice. Considering the transcriptomes of 
brain cell types using online databases, all types of brain cells express B-Raf and 
MEK1, which are the proteins that Dabrafenib and Trametinib inhibit (figure 
1.5)(Hawrylycz et al., 2012; Zhang et al., 2014). We would therefore predict that our 
two drugs of choice would inhibit the IIS cascade in the cell types we are interested 
in.  
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Figure 1.5. Expression levels of members of Insulin and Insulin-like Signaling Cascade in the 
mammalian brain. (A) RNAseq images of the 4 genes showing high levels of expression in the 
hippocampus, but with the CA3 cells showing comparatively less ERK1 and IGF1R expression. (B)
(C)  RNAseq graphs showing relative expression. Panels in A modified from 
http://mouse.brain-map.org/, B from http://web.stanford.edu/group/barres_lab/brain_rnaseq.html, 
and C from http://www.brainrnaseq.org. F. Astro - Fetal Astrocytes, M. Astro – Mature Astrocytes, 
Oligo – Oligodendrocytes, Mic/Mac – Microglia/Macrophages, Endo – Endothelial, OPC – 
Oligodendrocyte Precursor Cells, NFO – Newly Formed Oligodendrocytes, MO – Mature 
Oligodendrocytes. FPKM - Fragments per kilobase of transcript sequence per million mapped 
fragments 
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With two suitable clinically approved IIS inhibitors identified, we investigated the 
repurposing of Trametinib and Dabrafenib by testing these drugs in primary neuronal 
and astrocyte cultures, before testing for neuroprotective effects in our developed 
model of acute neurodegeneration, and finally investigated the efficacy of using these 
drugs to inhibit IIS in the mammalian brain.  
 
 
Summary  
 
 
 
The most common diseases limiting human life expectancy and healthspan in 
developed nations are testimony to the success of biomedicine at reducing early life 
causes of mortality. The diseases responsible for early life mortality were 
overwhelmingly communicable, and predominantly had a clear exogenous initiating 
factor. Currently the diseases that are limiting human life expectancy and healthspan 
in developed nations are non-communicable diseases, which lack clear initiating 
factors, meaning that adequate treatment has proved difficult to identify. With this 
change in the type of disease has also come a change in the types of organs affected 
also. Neurodegenerative disorders are a wide family of diseases affecting the brain 
and characterised by progressive neuronal loss, and have rapidly grown in prevalence 
with the increase in human life expectancy. Currently very limited adequate therapies 
are available to treat these disorders, with treatments often limited to symptomatic 
therapies. A crucial feature of neurodegenerative disease is that the neurons lost are 
irreplaceable. Very limited therapies have been developed that in any way target this 
neurodegeneration, and this presently unrestricted loss of neurons in these diseases 
will severely limit the patient outcome for those diagnosed with these diseases.  
 
This thesis investigates the IIS pathway as a potential source of novel therapeutics 
that could directly modulate neuronal cell death, with the aim of unearthing new 
therapeutic targets and drugs. Endogenous alterations in the IIS pathway have been 
observed in multiple neurodegenerative diseases, and decreasing IIS signalling by 
genetic and pharmacological means has been shown to reduce neurodegeneration. 
This puts the IIS cascade as a pharmacologically targetable molecular pathway that is 
implicated in neuronal cell death and neurodegeneration and is yet to be exploited for 
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therapeutic gain. By investigating endogenous changes of the IIS cascade in AD, the 
effect of endogenously increased IGF1 in acute neurodegeneration, and the potential 
for repurposing currently available IIS inhibitors, we hope to uncover novel 
therapeutic possibilities to target the neuronal cell loss that is so central to 
neurodegenerative diseases.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 52	
Chapter 2 
 
 
Materials and methods 
 
 
 
All mice experiments were conducted according to UK Home office regulations under 
the Animals (Scientific Procedures) Act 1986, as well as UCL local ethical 
guidelines.  
 
 
Experimental animals 
 
 
 
APP-KINL-G-F/NL-G-F mice were generated by Saito and Saido by knocking in a 
humanised Aβ sequence with three specific fAD mutations on a C57BL-6J 
background (Saito et al., 2014). The Swedish KM670/671NL mutation increases 
Aβ40 and Aβ42 creation, the Beyreuther/Iberian I716F mutation increases the Aβ42 
to Aβ40 ratio, and the Arctic mutation caused the mice to exhibit greater 
neuroinflammation and a swifter pathology (Citron et al., 1992; Guardia-Laguarta et 
al., 2010; Saito et al., 2014; Tsubuki et al., 2003). These mice therefore do not 
overexpress APP, but express wild type levels of APP from the endogenous mouse 
promoter with three fAD mutations, which gives progressive amyloid plaque 
deposition.  
 
All APP-KI mice used were housed and maintained in the RIKEN Brain Science 
Institute (Japan) by the Saido lab. Mice were housed 12 per cage (26 cm x 37 cm x 19 
cm), kept under standard housing condition in 12 hour light dark cycles, and allowed 
ad libitum access to food and water. Mice were sacrificed in Japan, and snap frozen 
tissue sent to us for analysis. All mice used were male. Wild type littermates were 
kept in identical conditions, and sent for comparison. 
 
TG4510 mice were generated by the Ashe lab (University of Minnesota) (Ramsden et 
al., 2005; Santacruz et al., 2005). These mice express a repressible form of human tau 
containing the P301L mutation (4R0N tau P301L), which in humans causes familial 
frontotemporal dementia (Hutton et al., 1998). The transgene is downstream of a 
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tetracycline operon–responsive element (TRE) under the Ca2+/ calmodulin dependent 
protein kinase II (CaMKII-α) promoter, with expression restricted to the forebrain 
(Ramsden et al., 2005; Santacruz et al., 2005). The mice used were the bitransgenic 
F1 progeny of responder transgene (TRE promoter upstream of mutated tau) and 
activator transgene (CaMKII-α upstream of tet-off open reading frame) mice, and 
expressed approximately 13 times the level of wild type murine tau. They are 
therefore an F1 mix of equal proportions of FVB/N (from one parental line), and 
C57BL-6 (from the other parental line). 
 
All TG4510 mice used were housed and maintained by Eisai Inc (Massachusetts). 
Mice were housed under standard conditions, under standard housing condition in 12 
hour light dark cycles, and allowed ad libitum access to food and water. Mice were 
sacrificed in the USA, and snap frozen tissue sent to us for analysis. All mice used 
were female. Wild type littermates were kept in identical conditions, and sent for 
comparison. 
 
Wild type animals used for testing Trametinib and GFP-S strain mice for organotypic 
slice preparation were from C57BL/6J colonies (Feng et al., 2000), kept in the 
University College London Biological Services Unit. Mice were housed 6 per cage 
from weaning, kept under standard housing condition in 12 hour light dark cycles, and 
allowed ad libitum access to food and water. All mice used were male. Processing of 
GFP-S mice for organotypic slices, and wild type mice following Trametinib 
treatment is discussed below. 
 
 
Primary cell cultures and organotypic brain slices 
 
 
 
Primary neuronal cultures 
 
 
 
Primary neuronal cultures were generated from C57BL/6J mice following a modified 
protocol from the protocol used by Dresbach et al (Dresbach et al., 2003). Postnatal 
mice between 0-1 days old (P0-P1) were killed by decapitation, with the brain quickly 
removed and placed in ice-cold dissection media (160mM NaCl, 5mM KCl, 1mM 
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MgSO4, 4mM CaCl2, 5mM HEPES, 5.5 mM glucose, 5µM phenol red, pH 7.4). 
Swiftly following brain removal, cortices and hippocampi were dissected under a 
light microscope in dissection media, and kept on ice in fresh dissection media. When 
all brains had been dissected, cortices and hippocampi were removed from dissection 
media diced, and incubated at 37oC for 30 minutes in enzymatic digestion media 
(dissection media, 1.5mM L-cysteine, 0.5mM EDTA, 5mM CaCl2, 30mM NaOH, 
100V papain, 1% DNaseI), with occasional agitation. Digested tissue was allowed to 
settle, digestion media removed, and inactivation media added (serum media (MEM 
w/Earle’s w/o l-glutamine, 5% fetal bovine serum (FBS), 0.4g/l glucose), 0.25%w/v 
bovine serum albumen (BSA)), for 2 minutes before removal, and then serum media 
was added. Cells were liberated from digested tissue via trituration, with the resulting 
cell suspension pipetted off from settled debris, pelleted at 1,000RPM for 5 minutes at 
room temperature, and then the pellet re-suspended, and plated at a density of either 
130,000/cm2 or 325,000/cm2 in poly-d-lysine coated 24 well plates, in neuron media 
(Neurobasal Media (ThermoFisher), 4% B27 with vitamin A, 1% Glutamax-I 
(ThermoFisher)).  
 
Half the neuron media was changed after 1 day and 7 days, and 10µM FUDR was 
added after 4 days to inhibit non-neuronal cell growth. From around 18-20 days, 
gradual cell death occurred in the cultures, so all experiments were performed on 
neurons between 10-17 days in vitro (10-17 DIV).  
 
 
Primary astrocyte cultures 
 
 
 
Primary astrocyte cultures were generated from C57-BL6 mice following the protocol 
of Schildge et al (Schildge et al., 2013). P2-P4 mice were killed via decapitation, with 
the brain quickly removed and placed in ice-cold HBSS. Following the removal of all 
brains, cortices and hippocampi were dissected and added to fresh ice cold HBSS. 
Dissected cortices and hippocampi were then diced, before being incubated at 37oC 
for 30 minutes with occasional agitation in digestion media (HBSS, 0.25% Trypsin). 
Following centrifugation at 300g for 5 minutes at room temperature, the supernatant 
was discarded, the pellet dissociated in glial media (high glucose DMEM, 10% FBS, 
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50 units Penicillin, 50µg Streptomycin), and mixed glia plated at 120,000/cm2 in a 
poly-d-lysine coated flask. Glial media was changed every 3 days.  
 
These mixed glial cultures were purified for astrocytes after 7 days by shaking at 
240RPM at 30oC in a heated shaker for 5 hours. This dislodged non-astrocyte glial 
cell allowing their removal, allowing pure astrocytes to be isolated via trypsinisation, 
and re-plated at a density of 120,000 cells/cm2 in 24 well plates. After a further 3-5 
days of incubations, a nearly confluent layer of astrocytes was present, which could 
then be used for our experiments.  
 
 
Forming bilaminar co-cultures  
 
 
 
To create bilaminar co-cultures, we modified the protocol of Shimizu et al (Shimizu 
et al., 2011). Primary neuronal and astrocyte cultures were grown separately as 
detailed above, with neuronal cultures grown on glass cover slips and astrocyte 
cultures grown on the bottom of 24 well plates. To facilitate cell death analysis, in 
some wells of the plate, astrocytes were grown at the same density but on glass cover 
slips. This was done to allow removal of astrocytes and neurons for PFA fixation, 
without negatively impacting on the other wells on the plate that were to be taken for 
protein or RNA. When neurons were 9-12 DIV, and astrocytes 11-20 DIV, the 
neuronal cover slips were suspended above the astrocyte cells by the addition of a 
small 3mm length of autoclaved plastic tubing to the bottom of each well of the 24 
well plate, before cover slips were inverted and placed on top (figure 4.1). The media 
in each well was changed from mixed glial media to neuronal media, with half the 
media (500µl) being from the well of the neuronal cover slip added, and half being 
fresh warmed neuron media.  
 
 
Organotypic brain slices 
 
 
 
Organotypic slices of the hippocampal formation were made from P5-7 C57BL-6 
GFP-S transgenic mice. Mice were decapitated and the brain swiftly removed into 
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cold slicing media (EBSS, 5mM HEPES). Removed brains were bisected down the 
midline, before angled sections 15% off midline were made from the dorsal surface, 
and this surface attached to the vibratome stage (Campden). This slice orientation 
preserved CA1 pyramidal neurons making these slices useful for examining these 
cells.  
Both hemispheres were glued to the vibratome stage and 300µm slices taken. The 
hippocampus was dissected out and transferred via glass pipette to 13mm filter paper 
(LCR 0.5µm; Millicell), sitting in inserts in 6 well culture plates (Millipore), three to a 
well. Each well contained 1 ml culture medium (50% MEM with Glutamax-1, 25% 
horse serum, 23% EBSS, 36.1 mM glucose, 50 units penicillin, 50 µg streptomycin 
and 6.25 units nystatin) that was changed three times a week. 
 
 
Culture treatments 
 
 
 
Dabrafenib and Trametinib treatment of primary neuronal and astrocyte cultures 
 
 
 
Once mature, primary neuronal and astrocyte cultures were treated with various 
concentrations of either Dabrafenib, Trametinib (Both Selleckchem), or the same 
volume of DMSO vehicle control. This was achieved by diluting 10µl of solution into 
40µl of fresh media, and adding this to the wells of treated cultures.  
 
 
 
Igf1 knockdown of bilaminar co-cultures 
 
 
 
Once bilaminar co-cultures were made, following 3-4 hours acclimatisation, the 
cultures were then treated with either siRNA against Igf1 (ThermoFisher, catalogue 
number 4390771) or non-targeting siRNA (Ambion, catalogue number 4457287). To 
transfect these cultures, 3µl/well Lipofectamine® RNAiMAX was diluted in 
50µl/well Opti-MEM®, with 5pM/well siRNA against either Igf1 or non-targeting 
siRNA was diluted in 50µl/well Opti-MEM®, before these dilutions were combined 
and incubated at room temperature for 5 minutes (all reagents from 
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LifeTechnologies). 50µl of Lipofectamine®-siRNA complex was then added to each 
well of treated cultures.  
 
 
 
 
Trametinib and dual Igf1 knockdown and Trametinib treatment of bilaminar cultures 
 
 
 
For sole Trametinib treatment, once bilaminar co-cultures were made, following 1 
hours acclimatisation, the cultures were then treated with either 10µM Trametinib 
dissolved in DMSO (1% final concentration DMSO), or 10µl of DMSO vehicle (1% 
final concentration DMSO), with both diluted by adding to 40µl neuron media before 
adding to the wells of treated cultures.  
 
For dual Trametinib and siRNA treatment, the outlined protocols for the sole 
administration of each treatment were both administered to the wells to be treated 
with both, with control wells being treated with both non-targeted siRNA and DMSO. 
 
 
Inducing cell stress via hypoxic condition exposure 
 
 
 
To apply a stressful hypoxic incident to our cultures, we modified the protocol 
outlined by Wang et al (Wang et al., 2014). Following the addition of Trametinib, 
siRNA, or vehicle, plates that were to be exposed to hypoxic condition were allowed 
to settle for 1 hour before being placed in hypoxic conditions. Plates were placed in 
between two sheets of heat sealable plastic, sealed using a heat sealer, and flushed for 
1 minute with 100% argon gas to displace oxygen. The bag was then sealed in an 
inflated state to allow easy observation of the preservation of a successful seal to the 
outside gaseous environment. Hypoxic bags were then placed within a cell culture 
chamber to maintain the cultures at 37oC. Cultures were exposed to hypoxic 
conditions for 5 hours, with the chamber purged of containing gas with argon once 
more after 2 ½ hours, and resealed. This purging step accounts for any dissolved gas 
coming out of solution during the previous two hours, therefore maintaining optimal 
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hypoxic conditions. At the end of the 5 hours in hypoxic conditions, plates were cut 
out of the sealed bag and placed back in the incubator.  
 
 
 
 
Molecular Biology and microscopy 
 
 
 
Mouse brain dissection  
 
 
 
For molecular biology examination of wild type mice treated with either Trametinib 
or vehicle, male wild type mice were decapitated and brains swiftly removed and 
dissected on ice. Following the isolation of cortex or hippocampus, tissue for protein 
and RNA analysis was immediately snap frozen on dry ice and stored at -80oC until 
required.  
 
For APP-KI and their relevant controls, brain samples sent from our collaborators 
were cut into segments whilst frozen and processed separately for protein or RNA. To 
achieve this, tissue was placed on a sterile petri dish on dry ice and one hemisphere of 
cortex was quartered from each sample. One quarter was then processed for protein, 
and another for RNA, with half of the brain kept at -80oC for future use if required. 
Samples were never allowed to thaw during this process. 
 
TG4510 samples had two hippocampal samples from each mouse separate, allowing 
analysis of either sample separately for protein or RNA.  
 
Human brain samples came in an eppendorf tube containing pieces of tissue, with one 
piece taken for protein and another for RNA. 
 
 
 
Brain tissue homogenisation for protein and gene expression analysis 
 
 
 
Mouse cortex, or hippocampus were sonicated (Branson sonifier, 450) for 30s at 9W 
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in ice cold RIPA buffer (1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 
0.15M NaCl, 20mM Tris.HCl (pH 7.4), 2mM EDTA (pH 8.0), 50mM sodium 
fluoride, 40mM β-glycerophosphate, 1mM EGTA (pH 8.0), 2mM sodium 
orthovanadate, 1mM PMSF, protease inhibitor tablet (Roche), 0.055 units aprotinin 
(Sigma), 1% phosphatase inhibitor cocktail (Sigma)). Samples were centrifuged at 
13,000RPM for 10 minutes twice, with supernatants kept each time and insoluble 
pellets disposed of. Half the volume of the resulting homogenate was separated and 
diluted with half the volume of 3X Laemmli buffer (188 mM Tris-Cl [pH 6.8], 3% 
SDS, 30% glycerol, 0.01% bromophenol blue, 15% β-mercaptoethanol) and boiled 
for 3 minutes before being stored at -20oC until required. Non-laemmli diluted 
homogenate was used for protein concentration quantification for each homogenate 
using the Bio-Rad Bradford protein assay by comparison to a standard curve 
generated from serial dilutions of bovine serum albumin. 
For gene expression analysis, mouse cortex or hippocampus samples were 
homogenised using a homogeniser for 30 seconds on ice using RNA lysis buffer 
(QIAGEN). Following homogenisation samples were aliquoted and stored at -80oC.  
 
 
 
Culture lysis to measure gene expression, cell signalling, and cell death changes in 
bilaminar cultures 
 
 
 
In solo astrocyte and neuronal cultures for protein and gene expression analysis, 
cultures were grown on the bottom of either 6 well or 24 well plates. To lyse wells for 
RNA and protein in bilaminar co-cultures, astrocytes were grown on the bottom of 
each well, with neurons suspended above on a glass coverslip. Coverslips were 
removed for lysis. For wells to be processed for fixation, astrocytes were also grown 
on coverslip and placed at the bottom of the well, with neurons once more suspended 
above them. These coverslips were removed to a new plate for fixation. 
 
To lyse for protein or RNA, neuronal cover slips were removed from above the 
astrocyte layer into different wells, and plates put on ice. Neuron and astrocyte 
cultures were then washed with ice-cold PBS 3 times, before 500µl RNA lysis buffer 
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(QIAGEN), or 75 µl of 2X Laemmli dye was pipetted onto the cultures. Cultures were 
then scraped with a pipette tip, incubated on ice for five minutes, scraped again, and 
then removed into 1.5ml eppendorf tubes. Duplicate wells had samples pooled, with 
RNA homogenate stored at -800C and protein homogenate boiled for 2 minutes in a 
heat block, and stored at -200C. 
 
For cell number counting in bilaminar co-cultures, cultures were fixed by adding 
500µl of 4% PFA to cultures containing 500µl media, and incubating for 15 minutes. 
Cultures were then washed 5 times with PBS, with PBS containing DAPI at a 
concentration of 1:10,000 used for the 4th wash. Cover slips were stored in PBS with 
0.02% sodium azide until imaged.  
 
 
Western blotting 
 
 
 
Protein samples were resolved by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) using 10% polyacrylamide gels with 15 well combs. For 
brain protein samples, proteins were diluted to a given weight, whereas culture 
homogenates were loaded blind onto the gel. A molecular weight ladder was also 
loaded to aid band identification (BioRad). Proteins were subsequently transferred to 
0.45µm nitrocellulose membrane (BioRad) by wet electrotransfer overnight at 30V.  
Following transfer, membranes were washed in Tris-buffered saline (30 mM NaCl, 
30mM Tris pH7.4)(TBS), blocked in 5% milk for 1 hour at room temperature, washed 
in TBS with 0.1% Tween-20 (TBST)(Sigma) 3 times for 5 minutes, and incubated in 
primary antibody in 5% milk/BSA in TBST overnight at 4°C (figure 2.1). Membranes 
were then washed in 0.1% TBST 3 more times for 5 minutes each, and then incubated 
in Horseradish peroxidase-conjugated secondary antibody specific to the species of 
the primary antibody (1:10000; Jackson ImmunoResearch) diluted in 5% milk in 
TBST for 1 hour at room temperature. Membranes were washed 3 more times for 5 
minutes in TBST before enhanced chemiluminescence detection kit (ECL, BioRad) 
was applied to the membrane for 4 minutes. Image acquisition and densitometric 
analysis was performed using ImageLab (v5.2, BioRad).  
Figure 2.1. Antibodies used for western blotting. A table of the specific antibodies 
used during western blotting, the supplier and product code, and the dilution they were 
used at. CST – Cell Signaling Technologies. 
Target 
Supplier and product 
code Dilution 
Phospho-Akt (Ser473) CST 4060 1:1000 
Phospho-Akt (Thr308) CST 2965 1:1000 
Total Akt CST 4691 1:1000 
Phospho-ERK1/2 
(Thr202/Tyr204) CST 9101 1:1000 
Total ERK1/2 CST 9102 1:1000 
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For phospho-protein density values, bands of interest were normalized against density 
values for total protein (e.g. pSer473-Akt normalized to total Akt). Total protein 
density values were normalized against total lane protein using the Ponceau S (Sigma 
Aldrich) stain.  
To immunoblot a membrane for both the phosphorylated and total protein, 
membranes were first probed for the phospho-protein, then stripped following 
chemiluminescence detection by agitating at 50oC in stripping buffer (60µM Tris 
base, 70µM Sodium dodecyl sulfate, 0.7% 2-Mercaptoethanol), before washing 6 
times for 5 minutes in TBST. The membrane was then ready for blocking, and re-
probing with primary antibody. 
 
Primer design and testing 
 
 
 
Primers for Igf1, IGF1, Rps28, and RPS28 were designed to span exon boundaries 
with PrimerBLAST (NCBI). Sequences were ordered with salt-free purification from 
Eurofins MWG Operon. Primers were tested in RT-PCR by incubating cDNA from 4-
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week-old wild type cortex with 0.25µM forward and reverse primers and 
SsoAdvanced PCR Mix (BioRad)  (cycling conditions 95oC-3 minutes, [95 oC-10s; 58 
oC-30s; 72 oC-30s] x40, 95 oC -1 minute), before running in a 3% agarose gel 
containing ethidium bromide and visualising using a Bio-Rad ChemiDoc MP imaging 
system.  
 
A single band of the correct size was observed for all primers, with bands being 
absent in controls where no reverse transcriptase was added to the reaction. Melt 
curve analysis was run on the product of a dilution series of cDNA, with qRT-PCR 
reactions containing SYBR green (Bio-Rad) allowing optimal cDNA concentrations 
to be used for each primer pair. A single peak corresponding to one product size was 
seen also for all primer pairs.  
 
 
 
RNA purification and cDNA conversion 
 
 
The mRNA samples were disrupted using a 21-gauge syringe and purified with the 
Qiagen miRNA easy mini kit treated with DNAse. cDNA was then made for each 
sample using the ThermoFisher High-Capacity cDNA reverse transcriptase kit, with a 
negative control reaction without reverse transcriptase also made to use as a control in 
RT-qPCR reactions.  
 
 
RT-qPCR 
 
 
 
To measure Igf1 expression levels in mouse brain homogenates, RT-qPCR was 
performed using 0.125 and 0.033 times dilutions of cDNA (0.05mg/ml stock 
concentration) for Igf1 and Rps28 respectively, using SYBR Green PCR Mix 
(BioRad) with the above cycling conditions in the CFX96 touch qRT-PCR detection 
system (Bio-Rad), and the same concentration of forward and reverse primers. For 
IGF1 expression in human brain samples identicle conditions were used, with the 
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exception of cDNA dilutions of 0.33 and 0.033 dilutions were used for IGF1 and 
RPS28 primers respectively. For cell culture lysates there was no dilution of cDNA. 
 
Samples were tested in triplicate with a no-RT control in a 96 well plate, with raw 
cycle threshold (CT) expression values normalised to Rps28 expression values.  
 
 
DAPI cell counting 
 
 
 
PFA fixed cover slips were imaged for DAPI staining in 4 areas of each coverslip at 
10X magnification on an EVOS® FL Auto Cell Imaging System (Life technologies). 
Images were then processed for counting using ImageJ (v1.48) by converting images 
to 8-bit format and counting using the Analyse Particles function. 
 
Dendritic spine imaging 
 
 
Organotypic slices were transferred to the chamber of a confocal microscope 
(Olympus Fluoview), and 30oC carbogen aerated artificial cerebral spinal fluid 
(ACSF)(125mM NaCl, 2.5mM KCl, 1.25mM NaH2PO4, 26mM NaHCO3, 2mM 
CaCl2, 1mM MgCl2, 25mM glucose) was circulated over the slice at a rate of 
1ml/minute. Using a mercury lamp fluorescent CA1 pyramidal cells of the 
hippocampus were located and suitable dendritic processes identified. Using the 
confocal microscope and the FluoView software (Olympus), dendritic processes were 
imaged at 60X magnification (water immersion Zeiss objective, NA 0.9) by taking 
images of a selected x y area at 3X mechanical zoom, and imaging at 0.2µm z axis 
steps until the complete dendrite was imaged. 
Dendritic spines were then counted manually by scrolling through image stacks using 
the ImageJ software, and the spine density calculated by dividing by the dendrite 
length. 
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Statistical analysis  
 
 
 
All statistical analysis was performed using Prism v6.2 (Graphpad Software Inc). 
Testing for significance between means was done using the Student’s t-test when 
individual comparisons were made, when multiple comparisons were made (e.g. 
within a plate of bilaminar co-cultures), 2-way ANOVA was performed. 
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Chapter 3 
 
Characterising endogenous changes to the Insulin and Insulin-like 
Signalling Cascade in Alzheimer’s disease 
 
 
Introduction  
 
The level of signalling through the Insulin and Insulin-like signalling (IIS) cascade 
can modulate the rate of ageing, with reductions in IIS by genetic and 
pharmacological means producing organisms with substantially increased life spans 
(Bjedov et al., 2010; Harrison et al., 2009; Holzenberger et al., 2003; Kenyon et al., 
1993; Slack et al., 2015; Tatar et al., 2001). Crucially this increase in lifespan is 
accompanied by an increase in healthspan, meaning a longer duration of healthy 
disease free life for these long-lived organisms. When genetically long-lived 
organisms are crossed with animal models of Alzheimer’s disease (AD) and 
Parkinson’s disease (PD), the progression of the neurodegenerative pathology is 
slowed, and neuronal cell loss is reduced (Cohen et al., 2006; Cohen et al., 2009; 
Cooper et al., 2015). This protection against neurodegeneration has also been 
demonstrated using pharmacological IIS inhibitors applied to animal models of 
neurodegenerative disease (Ashabi et al., 2013; Echeverria et al., 2009; Gladbach et 
al., 2014). This suggests that IIS inhibitors could be used therapeutically to ameliorate 
neurodegeneration, and this forms our overall hypothesis.  
 
With acute neurodegenerative diseases such as stroke and traumatic brain injury 
(TBI), the therapeutic window for intervention is small and well defined, and 
therefore the timing of potential IIS modulating therapies is straightforward. This is 
not so for chronic neurodegenerative diseases however, as disease pathogenesis and 
neuronal cell loss occurs over a far more extended time frame. Before IIS modulating 
therapies can be investigated in chronic neurodegenerative diseases therefore, the 
appropriate time point for IIS modulator application must be ascertained. We chose to 
do this for AD specifically, as this is the most prevalent chronic neurodegenerative 
disease. 
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AD has a long disease time course, including a long prodromal period with substantial 
neuronal cell loss present by diagnosis (Fox et al., 1996). Improved therapeutics are 
grossly lacking for this disease, with IIS modulating therapies therefore representing a 
novel approach to AD therapeutics. Endogenous alterations in IIS have been observed 
in the AD brain however (Ferrer et al., 2001; Steen et al., 2005; Talbot et al., 2012), 
and these alterations could interfere with or directly oppose any intended 
pharmacological IIS intervention. For example, brain IIS resistance could limit the 
efficacy of IIS stimulating therapies. Similarly, if these changes contribute to the 
pathological progression of these diseases, identifying the time point of these changes 
can aid the correct timing of IIS intervention therapies. Current characterisations of 
endogenous IIS changes in AD have focused on post mortem brain tissue, but these 
samples are from the very end stage of disease progression (Ferrer et al., 2001; Steen 
et al., 2005; Talbot et al., 2012). As it seems likely that successful AD therapies will 
have to be applied earlier in disease progression, it is crucial to consider IIS 
alterations earlier as well as later in the disease.  A more extensive characterisation 
will therefore aid us in avoiding the application of IIS modulating therapies at time 
points where endogenous IIS alterations may limit the efficacy of our proposed 
interventions. 
 
In order to best test our overall hypothesis in AD, we have therefore established how 
the IIS cascade is endogenously changed at different stages of AD pathogenesis, 
meaning that we have examined earlier pathological stages in AD than has previously 
been reported.  
 
 
Aims  
 
 
The aim of this chapter is to characterise the endogenous changes in the IIS cascade at 
different pathological components of AD, to aid the future testing of our main 
hypothesis; that IIS modulating therapies can ameliorate neuronal cell loss in 
neurodegeneration. This characterisation will include pathological stages of AD that 
are yet unexamined, that being early stages of disease development, which correspond 
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to pre-diagnosis AD. By identifying endogenous IIS changes that could interfere with 
our proposed IIS interventions, this characterisation will allow the optimisation of the 
timing for future IIS modulating therapies in AD. 
 
 
Methods  
 
 
To characterise IIS changes at multiple points in the disease time course we utilised 
two different mouse models of pathological components of dementia, representing 
different pathological stages of disease development in relation to human pathology. 
Given the temporal distinction in the development of these neuropathological 
hallmarks in human AD, with amyloid pathology preceding tau pathology, we 
examined IIS changes in response to amyloid and tau pathology individually, and 
finally measured IIS changes in post mortem human brain samples to characterise IIS 
changes at the end stage of AD development. We were therefore able to characterise 
endogenous IIS changes at different pathological stages of AD development. 
 
To model progressive amyloid pathology, we used the APP-KINL-G-F/NL-G-F (APP-KI) 
mouse model showing a progressive increase in Aβ40 and Aβ42 levels and subsequent 
progressing amyloid plaque deposition (Saito et al., 2014). We examined IIS changes 
at 2, 4, and 8 months of age in cortical tissue from male animals, which corresponds 
to the very beginning of amyloid pathology (increasing Aβ40 and Aβ42 and the first 
small amyloid plaques) at 2 months, midrange amyloidosis (increasing plaque 
number) at 4 months, and heavy amyloid pathology at 8 months (maximal plaque 
deposition)(Saito et al., 2014). To model progressive tau pathology we used the 
TG4510 mouse model, which shows progressive tau hyperphosphorylation and tangle 
accumulation, accompanied by extensive neuronal cell loss (Ramsden et al., 2005; 
Santacruz et al., 2005). This is a rapidly progressing disease model, with over 75% of 
hippocampal pyramidal neurons lost by 8 months of age. We examined IIS changes at 
2.5 months and 8 months in the hippocampus of female animals, corresponding to 
early tau pathology (increased p-Tau levels and pretangle development) and very late 
stage tau pathology (heavy tangle formation and substantial neuronal cell loss). These 
Figure 3.1. Details of the human brain samples used. Human frontal cortex samples 
from fAD, sAD, and non-demented control brain were used for analyzing the IIS 
cascade, with these samples coming from varying age and gender donors. 
Disease state Age Gender 
Familial AD 66 Male 
Familial AD 58 Female 
Familial AD 59 Female 
Sporadic AD 68 Female 
Sporadic AD 76 Female 
Sporadic AD 79 Female 
Control 56 Female 
Control 69 Male 
Control 68 Female 
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IIS changes were all made in comparison to wild type age matched mice of the same 
gender and mouse strain. Finally, as a preliminary means of examining final stage 
endogenous IIS changes, we examined post mortem human frontal cortex samples 
from fAD and sAD patients and non-demented controls, the patient details which can 
be seen in figure 3.1. In the future, further experimentation of this type will take place 
with a larger number of patient samples. Thorough descriptions of mouse models and 
how they correspond to human AD neuropathology, as well as the source of tissue 
used, is covered in chapter 1.  
 
To assess the levels of IIS signalling in these tissues, we examined multiple points in 
the IIS cascade.  As changes in IGF1 level have been repeatedly observed in 
neurodegenerative disorders (Beilharz et al., 1998; Connor et al., 1997; Madathil et 
al., 2013; Steen et al., 2005), we measured both IGF1 and Igf1 expression in the  
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human and mouse brain tissue via RT-qPCR. To examine signalling through both 
branches of the IIS cascade, we carried out western blotting using antibodies for the 
activation phosphorylation sites pS473 and pT308 on Akt (pS-Akt and pT-Akt) in the 
PI3K-Akt pathway (Alessi et al., 1996), and pT202/pY204 and pT185/pY187 on 
ERK1/2 (p-ERK) in the Ras-MAPK pathway (Canagarajah et al., 1997; Payne et al., 
1991). The level of phosphorylation at these sites was normalised by using total Akt 
and ERK1/2 protein antibodies, to account for possible changes in total Akt and 
ERK1/2 level in response to AD pathology. To establish if levels of total Akt or 
ERK1/2 were changed, we normalised Akt and ERK1/2 levels against total loaded 
protein using the Ponceau S stain. Levels of phosphorylation at Akt and ERK1/2 gave 
an indication of the level of signalling through each branch of the IIS cascade under 
different AD pathological conditions.  
 
 
Hypotheses 
 
 
1. The primary hypothesis underlying the experiments in this chapter is that as 
amyloid and tau pathology increase in the AD brain, the IIS cascade will be 
endogenously changed, and that the changes will differ at different stages of 
AD pathogenesis.  
2. Given the previous changes observed in the IIS cascade in neurodegeneration 
and AD, we hypothesised that increased IGF1 will be observed in human AD 
brains as well as increased Igf1 in the APP-KI and TG4510 models, with 
expression increasing with pathological progression in these models.  
3. With the implications of increased p-ERK levels in neuronal cell death, we 
also hypothesised that increased p-ERK levels will be observable in 2.5-month 
TG4510 tissue as neurotoxic tau species are beginning to occur. With 
extensive neuronal cell death present in the 8 month TG4510 and human AD 
brain, and neuronal cell death associated p-ERK increases likely lost once 
neurons die, significant increases in p-ERK levels were not predicted to be 
detectable in these samples. With limited neuronal cell loss reported in the 
APP-KI mouse model, we do not expect to see changes in p-ERK level in the 
brains of these animals.  
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Figure 3.2. Cortical Igf1 expression in APP-KI and wild type mice at 2, 4, and 8 
months of age. Igf1 is significantly increased in its expression in the cortex of APP-KI 
mice at 2 and 8 months, as measured by RT-qPCR. n=3 in all groups. Data shown is the 
mean +/- SEM. Student’s t-test * p<0.05 ** p<0.01 *** p<0.001. 
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Results 
 
 
Effects of progressive amyloid beta pathology on brain IIS signalling  
 
 
Igf1 expression levels as measured by RT-qPCR, showed a significant increase in 
expression in the cortex of APP-KI mice at 2 and 8 months, but not at 4 months, with 
an 84% increase at 2 months, and 160% increase at 8 months (fig 3.2, 2-months 
p=0.0481, 8-months p=0.0090). This therefore shows that Igf1 expression is raised in 
response to early increases in amyloid-beta elevation, and at late stage maximal 
plaque deposition, but not in intermediate stages of amyloid pathology. With 
increased Igf1 in 2 and 8 months we would expect to see a corresponding increase in 
signalling in the IIS cascade. 
 
Examining the levels of pS-Akt, pT-Akt and p-ERK by western blotting in the cortex 
of APP-KI and wild type mice allowed us to examine changes in signalling in both 
branches of the IIS cascade. In the cortex of 2-month APP-KI mice, there was  
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significantly increased phosphorylation at both Akt and ERK1/2 compared to that 
seen in wild type mice, with both activating phosphorylation sites on Akt increased in 
their level of phosphorylation (figure 3.3, p-ERK p=0.0008, pS-Akt p=0.0201, pT-
Akt p=0.0437). A 12-fold increase was seen in p-ERK levels, and a 2.8 fold increase 
in both pS-Akt and pT-Akt levels. This indicates that not only is Igf1 significantly 
increased in expression, but also that this may be increasing signalling through the IIS 
cascade in the cortex of the APP-KI mice.  
 
In the 4 month and 8 month mice however, the levels of phosphorylation at Akt and 
ERK1/2 did not significantly differ between the APP-KI and wild type mice (figure 
3.4). In the 4-month samples this was consistent with the lack of increase in the 
upstream activator Igf1’s expression. In the 8-month sample however, a very large 
increase in Igf1 expression is observed whilst there is a lack of increase in activation 
in the IIS cascade. This implies that the Igf1 increase is not activating the cascade. 
This is noteworthy as this may be supportive evidence for acquired Igf1 resistance as 
observed in previous studies (Talbot et al., 2012), although without testing on ex vivo 
tissue as was carried out in the Talbot et al paper, we cannot confirm whether this is 
the case. There was no change in total Akt or ERK1/2 protein level in any samples 
compared to wild type controls. These data suggest that early amyloid-beta elevation 
induces an increase in Igf1 expression accompanied by a substantial increase of 
signalling through both branches of the IIS cascade. By the time plaque deposition 
has reached saturation and the brain has a high number of plaques however, whilst 
Igf1 expression is again increased, the accompanying increased IIS signalling is not 
observable in either branch of the pathway suggesting resistance.  
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Figure 3.3. Changes in ERK1/2 and Akt phosphorylation in the cortex of 2 month 
old APP-KI mice. Significantly higher phosphorylation at ERK1/2 and Akt is 
observable in the cortex of 2 month old APP-KI mice compared with age matched wild 
type controls. In all (i) Representative western blot images (ii) Graphical representation 
of western blot data. (A) Significantly higher p-ERK levels are present in APP-KI tissue 
(B) Levels of phosphorylation are significantly higher at both activating sites on Akt. 
n=3 in all groups. Data shown is the mean +/- SEM. Student’s t-test * p<0.05 ** p<0.01 
*** p<0.001. 
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Figure 3.4. There are no changes in ERK1/2 and Akt signaling in the cortex of 4 and month old 
APP-KI mice. No significant change in IIS signaling is seen at ERK1/2 or Akt in the cortex of 4 or 8 
month old APP-KI mice compared with age matched wild type controls. In all (i) Representative 
western blot images (ii) Graphical representation of western blot data. (A) p-ERK levels are not 
significantly changed in APP-KI tissue (B) Levels of phosphorylation at both activating sites on Akt 
are not significantly altered in APP-KI mice. n=3 in all groups. Data shown is the mean +/- SEM. 
Student’s t-test * p<0.05 ** p<0.01 *** p<0.001. 
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Effects of rising hyperphosphorylated tau and neuronal cell loss of brain IIS 
signalling 
 
 
Using RT-qPCR, Igf1 expression was found to be significantly higher in the 8-month 
TG4510 hippocampus as compared to wild type tissue, but Igf1 expression was not 
significantly altered in 2.5-month TG4510 animals (fig 3.5, p=0.0005). This suggests 
that pretangles and tau hyperphosphorylation is not accompanied by increased Igf1 
expression, but the severe tau pathology and neurodegeneration seen by 8 months is 
accompanied by a substantial increase in expression, with a 70% increase observed in 
TG4510 tissue at this age.  
 
When signalling through the IIS cascade was measured, a significant increase in p-
ERK levels was observed between wild type and TG4510 tissue at 2.5-months but not 
8-months (fig 3.6, p=0.0035). A pattern of decreased Akt phosphorylation was 
observable at 2.5 and 8 months in TG4510 hippocampus (fig 3.6, pS-Akt 2.5-months 
p=0.0137. pT-Akt 8-months p=0.0099). There was a significant reduction in pS-Akt 
levels in 2.5-month TG4510 hippocampal samples (30% reduction), and a significant 
reduction in pT-Akt levels in 8-month TG4510 hippocampal samples (75% 
reduction). There was no change in total Akt or ERK1/2 protein level in any samples 
compared to wild type controls. Therefore whilst Igf1 expression is not changed at 2.5 
months but is increased at 8 months in TG4510 tissue, a significant reduction in Akt 
phosphorylation is observable at both time points albeit at different activating 
phosphorylation sites, with an early increase in p-ERK levels also present.  
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Figure 3.5. Hippocampal Igf1 expression in TG4510 and wild type mice at 2.5 and 8 
months of age. Igf1 is significantly increased in its expression in the hippocampus of 
TG4510 mice at 8 months but not at 2.5 months, as measured by RT-qPCR. n=5 in all 
groups. Data shown is the mean +/- SEM. Student’s t-test * p<0.05 ** p<0.01 *** p<0.001. 
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Figure 3.6. Phosphorylation levels of ERK1/2 and Akt in the hippocampus of 2.5 and 8 
month old TG4510 mice. Significant changes in Akt and ERK1/2 phosphorylation are seen 
in the hippocampus of TG4510 mice compared with age matched wild type controls. pS-Akt 
levels were significantly reduced at 2.5 months in TG4510 animals, with pT-Akt levels 
significantly reduced at 8 months. p-ERK levels are significantly increase in the 2.5 month 
TG4510 hippocampus. In all (i) Representative western blot images (ii) Graphical 
representation of western blot data. (A) p-ERK levels (B) pS-Akt and pT-Akt levels. n=5 in 
all groups. Data shown is the mean +/- SEM. Student’s t-test * p<0.05 ** p<0.01 *** 
p<0.001. 
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Changes in the IIS cascade in post mortem human brain tissue 
 
 
IGF1 mRNA levels were measured in fAD, sAD and non-demented control frontal 
cortex samples by RT-qPCR. Although we hypothesised that IGF1 levels would be 
increased in human AD brain tissue, there was no significant difference in IGF1 
expression levels between non-AD samples and either AD group (fig 3.7). If data 
from fAD and sAD samples was pooled as a single AD group increasing the power of 
the analysis, there was still no significant difference in IGF1 expression compared to 
non-demented controls. 
 
Levels of signalling through the IIS cascade in frontal cortex sample from fAD and 
sAD human patients were largely not significantly different compared to non-AD 
control samples, but in contrast to late stage TG4510 tissue, a significant increase in 
pT-Akt was seen in fAD (fig 3.8, p=0.0181,). If considered as a pooled AD group 
once more, there was no significant change in phosphorylation level at Akt or 
ERK1/2, with the previous significant increase in pT-Akt level in fAD tissue only 
showing a trend towards significance in the pooled AD group (p=0.0637). Whilst 
levels of phosphorylation at ERK1/2 and at pS-Akt were very steady in all samples, 
the pT-Akt levels varied widely in AD samples, with 2 out of 3 sAD samples 
increasing substantially, and all 3 fAD samples increasing in phosphorylation level.  
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Figure 3.7. Frontal cortex Igf1 expression in human brain samples from fAD, sAD 
and non-demented control patients. Igf1 is not significantly increased in its expression 
in the frontal cortex in either the fAD or sAD brain samples tested, as measured by RT-
qPCR. n=3 in all groups. Data shown is the mean +/- SEM. Student’s t-test * p<0.05 ** 
p<0.01 *** p<0.001. 
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Figure 3.8. ERK1/2 and Akt phosphorylation levels in the frontal cortex of human 
fAD, sAD, and non-demented controls. Significantly higher levels of phosphorylation 
at pT-Akt is observable in the frontal cortex of fAD patient brain samples compared with 
non-demented controls, although p-ERK and pS-Akt levels are not significantly altered. 
In all (i) Representative western blot images (ii) Graphical representation of western blot 
data. (A) No changes in p-ERK levels are present in fAD or sAD tissue (B) Levels of 
pT-Akt are significantly higher in fAD samples but not sAD, with pS-Akt levels being 
unchanged between groups. n=3 in all groups. Data shown is the mean +/- SEM. 
Student’s t-test * p<0.05 ** p<0.01 *** p<0.001. 
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Summary 
 
 
The overall aim of this thesis is to investigate the potential for IIS modulating 
interventions to be used as a means of positively modulating neuronal cell loss in 
neurodegeneration. In chronic neurodegenerative disorders the development of 
disease pathology occurs over a very protracted time frame, and endogenous IIS 
alterations have previously been reported in human post mortem AD brain tissue. In 
order to eventually successfully investigate our overall hypothesis in AD, we sought 
to characterise endogenous IIS changes in response to different pathological 
components of AD, that being progressive amyloid and tau pathology. This allows us 
to identify the appropriate time point in AD development for future testing of IIS 
based interventions, and therefore lays the foundation for future experimentation. In 
particular, by examining amyloid pathology alone in mice, it allowed an examination 
of earlier stages of AD development than is possible if just examining post mortem 
human tissue. The results of this chapter identified three points in AD pathology 
where a significant alteration in IIS is present, as well as identifying a more general 
pattern of increased Igf1 expression with pathological development of amyloid and 
tau (fig 3.9).  
 
The greatest change in IIS in the pathological stages of AD examined was during 
early rising amyloid pathology, as modelled by 2-month APP-KI mice (fig 3.9, A). At 
this point there is an increase in Aβ40 and Aβ42 levels as well as the first observable 
small amyloid plaques (Saito et al., 2014). This pathology is most similar to amyloid 
pathology decades before diagnosis, as by diagnosis far greater plaque deposition is 
present in the brains of patients. This early amyloid pathology induced an increase in 
Igf1 expression, and also a strong increase in phosphorylation at Akt and ERK1/2, 
with a particularly dramatic increase in p-ERK. This was unexpected. We 
hypothesised that Igf1 expression would increase with pathology accumulation, and 
yet at a disease stage with minor pathology, and no neuronal cell loss, a significant 
increase in Igf1 expression was observed. Similarly, whilst IGF1 is known to increase 
IIS signalling, such a strong increase in ERK1/2 signalling was hypothesised to occur 
when neuronal cell death was occurring, yet there is no neuronal cell death at this 
time point in this model. This suggests that whilst increased p-ERK has been  
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Figure 3.9. Changes in IIS at different pathological stages of AD. Diagrammatic 
representation of the changes in the IIS cascade at different points in AD pathogenesis. 
(A) Early rising Aβ has the most substantial effect on IIS with increased p-Akt, p-ERK, 
and increased Igf1 expression (B) At both early and late tau pathology, a decrease in p-
Akt is observable, albeit at pS-Akt in early pathology, and pT-Akt in late (C) At late 
stage AD in post mortem human tissue, increased pT-Akt is observable in fAD frontal 
cortex samples, but not sAD. Red represents increased signalling, blue represents a 
decreased signalling.  
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associated with neuronal cell death (Subramaniam and Unsicker, 2010), and increased 
p-ERK has been shown in the late stage human AD brain (Perry et al., 1999), 
substantial increases are also present at far earlier stages in pathological AD 
development, at least in the mouse. The physiological impact of these changes on AD 
disease progression is impossible to currently tell, but it seems that there is a strong 
response in IIS to the very early stages of amyloid pathology.  
 
IIS change was also observed when the first tau pretangle pathology developed in the 
2.5-month TG4510 mice, and also when advanced tau pathology and neuronal cell 
loss was present in 8-month TG4510 mice (fig 3.9, B). Whilst there was no increase 
in Igf1 expression at 2.5 months, there was a significant reduction in Akt 
phosphorylation and a significant increase in ERK1/2 phosphorylation, implying a 
reduction in signalling through this branch of IIS. This reduced Akt signalling was 
observed at late stage tau pathology also, but this was also accompanied by increased 
Igf1 expression. It is interesting to note that there was an increase in ERK 
phosphorylation levels but a decrease in Akt phosphorylation levels, showing that the 
branches of the IIS cascade can be independently modulated in their levels of 
signalling. Our hypothesis of increase p-ERK level with the start of neuronal loss in 
2.5-month TG4510 mice was correct, and also there was no p-ERK increase during 
more advanced tau pathology in 8-month TG4510 mice. With tangle containing 
neurons previously being shown to contain high p-ERK staining in human tissue 
(Perry et al., 1999), our 8-month TG4510 findings are at odds with previous data.  
 
Whilst examining phosphorylation levels of key IIS members as well as expression 
levels, gives an idea as to the level of signalling through this cascade, a future 
confirmation experiment should be carried out looking at changes in downstream 
expression levels of genes whose expression is affected by IIS level. For example, 
measuring expression levels of genes encoded by the FOXO transcription factors, 
such as Superoxide Dismutase 2 (SOD2) or the cell cycle regulator protein p27 
(Cdkn1b) by RT-qPCR would allow a downstream examination of IIS in these 
animals. If IIS is inhibited and increase in these genes expression would be expected.  
 
Overall our data from animal models of pathological features of AD suggests a 
difference in endogenous IIS alteration in response to increasing tau pathology 
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compared with the changes seen in response to increasing amyloid pathology, 
although the Igf1 expression increase is observed in both.  
 
In the latest stage of AD pathology that we could examine, that being post mortem 
human brain tissue, another pattern of IIS change was observed (fig 3.9, C). No 
increase in IGF1 was observed, with the only change in IIS signalling being an 
increase in pT-Akt levels. This differs from previous evidence of an observed 
decrease in Akt phosphorylation in the human AD brain (Steen et al., 2005), and 
increased IGF1 (Connor et al., 1997). As hypothesised, no increase was observed in 
p-ERK level in AD samples compared to non-AD controls. This difference to 
previous literature is likely a product of sample size, with our preliminary 
investigation only using 3 samples for each group, whereas most human data studies 
use hundreds of samples. Also, whilst data from mouse studies is examining 
differences in genetically and environmentally identical animals, data from humans is 
from genetically and environmentally heterogeneous samples, with the cause of death 
and comorbidities of samples unknown. Furthermore, IGF1 expression can be 
regulated at levels other than expression level.  
 
Overall, we have demonstrated that the IIS cascade is endogenously altered 
differently in response to different pathological components of AD. This 
characterisation has allowed the more appropriate timings of IIS modulating 
interventions to test our overall hypothesis in the future.  											
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Chapter 4 
 
 
Implications of increased Igf1 expression on acute neurodegeneration 
 
 
 
Introduction 
 
 
 
The overall hypothesis of this thesis is that IIS modulating interventions could be 
exploited for therapeutic gain in neurodegenerative disorders, and potential provide 
novel therapeutic options. Investigating this overall hypothesis is simpler with regards 
to the timing of intervention in acute neurodegenerative diseases (e.g. stroke, TBI) 
compared to chronic neurodegenerative disorders (e.g. AD, PD), as neuronal cell loss 
occurs immediately following the noxious incident, and then at a slower rate in 
subsequent weeks. Interventions to ameliorate neuronal cell loss must therefore occur 
within this time frame. The most appropriate way to modulate IIS during this period 
that could modulate neuronal cell loss in acute neurodegenerative diseases must now 
be investigated. 
 
Increased IGF1 protein and IGF1 expression, particularly in astrocytes, has been 
observed in a multitude of both chronic and acute neurodegenerative diseases 
(Beilharz et al., 1998; Connor et al., 1997; Li et al., 1998; Madathil et al., 2010; 
Nieto-Sampedro et al., 1982; Sandberg Nordqvist et al., 1996; Walter et al., 1997; 
Yao et al., 1995). Crucially this increased IGF1 is proximal to the source of injury in 
acute neurodegenerative disorders (Beilharz et al., 1998; Madathil et al., 2010). How 
this increased IGF1 impacts on neurodegeneration however is unclear.  
 
IGF1 can act as a survival factor in the adult brain. Exogenous administration of 
IGF1, or the overexpression of IGF1, is protective against neuronal cell death 
following a noxious stimulus in animal models of stroke and TBI (Carro et al., 2006; 
Guan et al., 2000; Guan et al., 1993; Johnston et al., 1996; Madathil et al., 2013). This 
pro-survival effect seems to have a dose response relationship however, where low 
levels of IGF1 administration elicited no neuroprotection against injury (Bergstedt 
and Wieloch, 1993; Johnston et al., 1996). Presumably the locally secreted IGF1 from 
astrocytes will be at low concentrations, meaning that interpreting the survival effect 
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of the observed endogenously raised astrocyte IGF1 is difficult to interpret in relation 
to these previous experiments.  
 
IGF1 is a potent activating factor of signalling through the IIS cascade (Laviola et al., 
2007). Reducing IIS signalling by genetic and pharmacological means however, has 
proved beneficial and neuroprotective in neurodegenerative disease models (Cohen et 
al., 2006; Cohen et al., 2009; Cooper et al., 2015; Freude et al., 2009; Killick et al., 
2009). With increased astrocyte IGF1 presumably increasing signalling through the 
IIS cascade in the brain, it would appear to have the opposite of the above protective 
effect, and perhaps instead contribute to neurodegeneration. 
 
There seems to therefore be a contradiction in the field, whereby pharmacologically 
and genetically lowering IIS signalling seems protective against neurodegeneration, 
and yet administering activators of this cascade also seem beneficial. A possible 
resolution to this conflict could be that an IGF1 resistant state and therefore reduced 
signalling through the cascade is beneficial, and that the exogenous administration of 
IGF1 thereby induces a resistant state. Whether this resistant state would be induced 
in such an acute time frame as that of the time that neuronal cell loss occurs in acute 
neurodegeneration, and whether local endogenous IGF1 release would be sufficient to 
stimulate this however, is unclear.    
 
Whilst most of these attempts to define the benefit of alterations to the IIS cascade in 
neurodegeneration have focused on enforcing gross changes on the system, all have 
overlooked the possible endogenous effects caused by the local IGF1 increase in 
astrocytes proximal to the site of noxious stimuli. With the IIS cascade being heavily 
implicated in neuronal cell death and neurodegeneration, and the apparent ubiquity of 
the IGF1 increase in acute neurodegenerative disorders, this endogenous IGF1 
increase could be modulated as a means of altering the IIS cascade to affect 
neurodegeneration. In this chapter we have investigated the implications of 
endogenous IGF1 increase on neurodegeneration.  
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Aims 
 
 
The aim of this chapter is to study the effect that raised astrocyte Igf1 during 
neurodegeneration has on neurodegeneration itself. To understand the mechanism 
behind any association, we have investigated how changes in neuronal cell death and 
neuronal number relate to IIS signalling changes in both neurons and astrocytes.  
 
 
Methods 
 
 
 
To investigate the effect that raised Igf1 had on neurodegeneration in acute 
neurodegenerative disorders, we developed an in vitro model of acute 
neurodegeneration that allowed us to induce neuronal cell loss and an increase in 
astrocyte Igf1, and subsequently modulated this expression via Igf1 siRNA knock 
down.  
 
The design of this in vitro model of acute neurodegeneration was based on the neuron 
astrocyte bilaminar co-culture model outlined by Shimizu et al, whereby primary 
astrocyte and neuron cultures are grown separately until mature, and then combined in 
one well, by suspending a coverslip with primary neurons attached above an astrocyte 
culture grown in the bottom of the well (figure 4.1 A)(Shimizu et al., 2011). The 
source of these cells was not a rat however, but generated from postnatal mice, 
modified from the protocols of Schildge et al and the primary neuron protocol used 
by Dresbach et al (Dresbach et al., 2003; Schildge et al., 2013). The generation of 
primary astrocytes and primary neurons, as well as their adaptation into bilaminar co-
cultures, is outlined in detail in the materials and methods chapter. Both primary 
neuron and astrocyte cultures were derived from dissected mouse cortices and 
hippocampi.  
 
To model acute neurodegeneration in these cultures they were exposed to hypoxic 
conditions for 5 hours. Cell number, Igf1 expression, and IIS signalling were then 
measured at 24 and 72 hours after the cessation of the hypoxic incident (figure 4.1 
B)(hypoxic cultures). These factors were also measured in co-cultures kept in 
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normoxic conditions for comparison (normoxic cultures). In our knock down 
cultures, siRNA against Igf1 was administered one hour prior to cultures entering 
hypoxic conditions, and for the same length of time in normoxic conditions, to 
examine any effect of knock down alone on cultures. In each plate wells were either 
treated with siRNA specific to the Igf1 sequence (knock down cultures), or non-
targeted siRNA as a control (control cultures). Therefore one plate was used for 
normoxic comparison, and a plate each for the 24 and 72-hour post hypoxia time 
points. On each plate were 2 wells to be lysed for RNA, 2 for protein, and one well 
for PFA fixation and DAPI staining (figure 4.1 B). This allowed a direct comparison 
between cell number, Igf1 expression and IIS signalling level, in wells either under 
control of knock down conditions within the same plate. Comparisons following 
hypoxia (in the 24 and 72 hour post hypoxia plates) are made relative to the normoxic 
control cultures. This also allows inter-experiment variability in the density of 
neuronal cultures to be accounted for, allowing a more sensitive detection of changes 
within experiments. 
 
To examine change in cell number and signalling through the IIS cascade in these 
cultures, we took cells for RNA, protein, and PFA fixed coverslips for DAPI staining 
(figure 4.1 C). To examine changes in signalling levels through the IIS cascade, we 
performed western blotting on our protein samples for specific activating 
phosphorylation sites on key members of the cascade, that being pS473 on Akt (pS-
Akt) (Alessi et al., 1996), and pT202/pY204 and pT185/pY187 on ERK1/2 (p-
ERK)(Canagarajah et al., 1997; Payne et al., 1991), and normalised these levels to 
total protein Akt and ERK1/2 levels. Western blotting for cleaved caspase 3 (CC3) 
was also performed on protein samples to examine levels of apoptosis. Igf1 
expression was assessed by RT-qPCR, and cell number was assessed by counting 
DAPI stained cells under a light microscope. 
 
 
Hypotheses 
 
 
 
1. The primary hypothesis in this chapter is that the endogenous Igf1 increase 
observed in acute neurodegenerative diseases contributes to neuronal cell 
death. 
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neurodegeneration and our experimental layout. (A) Model of a well of a bilaminar co-
culture. A cover slip with a primary neuronal culture is suspended over a primary astrocyte 
culture, allowing both to share the same media but be separated for analysis (B) Each 
experiment involved three plates, one under normoxic conditions, and two exposed to a 
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after. Each plate containing wells treated with either non-targeting siRNA or siRNA against 
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cover slip to another plate for fixation with PFA, and subsequent staining with DAPI, 
whereby four areas of each cover slip are imaged at x10 magnification and cell counts made. 
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neuronal cover slip moved into the corresponding wells, with each well then lysed for RNA 
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2. We also hypothesise that neuronal cell death can be reduced by preventing the 
endogenous Igf1 increase. 
3. The mechanism of Igf1 dependant neuronal cell death is through increased p-
ERK levels in neurons via astrocyte Igf1 increasing neuronal IIS signalling. 
 
 
 
Results 
 
 
 
Developing an in vitro model of acute neurodegeneration 
 
 
Although increased IGF1 is observed in astrocytes, and the main characteristic of 
neurodegenerative diseases is the gradual loss of neurons, changes in IIS have been 
observed in both cell types (Garwood et al., 2015; Talbot et al., 2012). To elucidate 
the effects that increased astrocyte IGF1 has on both astrocyte and neurons, we not 
only investigated the role of this cascade on neurodegeneration, but also on IIS levels 
in both neurons and astrocytes separately. We therefore developed an in vitro model 
where we could induce neurodegeneration and astrocyte Igf1 expression, but 
separately analyse cell number change and IIS signalling levels in neurons and 
astrocytes.  
 
 
Inducing an endogenous increase in astrocyte Igf1 expression in response to a 
noxious stimuli 
 
 
Our first aim in developing our in vitro model of acute neurodegeneration 
accompanied by increased astrocyte Igf1 was to ensure that our noxious stimulus 
induced an increase in astrocyte Igf1. With astrocytes being shown to be the cell type 
responsible for endogenous IGF1 increase in neurodegenerative diseases, we initially 
applied our noxious stimulus of a 5-hour hypoxic insult to primary astrocyte cultures. 
To ensure that our stressful stimulus induced Igf1 increase in only astrocytes, we also 
exposed separate primary neuronal cultures to the same stressful stimulus, and 
measured the Igf1 expression levels in both cultures via RT-qPCR. For comparison, 
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we kept some cultures in normoxic conditions, with future reference to Igf1 
expression change being relative to the levels seen in normoxic cultures measured via 
RT-qPCR. To aid in statistical analyse, raw expression levels were used for statistical 
tests. To emphasise this, in figure 4.2 we show graphs of both relative and raw Igf1 
expression changes. Subsequent figures will only show relative changes, but 
statistical analysis is always performed on raw expression data unless otherwise 
specified.  
 
Previous work examining Igf1 expression had shown that astrocyte expression 
increased 48 hours after traumatic head injury (Madathil et al., 2010) and 72 hours 
after hypoxic-ischaemic injury (Lee et al., 1996), whilst Igf1 expression seemed to be 
slightly decreased immediately after injury in both cases. We therefore chose to look 
for changes in Igf1 expression in our cultures 24 and 72 hours after the cessation of 
the hypoxic insult. Our expectation was to observe an increase in Igf1 expression in 
the astrocyte culture, with no change, or a decrease in expression in the neuronal 
cultures, as seen in previous literature (Clawson et al., 1999).  
 
In pure astrocyte and pure neuronal cultures no increase in Igf1 expression was 
observed at either time point following the hypoxic incident (figure 4.2 A). Hypoxia 
was successfully induced however, as shown by the significant increase in hypoxia 
inducible factor 1A (Hif1a) transcription following the hypoxic incident (figure 4.2 B, 
+24 hours astrocytes p=0.0155, +72 hours astrocyte p=0.05, +24 hours neurons 
p=0.0457). This increase is in accordance with previous work showing an increase in 
Hif1a expression from low baseline expression levels following a hypoxic incident 
(Wiener et al., 1996). Under these experimental conditions, cell stress alone was 
insufficient to induce an increase in Igf1 expression in either pure primary astrocytes 
or neurons.  
 
Astrocytes and neurons are known to communicate in a variety of ways, for example 
via diffusible factors (Fields and Stevens-Graham, 2002). Furthermore, Igf1 
expression has been shown to be in proximity to the site of damaged and dying 
neurons in traumatic brain injury (Madathil et al., 2010). Considering this mode of 
astrocyte-neuron communication and the Madathil et al study, we postulated that 
diffusible factors from nearby stressed neurons was a requirement for astrocytes to 
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increase Igf1 expression in response to a noxious stimulus. We therefore next 
modified a bi-laminar co-culture system from the protocol of Shimizu et al, allowing 
us to suspend a cover slip with primary neurons grown on it, above primary astrocytes 
grown on the bottom of the wells of a 24 well plate, whilst both cultures shared the 
same medium (Shimizu et al., 2011)(see figure 4.1, B).  
 
This bi-laminar co-culture represents a system where astrocytes and neurons can co-
exist and share the same medium and hence the same environment and factors, whilst 
being separable for analysis. To ensure that we do not miss an interaction due to a low 
dose of expressed neuronal factor, we carried out this experiment with bilaminar co-
cultures containing neuronal cultures plated either at a density of 200,000 
neurons/cm2 or 500,000 neurons/cm2. These bilaminar co-cultures were exposed to 
the same 5-hour hypoxic incident as was applied to single cultures previously, with 
cover slips then removed for separate neuronal and astrocytic Igf1 expression analysis 
via RT-qPCR at both 24 and 72 hours post cessation of the hypoxic incident. Again a 
normoxic culture, in this instance a bilaminar co-culture, was kept and processed for 
comparison. 
 
Astrocyte cultures in co-culture with high density neuronal cultures showed a 
significant 150% increase in Igf1 expression at 72 hours post hypoxia (fig 4.2 C, 
p=0.0300). In the low-density cultures however, no significant increase in Igf1 
expression was shown at either time point post hypoxia (fig 4.2 D). High density 
neuronal cultures present in the co-culture showed a significant decrease in Igf1 
expression at 24 hours following the hypoxic incident, but no significant difference at 
72 hours post hypoxia or in the low density cultures (figure 4.2 C D, p=0.0055). 
Overall, this indicates that not only are neurons required at the time of a noxious 
stimulus for the increased expression of Igf1 in astrocytes, but also there is a dose 
response relationship, whereby a higher number of neurons lead to a larger increase in 
Igf1 expression. With our success in mimicking the phenomenon of endogenously 
increased astrocyte Igf1 expression in response to a noxious stimulus, we now have a 
model where we can manipulate this response and thereby see how it influences 
neurodegeneration. As only the higher density of neurons resulted in a significant 
increase in the level of Igf1 expression, we continued all further experiments with this 
density of neurons.  
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Figure 4.2. Changes in expression of Igf1 and Hif2a in astrocytes and neurons in either 
single cultures of bilaminar co-cultures, either under normoxic conditions or following a 
5 hour hypoxic incident as measured by RT-qPCR. In all: (i) raw RT-qPCR data of Igf1 
expression level relative to the housekeeping gene Rps28, (ii) relative RT-qPCR data of Igf1 
expression relative to the housekeeping gene Rps28, then relative to the ratio in normoxic 
conditions (A) Igf1 expression does not change following a hypoxic incident in single 
astrocyte and neuronal cultures (B) Hif2a levels significantly increase in astrocytes and 
neurons following a hypoxic incident (C) Igf1 expression significantly increases in astrocytes 
following a hypoxic incident when in a bilaminar co-culture with neurons at a density of 
500K/cm2 (D) A smaller and not significant increase in astrocyte Igf1 expression is observed 
following a hypoxic incident when astrocytes are in a bilaminar culture with neurons plated at 
200K/cm2. Data shown is the mean +/- SEM. Student’s t-test * p<0.05 ** p<0.01 *** 
p<0.001. Astrocytes in black, neurons in brown. A - n=4 cultures B – n=5 cultures C – n=3 
cultures. 
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Characterising neurodegeneration and IIS change in our in vitro model 
 
 
In order to assess neurodegeneration in co-cultures under the above conditions, we 
measured cell number and IIS signalling levels at +24 and +72 hours’ following a 
hypoxic insult. Bilaminar cultures not exposed to hypoxia were used for comparison 
of IIS levels and cell number. Unless otherwise stated, changes reported are in 
relation to normoxic control cultures therefore. 
 
A significant neuronal loss occurred at 24 hours and 72 hours post hypoxia, with a 
30% and 40% decrease in neuronal number (figure 4.3 A, +24 hours p=0.0374, +72 
hours p=0.0069). This was accompanied by a significant increase in Cleaved caspase 
3 (CC3) levels, with a 160% increase at 72 hours post hypoxia (fig 4.3 B, p=0.0448).  
 
Examining IIS changes following a hypoxic incident, we observed no significant 
increase in p-ERK levels in neurons at either time point post hypoxia (figure 4.3 C). 
Similarly we also saw no increase in pS-Akt levels in neurons at either time points 
following hypoxia (figure 4.3 A). This would suggest that the substantially increased 
astrocyte Igf1 has not caused an increase in signalling through the IIS cascade in 
neurons, despite IGF1 also being a strong activator of Akt and ERK1/2 
phosphorylation.  
 
We then examined correlations between astrocyte Igf1 change and neuron IIS change 
to examine interactions between these factors. If change in neuronal p-ERK level is 
plotted against changes in astrocyte Igf1 expression, then a correlation between these 
levels exists (fig 4.4 A, p=0.0418). This indicates that an increase in Igf1 expression 
leads to an increase in p-ERK levels, however the equation of the regression line is: 
 ! = 0.1937! + 0.8043 
 
This would mean that for a doubling of p-ERK level, an increase of 6.2 times the Igf1 
level observed in astrocytes under normoxic conditions would be required, and for a 
tripling of p-ERK levels, an 11 fold increase in Igf1 expression would be required. 
Furthermore, plotting the change in neuronal pS-Akt levels against the change in 
astrocyte Igf1 expression, we see no significant correlation.  
Figure 4.3. Bilaminar co-cultures of primary astrocytes and primary neurons when 
exposed to a 5 hour hypoxic incident, show profound neuron loss, an increase in 
apoptosis, but no change in ERK or AKT signaling. (A)(i) DAPI images of neuronal 
cultures separated from the bilaminar co-culture after being in normoxic conditions, or 24 and 
72 hours after the cessation of hypoxic conditions and (ii) the graphical representation of this 
neuronal cell count. (B)(i, ii) Western blotting for CC3 shows that hypoxia causes an increase 
in apoptosis (C, D, i and ii) Western blotting showing no hypoxia induced changes in either 
pS-Akt or p-ERK levels. Data shown is the mean +/- SEM. Student’s t-test * p<0.05 ** 
p<0.01 *** p<0.001. n=5 cultures. 
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With our co-culture model allowing the separation of astrocyte and neuronal cultures, 
we also examined the effect of increased astrocyte Igf1 expression on IIS signalling 
and cell number in astrocytes. Astrocyte culture number under normoxic conditions, 
and 24 and 72 hours after hypoxia, was prone to substantial variability, with no 
overall pattern of an increase or decrease in astrocyte number with hypoxia (fig 4.5, 
A). There was however a significant increase in CC3 signal at 72 hours post hypoxia 
(fig 4.5 B, p=0.0042), indicating an increase in apoptosis at this time point in 
astrocytes, despite there being no decrease in astrocyte cell number at this time point.  
 
Steady levels of p-ERK and pS-Akt were observed in astrocyte cultures under 
normoxic conditions and at both time points after hypoxia in astrocytes, with no 
significant difference between normoxic and hypoxic conditions (figure 4.5 C, D). 
We also observed no correlation between astrocyte Igf1 increase and astrocyte p-ERK 
of pS-Akt level changes (figure 4.5 E, F). Despite no change in IIS signalling level or 
astrocyte cell number, we did see high levels of variability in astrocyte number in 
experiments, as well as occasional increases in pS-Akt levels in certain experiments.  
 
We have therefore successfully identified an in vitro cellular model of induced acute 
neurodegeneration. Progressive neuronal cell loss following the short-term hypoxic 
incident is accompanied by increased astrocyte Igf1 expression, allowing us to 
modulate the Igf1 increase and investigate the effect this has on neuronal cell death 
and IIS changes.  
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Figure 4.5. Characterization of cell loss and IIS signaling in astrocytes in a bilaminar 
co-culture under either normoxic conditions or at time points following a hypoxic 
incident. (A)(i) DAPI images of astrocyte cultures separated from the bilaminar co-culture 
after being in normoxic conditions, or 24 and 72 hours after the cessation of hypoxic 
conditions and (ii) the graphical representation of this astrocyte cell count. (B)(i, ii) Western 
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association between astrocyte Igf1 and IIS signalling in astrocytes. Data shown in A-D is the 
mean +/- SEM. A-D, Student’s t-test * p<0.05 ** p<0.01 *** p<0.001. E-F, Pearson’s R test 
ns = not significant. n=4 cultures. 
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The role of endogenously increase Igf1 on neurodegeneration 
 
 
 
In order to assess whether the increase in astrocyte Igf1 expression was causal in the 
neuronal loss observed in these cultures, we compared bilaminar cultures with and 
without knock down of the Igf1 gene. 
 
 
Effects of Igf1 knock down during a hypoxic incident on neuronal cell loss and 
neuronal IIS signalling 
 
 
 
Firstly we established that our siRNA succeeded in limiting Igf1 expression increase 
under our experimental conditions by examining Igf1 expression levels in our knock 
down cultures versus our control cultures via RT-qPCR. As shown in figure 4.6 B, 
there was a significant effect of siRNA treatment in Igf1 expression in astrocytes with 
siRNA treatment, with a significant increase in expression in 72 hours post hypoxia 
control astrocytes but no other cultures (treatment p=0.0066, +72 hour post hypoxic 
control astrocytes vs normoxic control astrocytes p=0.0238).  
 
The knock down of Igf1 with siRNA caused a significant 15% loss of neurons 
compared to non-targeting siRNA in the absence of hypoxia (fig 4.6, C ii, p=0.0490). 
Therefore in order to understand the role of raised astrocyte Igf1 in hypoxia induced 
neurodegeneration, we thus compared neuronal cell death after hypoxia in knock 
down and control cultures, relative to their own normoxic control conditions. When 
this was done, there was a significant effect of treatment on neuronal cell loss, with a 
significant reduction at 72 hours post hypoxia (fig 4.6 C iii, treatment effect 
p=0.0180, 72 hours cell loss p=0.0298). In control cultures there is a 40% reduction in 
neuronal number at 72 hours following hypoxia compared to control normoxic 
cultures, whereas in knock down cultures there is only a 10% reduction in neurons 
between knock down cultures 72 hours after hypoxia compared to knock down 
normoxic cultures.  
 
This neuroprotective effect can be observed in a different way by plotting astrocyte 
Igf1 expression increase against the percentage of neurons lost. When change in 
astrocyte Igf1 expression levels and neuronal cell death levels at 72 hours post  
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Figure 4.6. Knocking down and therefore preventing the increase in astrocyte Igf1 
expression, is mildly toxic to neurons, yet protects against hypoxia induced neuronal 
cell death. (A) Diagrammatic representation of the siRNA culture experiment (B) Igf1 levels 
were decreased and prevented from rising in astrocytes following siRNA treatment, with a 
significant effect of treatment by 2-way ANOVA (C) Knocking down Igf1 expression was 
slightly toxic, yet ameliorated hypoxia induced neuronal cell death (i) DAPI images of 
neuronal cultures under 10X magnification, in normoxic conditions and 24 and 72 hours after 
hypoxia, in control and knock down cultures (ii) Under normoxic conditions knocking down 
Igf1 significantly reduces neuron number (iii) Accounting for this toxicity by plotting change 
in neuronal number relative to normoxic knock down cultures, a significant reduction in 
neuronal loss compared to control cultures is apparent (iv) When knock down and control 
culture data are plotted together, 72 hour post hypoxia neuronal loss significantly correlates 
with increased astrocyte Igf1 expression at 72 hours (D) No change in CC3 level is observed 
with Igf1 knock down. Data shown in all but C iv is the mean +/- SEM. C ii -Student’s t-test, 
B Ciii Dii 2-way ANOVA, C iv, Pearson’s R * p<0.05 ** p<0.01 *** p<0.001. Control 
cultures in black, knock down cultures in yellow. n=3 in each treatment. 
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hypoxia for knock down cultures (relative to normoxic knock down cultures) are 
pooled with the control cultures, a significant correlation is found (fig 4.6, C iv; 
p=0.0287). This suggests two things: that the normal level of Igf1 expression in these 
cultures is required for normal neuronal health with a reduction in this being toxic, 
and secondly that the astrocyte Igf1 increase following hypoxia is contributing to 
hypoxia induced neuronal cell death. 
 
We next investigated the mechanism behind the observed Igf1-dependant neuronal 
cell death, by examining how Igf1 knock down affected CC3 levels and IIS signalling 
following a hypoxic incident. In control cultures, CC3 levels were significantly 
increased 72 hours post following hypoxia. Despite Igf1 knock down conferring 
neuroprotection, there was no reduction in CC3 levels in knock down cultures 
compared with control cultures at either time point following hypoxia, whether CC3 
level change was measured relative to normoxic control culture levels, or normoxic 
knock down culture levels (fig 4.6, D). Similarly there was no effect of treatment on 
CC3 level. The lack of change in CC3 levels in normoxic knock down cultures 
compared to normoxic control cultures implies that the neurotoxicity of Igf1 knock 
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down is not through apoptotic mechanisms. This also suggests that the 
neuroprotection observed following a hypoxic incident by blocking the astrocyte Igf1 
increase, is similarly not due to apoptotic neuronal cell death mechanisms.  
 
We hypothesised that endogenous astrocyte Igf1 increase not only contributes to 
neuronal cell death, but also does so via activation of the IIS cascade in neurons, 
thereby increasing p-ERK levels. As detailed earlier, there was no significant increase 
in p-ERK levels in neurons in control cultures following a hypoxic incident. Similarly 
there was no increase in p-ERK levels in knock down cultures at either time point 
following hypoxia, nor an effect of treatment (fig 4.7 A i). There was also no 
significant change in the p-ERK levels in knock down cultures compared to control 
cultures.  
 
Examining further the relationships between astrocyte Igf1 expression change, 
neuronal p-ERK change, and neuronal cell death, we examined correlations between 
these variables. Under control culture conditions a significant correlation exists 
between change in astrocyte Igf1 expression and relative neuronal p-ERK level, 
however there is no correlation between these factors for the knock down cultures, 
when considered independently or when pool with control culture data (fig 4.7 A ii). 
When changes in neuronal p-ERK levels relative to normoxic knock down culture 
levels were plotted against the percentage of neurons lost relative to normoxic control 
numbers, a highly significant association was observed (fig 4.7 A iii, p=0.0003). This 
was not the case when examining this association in control cultures. This indicates 
that an increase in p-ERK levels is associated with increased neuronal cell death in 
knock down cultures, despite astrocyte Igf1 being knocked down, and astrocyte Igf1 
not correlating with p-ERK levels.  
 
Considering levels of phosphorylation at Akt in response to hypoxia under knock 
down conditions, there is similarly no significant change in pS-Akt level post hypoxia 
(figure 4.7 B). There was also no significant difference in pS-Akt levels between 
control cultures and knock down cultures, nor an effect of treatment. There was 
similarly no correlation between change in neuronal pS-Akt level and change in 
astrocyte Igf1 expression level in knock down cultures (fig 4.7 B iii).  
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Figure 4.7. Changes in p-ERK and pS-Akt levels in neurons following a hypoxic 
incident in knocked down and control cultures. (A) Changes in neuronal p-ERK levels in 
knock down cultures were variable and not significantly different from the levels seen in 
control cultures (i) Graphical representation of changes in p-ERK levels in neuronal cultures. 
Due to variability in p-ERK levels no representative images were possible. (ii) A significant 
interaction is seen between increased astrocyte Igf1 levels and neuronal p-ERK levels in 
control cultures, but no association between these two factors is observed in knock down 
cultures (iii) A highly significant association is shown between neuronal p-ERK and neuronal 
cell loss in knock down cultures. (B) There were no significant differences in pS-Akt levels 
in knock down cultures compared to vehicle treated cultures, (i) Western blots of knock 
down and control cultures (ii) Graphical representation of this (iii) No association is 
observed between increased astrocyte Igf1 level and changes in neuron pS-Akt level. Data 
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Effects of Igf1 knock down during a hypoxic incident on astrocyte number and IIS 
levels 
 
 
 
With Igf1 knock down proving to be acutely neurotoxic, we also examined astrocyte 
cell number change as well as astrocyte IIS levels in response to Igf1 knock down. 
Despite variability in astrocyte number similar to that observed in our control 
cultures, no significant change in astrocytes number was observed under either 
normoxic conditions or at either time point following hypoxic conditions when Igf1 
was knocked down, and there was no effect of treatment (fig 4.8 A). This was the case 
whether change in astrocyte number was relative to normoxic control culture 
astrocyte number, or relative to normoxic knock down astrocyte number. 
Furthermore, no significant correlation was observed between astrocyte Igf1 increase 
and change in astrocyte number (fig 4.8 A iii).  
 
Levels of apoptosis as measured by CC3 level, were unchanged in astrocytes from 
knock down cultures relative to control cultures under normoxic conditions, and at 
both time points following hypoxia (fig 4.8 A iv). Similarly no significant difference 
in either p-ERK or pS-Akt was seen following Igf1 knock down compared with 
control cultures, with no significant change in levels of either following hypoxia in 
knock down cultures (fig 4.8 B C).  
 
These data suggests that astrocyte Igf1 expression does not signal to astrocytes 
themselves via the IIS cascade, and that the increase in Igf1 level does not affect 
astrocyte cell number or levels of astrocyte apoptosis.  
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Figure 4.8. Knocking down and therefore preventing the increase in astrocyte Igf1 
expression, does not effect astrocyte number or IIS levels following a hypoxic incident. 
(A) There is no significant change in astrocyte number following Igf1 knock down, but 
apoptosis is still increased 72 hours post hypoxic incident (i) DAPI images of astrocyte 
cultures under 10X magnification, in normoxic conditions and 24 and 72 hours after hypoxia, 
in control and knock down cultures (ii) graphical representation of this (iii) Plotting Igf1 
change against change in astrocyte number showed no association between these factors (iv) 
Despite no overall change in astrocyte number, increased apoptosis is present in both vehicle 
treated and siRNA treated cultures 72 post hypoxia (B)(C) p-ERK and pS-Akt levels did not 
change in control or knock down cultures following a hypoxic incident (i) Typical western 
blot images (ii) graphical representation of western blot data. Data shown is the mean +/- 
SEM, except A iii. 2-way ANOVA in all but Pearson R in A iii * p<0.05 ** p<0.01 *** 
p<0.001. Vehicle treated cultures in black, Igf1 siRNA treated cultures in yellow. n=3 in each 
treatment. 
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Summary 
 
 
 
This thesis aims to investigate whether alterations to the IIS cascade can be used to 
modulate neuronal cell death in neurodegenerative diseases. This chapter focuses on 
investigating how the increased levels of astrocyte Igf1 proximal to the source of 
injury in acute neurodegenerative diseases impacts on neuronal degeneration itself. 
Whilst overexpressing human IGF1 in mouse astrocytes following a traumatic brain 
injury reduced neurodegeneration (Madathil et al., 2013), what effect the endogenous 
increase in astrocyte IGF1 had on neurodegeneration has until now remained 
unexplored. We investigated the consequence of this endogenous change by designing 
an in vitro model of induced neurodegeneration in a primary neuronal/astrocyte 
bilaminar co-culture.  
 
This model showed increased expression of astrocyte Igf1 and progressive neuronal 
cell loss following a short-term hypoxic insult. By preventing this astrocyte Igf1 
increase via siRNA administration at the time of hypoxic insult, we identified that 
Igf1 increase during acute neurodegeneration contributes to neuronal cell death. This 
finding is at odds to previous findings of Igf1 being a protective factor, and therefore 
further work should be carried out to investigate this phenomenon further. The 
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mechanism by which Igf1 caused neuronal cell death, and therefore mechanisms 
behind the protective effect of its inhibition, was not as we had expected. The results 
of this chapter have therefore identified a novel potential mechanism of modulating 
the IIS cascade during acute neurodegeneration to ameliorate neuronal cell loss. 
 
We had hypothesised that Igf1 would contribute to neuronal cell death, but we had 
also hypothesised that it would do so by increasing IIS signalling and therefore p-
ERK levels in neurons, with increased p-ERK levels being shown in previous studies 
to be a neuronal cell death signal (Chen et al., 2009; Luo and DeFranco, 2006). 
Although gross significant changes in p-ERK levels were neither observed in vehicle 
treated or siRNA treated cultures following hypoxia, in vehicle treated cultures the 
increase in p-ERK level correlated with the change in astrocyte Igf1. When Igf1 was 
knocked down, p-ERK levels in neurons still showed the capacity to increase, and 
furthermore correlated strongly with the levels of cell death in the cultures. This 
firmly suggests that IGF1 does not induce cell death via an increase in p-ERK levels, 
but rather signals through a different mechanism. Furthermore, there was no reduction 
in the levels of apoptosis when Igf1 was knocked down, suggesting that the 
neuroprotective effect of preventing the endogenous Igf1 increase during 
neurodegeneration, is through a different mechanism to both of those investigated.  
 
Preventing Igf1 increase following a hypoxic insult proved to be neuroprotective, 
however our knock down of astrocyte Igf1 was also mildly toxic to neurons under 
normoxic non-stressed conditions, masking the neuroprotective effect unless this 
initial toxicity is taken into consideration. This therefore represents a novel 
mechanism of neuronal cell death in acute neurodegeneration, and a novel 
opportunity to intervene in neuronal cell death via endogenous IIS modulation. The 
exploitation of this for possible therapeutic gain would depend heavily on being able 
to reduce the short-term increase in Igf1 expression, whilst not lowering the 
expression beyond baseline levels. A potential way of doing this would be with 
IGF1R inhibitors, and titrating the dosage to give sufficient inhibition to block an 
increase but not limit baseline levels. Before this can be explored further however, an 
IGF1R receptor inhibitor would need to be investigated in the same cell culture model 
that we have used, to see if the same neuroprotection can be elicited that we have 
seen, but without causing neurotoxicity.  
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Chapter 5 
 
 
Repurposing clinically approved IIS inhibitors to treat acute 
neurodegeneration 
 
 
 
Introduction  
 
 
Various studies have demonstrated that genetically decreasing signalling through the IIS 
cascade in animal models of chronic neurodegeneration can ameliorate and slow the onset of 
the pathology in these models, as well as reducing neuronal cell death (Cohen et al., 2006; 
Cohen et al., 2009; Cooper et al., 2015; Freude et al., 2009; Killick et al., 2009). 
Pharmacological inhibitors of this pathway have also shown beneficial effects when applied 
to animal models of neurodegenerative disease. Many of these inhibitors focus on the Ras-
Raf-ERK branch of the IIS pathway, and it is inhibitors of this branch that we focus on in this 
chapter.  
The clinically approved c-Raf inhibitor Sorafenib has been shown to ameliorate neuronal cell 
death in culture, and furthermore rescues working memory deficits in a mouse model of fAD 
(Echeverria et al., 2008; Echeverria et al., 2009). Ashabi et al have also demonstrated that 
using the experimental non-clinically approved MEK inhibitor U0126 can mitigate 
neurodegeneration in mice where Aβ fibrils were injected into their brains (Ashabi et al., 
2013). Pharmacologically inhibiting the Ras-Raf-ERK pathway in chronic neurodegenerative 
diseases in humans could prove difficult however. With the long duration of neuronal cell 
loss, and common side effects associated with IIS inhibition, applying Ras-Raf-ERK 
inhibitors at the correct point in disease pathogenesis to ameliorate degeneration whilst 
limiting serious side effects, would be difficult. Acute neurodegenerative diseases have a far 
smaller window for therapeutic intervention however; meaning the timing for disease 
intervention is simplified, and the long-term side effects of IIS inhibitor treatment are 
mitigated by the reduced time frame of drug administration. Evidence showing that inhibition 
of the Ras-Raf-ERK cascade reduces infarct size and neurodegeneration in mouse models of 
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stroke when administered during or after the ischaemic incident, indicates that inhibitors of 
this cascade are a promising therapeutic target for acute neurodegenerative diseases 
(Gladbach et al., 2014; Namura et al., 2001; Wang et al., 2003).  
An over activation in the proliferative Ras-Raf-ERK pathway is a frequent feature in many 
cancers. This has resulted in the development of many compounds to inhibit specific 
members of this pathway, with many of these being approved for human use as 
chemotherapy agents (Roberts and Der, 2007; Wellbrock et al., 2004). With pharmacological 
Ras-Raf-ERK inhibition seeming a promising approach to treat acute neurodegenerative 
disease, these anti-cancer drugs could potentially be repurposed for use in acute 
neurodegeneration. This chapter therefore investigates the possibility of repurposing drugs 
that inhibit the IIS cascade that are already approved for use in humans, for the alternative 
use of intervening in neuronal cell death cascades and preventing neurodegeneration.  
 
 
 
Aims  
 
 
This chapter investigates the possibility of repurposing the clinically approved MEK inhibitor 
Trametinib and B-Raf inhibitor Dabrafenib, for the alternative use of ameliorating neuronal 
cell death in acute neurodegenerative disease. We tested the proof of principle of the 
neuroprotective effects of our chosen inhibitor Trametinib in our developed model of acute 
neurodegeneration, before beginning testing it for efficacy in inhibiting Ras-Raf-ERK in the 
mammalian brain.  
 
 
Methods  
 
 
Initially to test our inhibitors for successful p-ERK level reduction in cells of the mammalian 
brain, we applied Trametinib and Dabrafenib to the media of primary neuronal and astrocyte 
cultures, modified from the protocols of Schildge et al and the primary neuron protocol used 
by Dresbach et al (Dresbach et al., 2003; Schildge et al., 2013). This allowed us to confirm 
that multiple cell types in the brain are inhibited by our drugs of choice, whilst also allowing 
us to test for feedback stimulation of the pathway that had been reported with some IIS 
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inhibitors previously (Anforth et al., 2012; Hatzivassiliou et al., 2010; Poulikakos et al., 
2010).  
To test the neuroprotective effects of Trametinib in an in vitro model of acute 
neurodegeneration, primary cultures were used to form the bilaminar co-cultures described in 
chapter 4. Trametinib was applied 1 hour prior to the 5 hour hypoxic incident, with cell 
number, Igf1 expression, and IIS signaling measured at 24 and 72 hours after the cessation of 
the hypoxic incident, as well as in a culture under normoxic conditions for control 
comparison (figure 5.5 A) (Trametinib treated). Wells treated with the same volume of 
DMSO in the same experimental condition (normoxia or hypoxia) were used as a control 
(vehicle treated). Therefore, as in chapter 4, one plate was used for normoxic comparison, 
and a plate each for the 24 and 72-hour post hypoxia time points, with plates containing 2 
wells to be lysed for RNA, 2 for protein, and one well for PFA fixation and DAPI staining 
(figure 5.5 A). Comparisons following hypoxia (in the 24 and 72 hour post hypoxia 
plates)(hypoxic cultures) are made relative to the normoxic control cultures (normoxic 
cultures).  
 
Cell number, and therefore neuronal cell death, was assessed by counting DAPI stained cells 
under a light microscope from neuronal cultures separated from the bilaminar co-cultures. 
We examine changes in signaling levels through the IIS cascade in these cultures, by western 
blotting for the activating phosphorylation sites pS473 on Akt (pS-Akt) (Alessi et al., 1996), 
and pT202/pY204 and pT185/pY187 on ERK1/2 (p-ERK)(Canagarajah et al., 1997; Payne et 
al., 1991), and normalised these levels to total protein Akt and ERK1/2 levels. Western 
blotting for cleaved caspase 3 (CC3) was also performed on protein samples to examine 
levels of apoptosis. Igf1 expression was assessed by RT-qPCR. This allowed us to not only 
investigate the neuroprotective mechanisms of Trametinib administration to an in vitro model 
of acute neurodegeneration, but also investigate how this inhibition affected signaling 
through the IIS cascade in these cultures. 
 
To investigate the administration of Trametinib to mice, we first assessed the toxicity of 
Trametinib on ex vivo mouse brain tissue by applying Trametinib for up to 14 days to the 
media of hippocampal organotypic brain slices from GFP expressing mice. We measured 
spine density on CA1 pyramidal neurons by imaging live slices using confocal microscopy, 
and also established Trametinib still inhibited MEK via western blotting in the same slices. 
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Trametinib was administered to mice via two mechanisms, via intracerebroventricular (ICV) 
injection, and via oral gavage. ICV was carried out by drilling a small hole in the skull over 
the ventricles, and lowering a needle into the ventricular space then injecting Trametinib, 
following the protocol of DeVos and Miller (DeVos and Miller, 2013). Oral gavage of 
Trametinib was given orally by gavage following standard procedures, and administered 
concurrently with intraperitoneal injection of Elacridar. All mice used were male wild type 
C57BL-6 strain, aged 4-6 months. For comparison, mice were also treated using the above 
methods, but with the same volume of vehicle, for comparison. 
 
Throughout this chapter the level of inhibition through the Ras-Raf-ERK branch of the IIS 
cascade was established by western blotting for the above-mentioned activating sites on 
ERK1/2, and normalising by total ERK1/2 levels. 
 
 
 
Hypotheses 
 
 
1. We hypothesise that Trametinib will be neuroprotective when administered to our in 
vitro model of acute neurodegeneration, and therefore result in less neuronal cell 
death 
2. This reduction in neuronal cell death will reduce astrocyte Igf1 expression increase 
observed in non-treated bilaminar cultures 
3. We also hypothesised that Trametinib will reduce p-ERK levels in the mammalian 
brain when administered orally to mice 
4. We therefore hypothesise that Trametinib could be repurposed to treat acute 
neurodegeneration 
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Results 
 
 
In vitro testing 
 
 
IIS inhibition in primary neuronal and astrocyte cells using Trametinib and Dabrafenib 
 
 
 
Variability has been shown between different cell lines with respect to their susceptibility to 
inhibition by IIS inhibitors (Gilmartin et al., 2011). To test the susceptibility of neurons and 
astrocytes to inhibition by Trametinib and Dabrafenib, primary cell cultures of neurons and 
astrocytes were treated with Trametinib and Dabrafenib.  To then test these drugs in our 
bilaminar co-culture model to test for neuroprotection following a noxious insult, we also 
established the desired concentration of each drug to add to the media.  
 
Initially neurons and astrocytes were treated once with each drug, with cells lysed for protein 
24 hours after treatment. Trametinib or Dabrafenib was applied in rising concentrations of 
0.1µM 1µM 10µM and 100µM, diluted in the culture medium. Control cultures were treated 
with the same volume of DMSO as the 100µM Trametinib wells, 15µl, without drug.  
 
Trametinib treated astrocytes show a reduction of p-ERK in a dose dependent manner, with 
95% inhibition achieved with the lowest dose of 0.1µM, rising to 98% inhibition at 10µM 
(figure 5.1, A B). Interestingly, the 100µM dose resulted in the death of the cells, indicating 
that there is a maximal dose for Trametinib before it is toxic to astrocytes, at least in culture. 
For Dabrafenib, lower concentrations of the drug did not inhibit ERK phosphorylation, with a 
slight increase observed, but reduction of 40% and 65% were seen at concentration of 10µM 
and 100µM. This inhibition is less than that caused by Trametinib administration, with a 
significantly higher concentration required to achieve a reduction in p-ERK. The lack of cell 
death in Dabrafenib treated cultures compared with cell death in 100µM treated Trametinib 
cultures, suggests we have not tested maximal concentrations of Dabrafenib in cultures. 
 
For treated neurons, the same trend is seen, with increased concentrations of Trametinib and 
Dabrafenib negatively correlating with p-ERK levels (figure 5.1 C D). The reduction in  
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phosphorylation levels from Trametinib treatment is not as severe in neuronal cultures as it 
was in astrocyte culture however, with only a 60% reduction with 0.1µM, increasing to 80% 
reduction with 100µM. Furthermore, the highest concentration of 100µM Trametinib did not 
cause the whole neuronal cultures to die whereas it did in astrocyte cultures. Dabrafenib 
treatment in neurons was again less potent than Trametinib treatment, with a maximal 
reduction in phosphorylation levels at the highest dose of 100µM of 55%. This would again 
imply that a higher concentration of Dabrafenib could be used if a more profound inhibition 
of p-ERK was desired in culture. Therefore both Dabrafenib and Trametinib successfully 
inhibit MEK and B-Raf in astrocyte and neuronal cultures. 
 
Whilst previous work with Trametinib has raised no issues other than the usual side affects 
associated with chemotherapy agent administration, we were concerned with previous 
evidence that Dabrafenib treated patients have an increased incidence of squamous cell 
carcinoma. As this is thought to be due to a feedback increase in IIS signalling that has been 
observed with the long term administration of similar ATP-competitive Raf inhibitors in wild 
type B-Raf cells (Anforth et al., 2012; Hatzivassiliou et al., 2010; Poulikakos et al., 2010), 
and the patients we are aiming to repurpose to will be wild type for B-Raf, we carried out a 
longitudinal study in cultures to ensure that Dabrafenib did not increase IIS signalling in the 
brain.  
 
When astrocyte cultures were treated with 100µM Dabrafenib every second day over the 
duration of 7 days, there was a different effect on ERK1 and ERK2 phosphorylation levels; 
with prolonged drug exposure leading to decreased ERK1 phosphorylation but increased 
ERK2 phosphorylation (figure 5.2). These changes were seen at all time points following the 
start of drug addition, but by 7 days the phosphorylation level of ERK1 had begun to return 
to approaching non-treated level, with the increase in ERK2 phosphorylation rising 
dramatically. Again as was shown earlier, 100µM of Dabrafenib appeared to reduce total 
ERK levels when compared to time matched sham treated cultures (figure 5.2). These results 
indicate that when wild type primary astrocytes are treated with a sufficient dose of 
Dabrafenib to reduce p-ERK levels to below 50% of normal levels, not only does this cause 
total ERK levels to decrease, but that it leads to the paradoxical increases in p-ERK2 levels. 
The lack of potency in reducing p-ERK levels, combined with its reduction of t-ERK levels 
and its paradoxical stimulation of ERK2 phosphorylation, makes Dabrafenib an unsuitable  
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drug to test our hypothesis, and unsuitable for further consideration as a repurposable IIS 
inhibitor. 
 
Whilst Dabrafenib appears to be unsuitable for testing our hypotheses, Trametinib is 
efficacious in both neurons and astrocytes in vitro. We therefore used Trametinib as our sole 
drug for investigating our hypothesis.  
 
 
Trametinib is neuroprotective in a cellular model of hypoxia induced neuronal cell death 
 
 
 
Using the same in vitro model of hypoxia induced acute neurodegeneration as used in chapter 
4, we applied 10µM Trametinib one hour prior to the time of hypoxic insult, and investigated 
the possible neuroprotective properties of this drug by measuring neuronal cell number 
change and apoptotic markers between Trametinib treated cultures and cultures treated with 
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the same volume of DMSO vehicle (fig 5.3, A). Cell number and apoptosis levels were 
measured in cultures under normoxic conditions to see if Trametinib affected neuronal cell 
death independently of the stressful stimulus, and at 24 and 72 hours after the hypoxic 
incident. Similar data was also taken for astrocytes to investigate the role of IIS in astrocyte 
number change in response to a stressful stimulus. To gain further insight into the role that 
IIS plays in cell death, we lysed cells at the time points and conditions mentioned for protein 
and RNA also, allowing us to relate cell death to astrocyte Igf1 gene expression levels, and 
levels of p-ERK and pS-Akt. 
 
In bilaminar co-cultures treated with Trametinib, a near complete reduction in neuron p-ERK 
levels was achieved (figure 5.3 B). Hypoxia induced neuronal cell death and accompanying 
increase in apoptosis observed under vehicle treated conditions, is significantly reduced in 
cultures treated with Trametinib. A significant reduction in neuronal cell loss is observable at 
72 hours post hypoxia, with a 15% and 22% loss of neurons at 24 hours and 72 hours post 
hypoxia with Trametinib treatment, compared to 30% and 40% lost in vehicle treated cultures 
(figure 5.3, p=0.0149). A significant effect of treatment on neuronal cell loss was also 
observed (p=0.0187). CC3 level in neurons is also significantly affected by Trametinib 
(p=0.0081), with a trend towards a reduction at 72 hours post hypoxia, (p=0.0866). Whereas 
Igf1 knockdown was neuroprotective following the hypoxic incident, but neurotoxic under 
non-stressed conditions, no decrease in neuronal number was observed with Trametinib 
treated cultures under normoxic conditions. The reduction of neuronal cell loss and reduction 
of CC3 levels in neurons following a noxious stimulus when treated with Trametinib, 
strongly suggests that Trametinib is neuroprotective.  
 
Whilst we hypothesised that Trametinib treatment would be neuroprotective, we also 
predicted that Trametinib treated cultures would reduce the magnitude of astrocyte Igf1 
increase due to the decrease in neuronal cell loss. Whilst we observed a trend towards an 
effect of treatment in astrocyte Igf1 cultures (p=0.0603), this effect was an increase in 
astrocyte Igf1 expression in Trametinib treated cultures under normoxic conditions and 24 
hours after hypoxia (figure 5.4 A, p=0.0357, 0.0193). These increases in astrocyte Igf1 
expression in Trametinib treated cultures matched the magnitude of increase in Igf1 
expression seen 72 hours post hypoxia in vehicle treated cultures (~250% times normoxic 
vehicle treated Igf1 expression level). Crucially as this Igf1 increase is apparent even under 
normoxic conditions, it suggests that the increase is dependant on Trametinib administration  
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ANOVA * p<0.05 ** p<0.01 *** p<0.001. Vehicle treated cultures in black, Trametinib 
treated cultures in green. n=5 cultures. 
i ii 
i ii 
D
A
PI
 c
ou
nt
 
C
C
3 
le
ve
l 
0 2 4 6
-20
0
20
40
60
IGF1 expression
%
 N
eu
ro
na
l l
os
s
Igf1 expresion - Neuronal loss 
0 24 72
0
2
4
Time relative to end of hypoxia
Ex
pr
es
si
on
 re
la
tiv
e 
to
 n
on
-h
yp
ox
ic
 c
ul
tu
re
s Control
KD
Trametinib
Tram+KD
** **
0 
2 
4 
Figure 5.4. Trametinib application induces an increase in astrocyte Igf1 expression, 
which does not correlate with neuronal cell death. (A) RT-qPCR for Igf1 in astrocyte 
cultures from bilaminar co-cultures treated with Trametinib show a significant increase 
in Igf1 expression in Trametinib treated cultures under normoxic conditions and at 24 
hours post hypoxia. (B) No significant correlation between neuronal loss and Igf1 
expression was observed when data from Igf1 siRNA (purple) vehicle treated (black) and 
Trametinib treated (green) cultures were pooled. Data in A mean +/- SEM, 2-way 
ANOVA, B Pearson’s R test * p<0.05 ** p<0.01 *** p<0.001). n=5 cultures for 
Trametinib, n=5 for wild type, n=3 for KD.  
Astrocyte Igf1 expression 
2 6 4 0 
%
 N
eu
ro
na
l l
os
s 
20 
0 
40 
60 
B 
-20 
A 
Hours after hypoxia 
Normoxic +24 +72 
Ig
f1
 e
xp
re
ss
io
n 
	 116	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
rather than the hypoxic incident, thereby suggesting that decreased p-ERK levels induced an 
increase in Igf1 expression in astrocytes to the same magnitude as a noxious insult.  
 
In chapter 4 when pooled astrocyte Igf1 expression at 72 hours post hypoxia from control 
cultures and Igf1 knock down cultures was plotted against neuronal cell death, a positive 
correlation was seen, whereby higher Igf1 expression was associated with higher neuronal 
death. When Trametinib treated data from 72 hours post hypoxia was also pooled with the 
other data the correlation was not significant (figure 5.4 B, p=0.1115). However, with 
increased astrocyte Igf1 expression following a noxious stimulus being shown in chapter 4 to 
be neurotoxic, the increased astrocyte Igf1 expression observed in Trametinib treated cultures 
could be a confounding variable in our examination of Trametinib as a neuroprotective agent, 
and could be limiting its neuroprotective potential. To establish if this induced Igf1 
expression increase has any effect on the usefulness of Trametinib as a neuroprotective agent, 
we carried out the same hypoxia insult on bilaminar co-cultures, but applied both Trametinib 
and siRNA against Igf1, to examine what effect Trametinib had without Igf1 expression 
increase.  
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Combined Trametinib administration and Igf1 knock down is similarly neuroprotective in a 
cellular model of hypoxia induced neuronal cell death 
 
 
 
Firstly we ascertained that astrocyte Igf1 expression was successfully prevented from 
increasing in Trametinib+KD cultures, and found that there was a significant effect of 
treatment on astrocyte Igf1 expression between Trametinib plus Igf1 siRNA treated cultures 
than Trametinib treated alone (figure 5.5, p=0.0488). The Tramatinib+KD culture Igf1 
expression levels were similar to that of vehicle treated cultures. Similarly we also confirmed 
that neuronal p-ERK levels were reduced in Trametinib+KD cultures as was observed in solo 
Trametinib cultures (fig 5.5, C), with near complete reduction in p-ERK levels observed in 
neuronal cultures when treated with Trametinib+KD. 
 
Cultures treated with Trametinib and Igf1 siRNA showed decreased neuronal cell death 
compared to vehicle treated controls at +72 hours post hypoxia (figure 5.5 D, p=0.0335). The 
difference between Trametinib+KD cell loss at 24 and 72 hours post hypoxia, and that of 
either solo treatment, was not significantly different. This suggests that whilst the 
Trametinib+KD treated cultures were protected from neurodegeneration following a hypoxic 
incident by combined treatment, the neuroprotection of solo Igf1 knock down and solo 
Trametinib treatment was not additive when combined. This further suggests that the 
increased astrocyte Igf1 expression following solo Trametinib treatment did not limit the 
neuroprotection of Trametinib. Interestingly, no significant decrease in neuronal number was 
observed under normoxic conditions in Trametinib+KD cultures, in contrast to the loss of 
neurons in solo siRNA treated cultures. This suggests that the neurotoxicity of reduced Igf1 
expression under normoxic conditions is protected against by combined Trametinib 
treatment.  
 
In Trametinib+KD treated cultures, the p-ERK reduction was once more accompanied by a 
near complete reduction in CC3 signal, with a highly significant effect of treatment (fig 5.6 
A, p=0.0028.). This indicated that apoptosis was similarly reduced in Trametinib+KD treated 
cultures as in Trametinib solo treated. Unlike previous experiments, pS-Akt levels showed an 
increase in Trametinib+KD cultures compared to vehicle treated cultures, with a highly 
significant effect of treatment (p<0.0001), a trend towards an increase at 72 hours post 
hypoxia (p=0.0791), and a significant increase 24 hours post hypoxia (fig 5.6 B, p=0.0230).  
 
0 24 72
0.5
1.0
Neurons DAPI
Untreated
Trametinib
Trametinib+KD
KD
Trametinib+KD  
 
Vehicle 
 
Normoxic Normoxic +24 +24 +72 +72 
Hours after hypoxia Hours after hypoxia 
p-ERK 
t-ERK 
A 
Ve
hi
cl
e 
Tr
am
et
in
ib
+K
D
  
 
Normoxic 
Hours after hypoxia 
+24 +72 
C 
DAPI count 
1.0 
0.5 
Normoxic 
Hours after hypoxia 
+24 +72 
D 
*
DMSO+non targeting siRNA Trametinib+KD Trametinib+siRNA added 
+ 
1 
ho
ur
 
H
Y
PO
X
IA
 
5 
ho
ur
s 
+ 
24
 h
ou
r 
Ly
se
d 
fo
r R
N
A
  
an
d 
pr
ot
ei
n 
Fi
xe
d 
fo
r D
A
PI
 
Ly
se
d 
 
an
d 
 
fix
ed
 
+ 72 hour 
i ii 
0 24 72
0
2
4
Time relative to end of hypoxia
Ex
pr
es
si
on
 re
la
tiv
e 
to
 n
on
-h
yp
ox
ic
 c
ul
tu
re
s
Control
KD
Trametinib
Tram+KD
0 
2 
4 
Hours after hypoxia 
Normoxic +24 +72 
* **
B 
D
A
PI
 c
ou
nt
 
Ig
f1
 e
xp
re
ss
io
n 
Figure 5.5. Combined Trametinib and Igf1 siRNA administration to bi-laminar astrocyte-
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Despite astrocyte Igf1 increase following a noxious incident being neurotoxic, the increased 
astrocyte Igf1 expression observed following Trametinib treatment does not limit the 
neuroprotection of the drug. Furthermore the neuroprotection from reducing Igf1 expression 
and reducing p-ERK levels are not additive when combined. 
 
 
The effect of Trametinib, and combined Trametinib and Igf1 siRNA administration on 
astrocytes in a cellular model of hypoxia induced neuronal cell death 
 
 
 
One of the key advantages of our co-culture model is the ability to treat and manipulate the 
conditions in which the co-culture exists, but then be able to separate the cell types to analyse 
them separately. We therefore applied the same investigation of measuring changes in IIS 
signalling and change in cell number in the astrocyte cultures from our bilaminar co-cultures 
treated with Trametinib, Trametinib+KD, or control conditions.  
 
In both Trametinib and Trametinib+KD treated cultures a near complete reduction in p-ERK 
levels was observed (fig 5.7, A). We also showed previously that a significant reduction in 
astrocyte Igf1 expression was seen in Trametinib+KD cultures, whereas a significant increase 
in Igf1 was observed in solo Trametinib treated cultures (figure 5.5 A). When either 
Trametinib or Trametinib+KD treatments were applied to the cultures at the time of the 
noxious incident, no change in astrocyte number at 24 or 72 hours post hypoxia was observed 
when change was relative to vehicle treated normoxic astrocyte cultures (figure 5.7 B). There 
was however a significant increase in astrocyte number in Trametinib and Trametinib+KD 
treated normoxic cultures compared to vehicle treated normoxic cultures (Trametinib 
p=0.0495. Trametinib+KD p=0.0388). As with the neurotoxicity observed following Igf1 
siRNA treatment (chapter 4), it may be that there is a change in cell number in Trametinib 
and Trametinib+KD treated cultures following hypoxic conditions when the change in 
number is relative to non-vehicle treated normoxic controls, thereby taking into account the 
change in cell number under normoxic conditions with treatment. However when analysis 
was carried out this way there was once again no significant change in astrocyte number 
following a hypoxic incident.  
 
The reduction in p-ERK levels in astrocytes when treated with Trametinib or Trametinib+KD 
was accompanied by a reduction in CC3 levels, implying that apoptosis was reduced in these  
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Cultures. In Trametinib and Trametinib+KD treated cultures there was an effect of hypoxia 
on CC3 level, as well as an effect of treatment, and a significant interaction between these 
factors. Astrocyte pS-Akt levels were not significantly changed with Trametinib or 
Trametinib+KD treatment under normoxic or post hypoxic cultures (figure 5.8).  
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In vivo Trametinib administration in mice 
 
 
 
We have successfully shown that Trametinib administration in a cellular model of acute 
neurodegeneration shows neuroprotective affects that are not limited by its induction of 
increased astrocyte Igf1 expression. With our hypothesis of attenuating p-ERK levels being 
neuroprotective against neurodegeneration being supported by our in vitro model, we 
proceeded with investigating Trametinib in vivo administration in mice. 
 
 
Safety assessment of Trametinib for in vivo application 
 
 
 
It was necessary to establish that Trametinib was not toxic to intact brain tissue before in vivo 
experimentation could begin. To do this we used hippocampal organotypic slices, thin slices 
of mouse brain that preserve brain structures and circuitry, from GFP expressing mice. The 
10% of glutamatergic neurons in these slices that express GFP allowed detailed observation 
of the morphology of neurons via confocal microscopy. With decreased dendritic arborisation 
and decreased spine number being indicative of neuronal stress and damage (Campana et al., 
2008; Magarinos and McEwen, 1995), we investigated the toxicity of Trametinib 
administration on ex vivo brain tissue by measuring dendritic spine density and gross 
dendritic arborisation of CA1 neurons in the hippocampus when treated with Trametinib or 
the same volume of DMSO. 
 
Organotypic slices were treated with 10µM Trametinib for up to 2 weeks, adding Trametinib 
to the culture medium every three days with control slices treated with the same volume of 
DMSO in otherwise parallel conditions. The brain slices were then taken for confocal 
imaging of CA1 pyramidal neurons of the hippocampus at 5 and 14 days from the start of 
Trametinib application, to examine changes in spine density and dendritic arborisation with 
treatment. These slices once imaged were then snap frozen and homogenised for protein, 
allowing us to quantify Trametinib inhibition of p-ERK levels in ex vivo brain tissue for up to 
14 days.  
 
Organotypic p-ERK levels were nearly undetectable in the Trametinib treated slices 
compared to vehicle treated slices (figure 5.9, A), yet confocal microscopy showed that not 
only did the neurons show comparable dendritic arborisation to the vehicle treated slices, but  
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there similarly was no significant difference in spine density between the treatments (figure 
5.9 B). It therefore seems that this dose of Trametinib is well tolerated by mouse brain tissue, 
and we therefore felt confident that in vivo procedures would not result in brain toxicity. 
 
 
In vivo Trametinib application in adult mice 
 
 
 
There is evidence to suggest that Trametinib shows poor brain bioavailability when 
administered orally in mice and humans (Vaidhyanathan et al., 2014). The mechanism 
limiting its brain bioavailability is the actions of the efflux protein P-glycoprotein (P-gp) but 
not the common breast cancer resistant protein (Bcrp) (Vaidhyanathan et al., 2016).  P-gp 
(official gene name: ABCB1 in humans, Abcb1a in mice) is an ATP dependant membrane 
bound transport protein found in epithelial cells throughout the body, and crucially is 
expressed in the luminal membrane of capillary endothelial cells in the brain (Schinkel, 
1999). This suggests that it is the crossing of the blood brain barrier that acts as the limiting 
step in Trametinib’s brain bioavailability. This would limit the brain bioavailability of all 
systemic administration routes of Trametinib; including oral, intravenous, and intraperitoneal 
administration. This initially poses a substantial problem, as these are the most feasible routes 
of administration in experimental animals. Overall however with repurposing of Trametinib 
for human administration in mind, oral administration is the only method for which 
Trametinib is currently approved for in humans (National Institute for Health and Clinical 
Excellence, 2016). A potential way to overcome this would be to co-administer Trametinib 
with an inhibitor of the efflux protein that limits its entry to the brain. Before oral 
administration is investigated however, we first wanted to establish that Trametinib was still 
efficacious at inhibiting the mammalian brain when administered directly to the intact brain.  
 
With P-gp being expressed heavily in epithelial cells in the brain (fig 5.10), we administered 
Trametinib to the intact brain of 4-month old mice by intracerebroventricular injection; 
whereby a small volume of Trametinib (10 µl) in DMSO is injected directly into the 
ventricles of a mouse (DeVos and Miller, 2013). The same volume of DMSO vehicle was 
injected but containing no drug for control comparison. One group of mice received 
intracerebroventricular injections of Trametinib at 1mM, 100µM, and 10µM concentrations 
or DMSO vehicle, and were decapitated 24 hours after the injection, before cortex and 
hippocampal tissue was processed for western blotting to assess p-ERK levels. A second  
P-
gp
 
Figure 5.10. Expression levels of P-gp in the mouse and human brain. The efflux 
transporter P-gp that has been shown to limit the brain concentration of Trametinib, is 
nearly exclusively expressed in the epithelial cells of the human and mouse brain. Panels 
modified from http://www.brainrnaseq.org. F. Astro - Fetal Astrocytes, M. Astro – Mature 
Astrocytes, Oligo – Oligodendrocytes, Mic/Mac – Microglia/Macrophages, Endo – 
Endothelial, OPC – oligodendrocyte Precursor Cells, NFO – Newly Formed 
Oligodendrocytes, MO – Mature Oligodendrocytes. FPKM - Fragments per kilobase of 
transcript sequence per million mapped fragments 
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group of mice were injected with a concentration of 1mM of Trametinib or the same volume 
of DMSO intracerebroventricularly, and mice decapitated for analysis 1, 3, and 7 days after 
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injection. Usually when administering a drug, µg/kg is used as the measure of dosage. As we 
are dealing with a single organ however, and to avoid assumptions about whether the 
intracerebroventricularly injected drug remains in the brain or distributes around the whole 
body, we refrained from dosing based on a weight of tissue/animal and instead injected based 
on the concentrations mentioned above.  
 
Intracerebroventricular injections of Trametinib produced no decrease in p-ERK levels in the 
cortex or hippocampus of injected mice at any time point or with any concentration of drug 
(figure 5.11). This data suggests that the intracerebroventricular injection of Trametinib did 
not succeed in reducing p-ERK in vivo.  
 
The reason for this lack of effect is likely to be the actions of P-gp. We had assumed that by 
bypassing the blood brain barrier we would be able to administer Trametinib to the brain, 
avoiding the effects of P-gp, but this was not the case. To overcome this, we administered the 
P-gp inhibitor Elacridar at the same time as administering Trametinib, in an attempt to 
increase Trametinib’s in vivo brain inhibition. Vaidhyanathan and Elmquist showed an 
increase in brain Trametinib concentration when administered in P-gp knock out mice, 
(Vaidhyanathan et al., 2014), and similarly showed that the brain concentration of the PI3K 
inhibitor GSK2126458, also reduced in its brain bioavailability by the P-gp transporter (as 
well as the Bcrp transporter), was successfully increased by combining GSK2126458 
administration with the P-gp/Bcrp inhibitor Elacridar (Vaidhyanathan et al., 2016). Therefore 
we hypothesised that the brain bioavailability of Trametinib would be greatly increased with 
the co-administration of Elacridar.  
 
To replicate previous studies that had success in administering Trametinib and Elacridar in 
mice, we administered Trametinib by oral gavage in animals fasted for 2 hours at a dose of 
5mg/kg in a solution of 1% methocel/5%DMSO, with Elacridar administered by 
intraperitoneal (IP) injection at a dose of 10mg/kg in a solution of 30% microemulsion (6:3:1 
ration of Kolliphor EL, Di-ethyl ether, Glyceryl trioctanoate; see methods), 30 minutes prior 
to Trametinib administration (Vaidhyanathan et al., 2014; Vaidhyanathan et al., 2016; van 
Waterschoot et al., 2009). Control animals were treated in the same way with vehicle 
solutions minus Trametinib and Elacridar. We were concerned with the half-lives of these 
drugs, so decided also on a shorter time between drug administration and animal decapitation. 
Animals were therefore killed 5 hours after Trametinib administration, and hippocampus and 
cortex tissue tested by western blotting for p-ERK and t-ERK levels.  
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Figure 5.12 shows that a significant 37% reduction in ERK1/2 phosphorylation was seen with 
Trametinib administration on its own (p=0.0089), but a far stronger reduction in p-ERK level 
was seen when Trametinib was combined with Elacridar (p=0.0011). Furthermore there is a 
significant difference between the solo Trametinib treated and Trametinib Elacridar dual 
treatment (p=0.0242). It is interesting to note that oral administration of just Trametinib in 
figure 5.12 succeeded in reducing p-ERK levels in the brain, whereas just Trametinib injected 
into the brain in figure 5.11 did not. This could be due to multiple factors, including the far 
higher dose given orally to account for the unknown permeability of the blood brain barrier, 
but also because of the shorter interval between administration of drug and quantification of 
p-ERK level in the brain, being 5 hours for oral administration and 24 hours for 
intracerebroventricular injection. Whilst solo Trametinib succeeded in reducing brain p-ERK 
level when given at a 5mg/kg dose by oral gavage, the reduction in p-ERK is lower than we 
would want to achieve in order to test our hypothesis. The reduction in phosphorylation seen 
when Trametinib was combined with Elacridar however was at the level we want to achieve 
over a long time period to test the effect of IIS reduction on neurodegeneration. 
 
 
Unfortunately, despite our success in achieving in vivo p-ERK inhibition in the brains of 
mice, due to time constraints and the lack of access to an appropriate mouse model of acute 
neurodegeneration, testing the effects of Trametinib in vivo was not possible during my PhD 
studies, and will therefore be carried on further by my supervisor Dr Dervis Salih. 
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Figure 5.11. Injecting Trametinib intracerebroventricularly at a range of 
concentrations is ineffective at reducing p-ERK levels in the brains of wild type 4 
month old mice, regardless of the duration between injection and p-ERK 
measurement. (A) When taken 24 hours after injection,  1.5mg/kg Trametinib failed to 
change p-ERK levels in the cortex or hippocampus (i) Western blot images of p-ERK and 
t-ERK from cortex and hippocampal (ii) Graphical representation of this (B) When 
1.5mg/kg of Trametinib was injected intracerebroventricularly, and mice killed for 
analysis of cortex and hippocampus tissue to ascertain p-ERK levels, no change in p-ERK 
levels were observed in the cortex or injected mice at any time point, but an increase in p-
ERK levels was observed in the hippocampus of injected mice, peaking at 3 days post 
injection (i) Western blot images of p-ERK and t-ERK levels in the hippocampus and 
cortex (ii) graphical representation of this.  
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Figure 5.12. Co-administration of the P-gp inhibitor Elacridar with Trametinib 
increases brain MEK inhibition. 4-month old C57BL-6 mice were given either 5mg/kg 
oral Trametinib, 10mg/kg intraperitoneal Elacridar, both, or oral and intraperitoneal 
administration of the vehicles without any drug, with mice killed for analysis 5 hours after 
the Trametinib injection. Whilst Trametinib showed a significant decrease in p-ERK 
levels, when combined with the P-gp inhibitor Elacridar the reduction in p-ERK levels 
was greatly increased (A) Western blot images of p-ERK and t-ERK from the 
hippocampus of treated mice (B) Graphical representation of this. Data shown is the mean 
+/- SEM. Student’s t-test * p<0.05 ** p<0.01 *** p<0.001. n=3 mice. 
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Conclusion 
 
 
 
Previous studies have identified that pharmacological inhibitors of the IIS cascade are 
effective at reducing neurodegeneration in models of acute neurodegeneration. With the IIS 
cascade being frequently upregulated in cancers, many drugs have already been developed to 
inhibit IIS signalling to treat cancers, with many of these already being approved for use in 
humans. We therefore hypothesised that these clinically approved IIS inhibitors could be 
repurposed to intervene in the neurodegenerative process and potentially ameliorate 
neurodegeneration in acute neurodegenerative diseases.  
 
Testing two clinically approved IIS inhibitors, we found that whilst Trametinib and 
Dabrafenib were potent inhibitors of the IIS cascade in both astrocyte and neurons in culture, 
long term administration of Dabrafenib showed paradoxical activation of ERK1/2 signalling 
in cultures with no B-raf mutations. Therefore we chose only to investigate our hypotheses 
with Trametinib.  
 
Neuronal cell loss in our in vitro model of acute neurodegenerative disease was reduced by 
the application of Trametinib to cultures at the time of the hypoxia. This reduction in cell loss 
was accompanied by a reduction in CC3 signal, implying that apoptosis was similarly 
reduced by Trametinib treatment. We also hypothesised however that the endogenous 
astrocyte Igf1 increase observed in these cultures following hypoxia, would be reduced by the 
neuroprotection of Trametinib. This was not the case however, with an increase in astrocyte 
Igf1 expression in these cultures even under normoxic conditions. This raised the possibility 
that the Igf1 induced neuronal cell death observed in chapter 4, could be limiting the 
neuroprotection of Trametinib. When Trametinib was applied at the same time as knocking 
down Igf1 expression using siRNA however, no increase in neuroprotection was observed 
compared to those treated with Trametinib alone, implying that the Trametinib 
neuroprotection, and anti-Igf1 neuroprotection are not additive.  
 
With Trametinib showing proof of principle that it could ameliorate neurodegeneration, we 
then showed that Trametinib could be administered orally to decrease p-ERK levels in the 
brain. For Trametinib to be effective in the brain, inhibition of the efflux transporter P-gp 
with the co-administration of the P-gp inhibitor Elacridar at the same time as Trametinib 
administration was required. Combining these drugs lead to a potent reduction in p-ERK 
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levels in the hippocampus of wild type treated mice. With this successful inhibition of the IIS 
cascade in the brains of wild type mice, we are now in a position to apply this co-
administration approach to mice modelling acute neurodegenerative disorders, to fully test 
our central hypothesis, that IIS inhibitors can be repurposed to provide neuroprotection in 
acute neurodegenerative diseases.  
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Chapter 6 
 
 
Discussion 
 
 
 
In this thesis I have investigated the therapeutic potential of modulating the IIS 
cascade in the brain in neurodegenerative diseases. Neurodegenerative diseases are a 
leading cause of mortality and disability in developed nations, and despite the variable 
pathologies of this group of diseases, they have a unifying factor – the irretrievable 
loss of neurons in the brain.  
 
The IIS cascade is a molecular pathway able to modulate the rate of ageing in a range 
of organisms (Harrison et al., 2009; Holzenberger et al., 2003; Kenyon et al., 1993; 
Slack et al., 2015; Tatar et al., 2001), as well as modulate the progression of 
neurodegenerative diseases in experimental animals (Cohen et al., 2006; Cohen et al., 
2009; Cooper et al., 2015). Endogenous changes in the IIS cascade have been 
observed in various neurodegenerative diseases (Bondy and Lee, 1993; Ferrer et al., 
2001; Steen et al., 2005; Talbot et al., 2012). Furthermore, increased signalling at 
ERK1/2 has been implicated as a neuronal cell death mechanism, and has been 
observed in diseased neurons in the human neurodegenerative brain (Alessandrini et 
al., 1999; Almeida et al., 2005; Lu et al., 2008; Luo and DeFranco, 2006; Pei et al., 
2002; Perry et al., 1999; Subramaniam et al., 2005; Zhu et al., 2002). This cascade 
therefore seems uniquely poised as a target to intervene in the neurodegenerative 
process. We have therefore investigated the feasibility of modulating this cascade for 
therapeutic benefit. 
 
Targeting the IIS cascade has previously shown promising results, with the 
administration of IIS inhibitors decreasing infarct size in animal models of stroke and 
rescuing memory deficits in a mouse model of AD (Echeverria et al., 2009; Gladbach 
et al., 2014), and the overexpression of human IGF1 in astrocytes leading to less 
neuronal cell death in a mouse model of TBI (Madathil et al., 2013). Whilst these 
results show promise, no IIS inhibitors have been taken to clinical trial for treating 
neurodegenerative diseases. Key questions need to be addressed in order to fully 
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exploit the possible therapeutic potential of targeting the IIS cascade to treat 
neurodegeneration.  
 
We have focused on three areas demarcated into three results chapters addressing 
different questions about IIS modulation in neurodegeneration. Firstly, with the loss 
of neurons in chronic neurodegenerative diseases spanning years, to address the 
question of when IIS modulation would be most suitable as an approach to treat 
neurodegeneration in chronic neurodegenerative diseases, we characterised 
endogenous IIS changes in relation to different pathological components of AD. 
Chapter 3 therefore focused on characterising changes in the IIS cascade in mouse 
models of AD that model different disease components, and crucially occur at 
different times in the disease. 
 
Secondly, although an overexpression of human IGF1 in astrocytes has been shown to 
be neuroprotective following an acute neurodegenerative insult (Madathil et al., 
2013), how the endogenous increase in astrocyte IGF1 effects neuronal cell death has 
never been considered. This is an important question, as this endogenous IGF1 
increase is observed in multiple neurodegenerative diseases, and therefore seems to be 
a feature of neurodegenerative disease itself. Chapter 4 therefore addressed the 
endogenous Igf1 response and its role in neuronal cell death, using a novel bilaminar 
co-culture model of acute neurodegeneration, and considers whether these phenomena 
could be exploited for novel therapeutic gain.  
 
Finally in chapter 5, with experimental IIS inhibitors showing neuroprotective 
properties in mouse models of stroke, we investigate the repurposing of already 
clinically approved IIS inhibiting drugs to treat acute neurodegenerative diseases. 
This was done by establishing the suitability and practicality of using Trametinib to 
inhibit the IIS cascade in the mammalian brain, and also by testing the proof of 
principle in our in vitro model of acute neurodegeneration. By investigating these 
topics we have furthered the possible exploitation of the IIS cascade as a novel 
therapeutic target for improved therapeutic intervention in neurodegenerative 
diseases. 
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Endogenous changes in the IIS cascade in AD  
 
 
 
To characterise IIS changes at different pathological stages of the chronic 
neurodegenerative disease AD in chapter 3, we examined changes in expression of 
Igf1 and IGF1, and levels of phosphorylation at the activating phosphorylation sites of 
Akt and ERK1/2 (pS-Akt, pT-Akt, and p-ERK), in brain tissue from different aged 
APP-KI and TG4510 mice, and a preliminary investigation of human brain tissue. 
This allowed us to examine how IIS was changed in response to various pathological 
components of AD, that being rising amyloid beta and plaque levels in the APP-KI 
mice, rising phosphorylated tau and tau tangles in the TG4510 mice, and the very end 
stage of AD pathology with both advanced tau pathology and advanced amyloid 
pathology, in the post mortem human brain tissue.  
 
This characterisation identified 3 different points in AD pathology where IIS was 
differently altered. In 2-month old APP-KI mice where amyloid pathology was 
limited to increased Aβ40 and Aβ42 levels and the very first detectable small amyloid 
plaques, substantial increases in Akt and ERK1/2 phosphorylation was observed, with 
over a ten times increase in p-ERK level in APP-KI cortical tissue. In the TG4510 
hippocampus, Akt phosphorylation was decreased during both early tau pathology 
(hyperphosphorylated tau and tau pretangles), and very late stage tau pathology (tau 
tangles and substantial neuronal cell loss), albeit this reduction in phosphorylation 
was at pS-Akt in early, and pT-Akt in late tau pathology. Furthermore p-ERK levels 
were also increased in early tau pathology. Thirdly an increase at pT-Akt was 
observed in only fAD frontal cortex brain samples, but not sAD samples. Finally Igf1 
expression was increased in late stage tau pathology, as well as early and late (but not 
intermediate) amyloid pathology.  
 
Timings of therapeutic IIS intervention in AD pathogenesis 
 
 
The overall aim of characterising IIS during AD pathogenesis was to establish an 
appropriate time for therapeutic IIS modulation. It is useful to know that the majority 
of endogenous changes in the IIS cascade in AD pathogenesis occur at a very early 
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time point in both amyloid and tau pathological development, with limited changes in 
more advanced stages of pathology, including in human post mortem tissue. This 
would suggest that using IIS modulators at later stages of disease development would 
not be counteracted by endogenous IIS changes during disease development. 
However there is an indication of acquired IIS resistance in the APP-KI tissue could 
affect the efficacy of IIS interventions.  
 
With Igf1 increased in 2-month and 8-month tissue in the cortex of APP-KI mice, but 
p-ERK and pS-Akt levels only increased at 2-month, it seems that Igf1 increases 
downstream IIS signalling in 2-month tissue but not in 8-month. This could be 
evidence of induced Igf1 insensitivity in the APP-KI mouse brain. Furthermore, the 
reduction in Akt phosphorylation in late stage TG4510 tissue, when Igf1 expression 
was greatly increased, also suggests that this tissue may be insensitive to Igf1. This 
insensitivity would fit with human findings of an IGF1 resistant brain state (Talbot et 
al., 2012). However to verify this indication of acquired IIS insensitivity, as 
mentioned in chapter 3, an examination of downstream IIS gene expression should be 
undertaken, as well as possibly carrying ex vivo stimulation as was the case in human 
brain tissue (Bomfim et al., 2012). Overall it seems distinctly possible that APP-KI 
and TG4510 mice develop an Igf1 resistant brain state. Therefore when testing IIS 
modulators in AD, we must be vigilant of the possibility of acquired IIS resistance 
potentially limiting the efficacy of our treatments.  
 
It would be interesting to investigate further the strong IIS change with the earliest 
amyloid pathology development, as if this IIS change impacts on disease progression, 
it could represent a novel site of disease intervention.  
 
 
Phosphorylated ERK1/2 in AD 
 
 
Our characterisation of IIS in different pathological stages of AD has also allowed us 
to examine the link between raised ERK1/2 phosphorylation and neuronal cell death. 
With previous literature implying raised p-ERK was associated with neuronal cell 
death signals, and increased p-ERK staining being shown in the neurons of the human 
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AD brain that contained tau tangles (Pei et al., 2002), we expected to observe 
increased p-ERK in tissue where neuronal cell death was occurring, primarily 
therefore TG4510 tissue and human AD tissue.  
 
An increase in p-ERK was observed in 2.5-month TG4510 tissue, and a substantial 10 
times increase was present in APP-KI tissue from the earliest beginnings of amyloid 
pathology. With no observable increase in neuronal cell death in the APP-KI model, it 
is highly unlikely that this increased p-ERK is associated with neuronal cell death. 
Similarly there is limited neuronal cell death at 2.5 months in TG4510 mice, 
especially compared to 8-month TG4510 tissue where no change in p-ERK level was 
observed. With no detectable difference in p-ERK levels in older TG4510 or human 
AD tissue, our data suggests that there is no increase in p-ERK levels during neuronal 
cell death, but there are earlier increases in p-ERK level that are likely not associated 
with neuronal cell death.  
 
This is contrary to previous data suggesting increased p-ERK in tangle containing 
neurons in human AD (Pei et al., 2002), and data suggesting a role for increased p-
ERK in neuronal cell death (Chen et al., 2009; Luo and DeFranco, 2006). This could 
be due to our detection method, western blotting, not being as sensitive as the 
immunohistochemistry employed in the previous study (Pei et al., 2002). Therefore 
whilst our evidence suggests no significant increase in p-ERK levels at times of 
neuronal cell loss, we would like to confirm this using immunohistochemistry in our 
tissue to investigate whether more subtle changes have occurred. However the clear 
change in young APP-KI tissue suggests that raised brain p-ERK levels are not 
always indicative of neuronal cell death. 
 
One possible implication of the increased p-ERK observed in the 2-month APP-KI 
brain, is the role of ERK1/2 as a tau kinase. Increased Aβ42 levels and amyloid 
plaques precede AD associated tau pathology in human AD, but what causes amyloid 
pathology to progress to tau hyperphosphorylation and tau tangles is unclear. With 
observations of increased p-ERK in tangle containing neurons in human AD (Pei et 
al., 2002), and it seeming that early amyloid pathology substantially increased p-ERK 
levels in our data, amyloid induced p-ERK increase could provide a link in the 
pathological progression of AD. With the beginnings of tau pathology in AD 
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occurring at a more advanced stage of amyloid pathology however, with plaques 
present, and the lack of increased p-ERK signal in later ages of APP-KI mice with 
more advanced plaque deposition, it seems unlikely that the increase in p-ERK levels 
observed in 2 month old APP-KI mice is responsible for initiating tau pathology. 
Furthermore, no increase in p-Tau levels were observed in characterisations of this 
mouse line (Saito et al., 2014). However, given the observation of increased p-Tau in 
other amyloid pathology mice (Howlett et al., 2008), perhaps if APP-KI mice are 
examined at an older age increased p-Tau may also be present.  
 
 
Igf1 increase in AD 
 
 
 
In both APP-KI and TG4510 mouse models, Igf1 expression increased as the 
pathological components of the disease also increased, however no increase was 
observed in moderate pathology in 4-month APP-KI mice. This increased Igf1 
expression was corroborated by significantly higher levels of Igf1 expression as 
shown from online databases of gene changes in multiple other mouse models of 
pathological components of AD, with Igf1 being one of the most significantly 
increased genes in its expression compared to wild type mice (Matarin et al., 2015). 
Our work therefore corroborates raised astrocyte Igf1 expression being a feature of 
the chronic neurodegenerative disease AD. 
 
 
Consideration of whole tissue analysis and future experiments 
 
The primary question addressed in this section was how IIS changes in the brain 
during AD pathogenesis. We addressed this question with techniques using whole 
brain lysates –western blotting and RT-qPCR. Whilst this is a useful way of 
examining this tissue for changes in gene expression and protein levels, the brain is 
composed of various cell types that will all contribute to the overall signal measured 
by whole lysate techniques. This cellular heterogeneity needs careful consideration in 
order to sensibly view our findings.  
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The overall signal measured by whole brain lysate techniques is contributed to by all 
cell types in the brain, with each cell type contributing a certain proportion to the 
signal based on the abundance of these cells and expression levels of genes in 
different cell types. Crucially, in neurodegeneration the relative proportion of these 
cells changes. For example the neuronal proportion is reduced from 
neurodegeneration, and the glial proportion increased by astrogliosis and microgliosis. 
Therefore whilst gene expression or protein level changes may be observed between 
our AD samples and wild type or non-diseased samples, in which cell types these 
changes occur is impossible to ascertain with the techniques we have used. Whether 
these changes represent true changes or rather are a product of a change in brain 
sample cell type proportions also means making firm assertions based solely on whole 
tissue lysate data hazardous. It is also very possible that significant changes in one 
cell type population may be offset by the opposing changes in another cell type 
population, and are therefore unobservable by these techniques.  
 
To overcome these limitations, and allow us a more detailed investigation of 
individual cell type IIS changes in response to AD pathology, future experiments 
should be carried out. Firstly our western blot and RT-qPCR data could be normalised 
by neuronal, astrocyte, or microglial markers, to allow relative changes to specific cell 
types to be appreciated. Careful consideration of the markers would be needed 
however, utilising new identification of markers with greater specificity (Zhang et al., 
2014). This should also be accompanied by immunohistochemistry replicating our 
western blot data, which would allow us to observe the cell types in question that 
changes occur in. Unfortunately this was not possible with the preparations of mouse 
and human tissue that we had available at the time of this thesis. Whilst flow 
cytometry may be a possible technique to separate changes in specific cell types, the 
cell separation phase of this technique may loose crucial data due to the extensive 
projections of the cell types in question. With these cell type specific experiments, a 
more detailed conclusion can be made about endogenous IIS changes in response to 
changing AD pathology.  
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Endogenously raised IGF1 in neurodegenerative disease  
 
 
 
 
We directly tested the contribution of endogenous increases in Igf1 on acute 
neurodegeneration by developing an in vitro model of acute neurodegeneration. This 
model showed progressive neuronal cell loss following a noxious insult, accompanied 
by an increase in astrocyte Igf1 level. By comparing cultures with Igf1 knocked down 
to those where Igf1 increased following the hypoxic incident, allowed us to 
investigate the contribution of Igf1 increases on neurodegeneration and IIS signalling 
in both astrocytes and neurons. 
 
 
 
Astrocyte Igf1 contributes to neuronal cell death in acute neurodegeneration 
 
 
 
We identified that cultures with Igf1 knocked down showed less neuronal cell death 
following a hypoxic incident than cultures where astrocyte Igf1 increased post 
hypoxia. This implies that the increased astrocyte Igf1 following the hypoxic insult 
contributes to neuronal cell loss. This is unexpected given the Madathil et al 
overexpression findings, and would add an extra dimension to the dose response 
relationship between administered IGF1 concentration and neuroprotective effect seen 
in other papers, and emphasises the need to characterise endogenous changes 
(Madathil et al., 2013). To confirm this surprising result, we should carry out further 
control experiments to test this finding further.  
 
Crucially a recovery experiment should be performed, whereby Igf1 knock down is 
carried out, but a suitable concentration of Igf1 added to the media. If neuronal cell 
loss similar to noncoding-siRNA treated cultures was observed, then this would add 
substantial weight to our unusual finding. It would also be useful to repeat our 
experiment with either another siRNA against Igf1, or the addition of an Igf1R 
antibody to outcompete the binding of Igf1 to its receptor, in effect having the same 
effect as knocking down Igf1. By carrying out these further experiments, our unusual 
finding can be tested fully.  
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Our observation of the role of astrocyte Igf1 in neuronal cell health is not as simple as 
it being neurotoxic however. Igf1 knocked down cultures had fewer neurons under 
normoxic conditions, implying that a level of baseline astrocyte Igf1 expression is 
required for neuronal cell maintenance. This would make the conversion of the 
observed neuroprotective effect to a clinically applicable intervention more complex, 
as evidently the degree of Igf1 reduction is crucial to its effects on neurons.  
 
 
Mechanism of Igf1 induced neurotoxicity 
 
 
Whilst astrocyte Igf1 increase seemed to signal to neurons as shown by the 
association between astrocyte Igf1 increase and neuronal p-ERK increase, no 
significant increase in p-ERK or pS-Akt was observed in neurons following hypoxia. 
Igf1 knockdown similarly did not affect p-ERK levels in neurons. Therefore the Igf1 
dependant neuronal cell death observed is unlikely to be via signalling through the IIS 
cascade.  
 
We suspected this could be because Igf1 is signalling in an autocrine manner to 
astrocytes, rather than in a paracrine fashion to neurons. In this circumstance I refer to 
autocrine as signalling amongst astrocytes or the single astrocyte that is increasing its 
expression of Igf1 signalling solely to itself, whereas paracrine is signalling to another 
cell type, in this case neurons. p-ERK and pS-Akt levels not only did not change in 
astrocytes following an increase in Igf1 expression, but any change did not correlate 
with Igf1 increase. This strongly suggests that the increased Igf1 expression in 
astrocytes does not signal through the IIS cascade to astrocytes, but does to neurons 
albeit weakly.  
 
How astrocyte Igf1 signals to neurons to cause neuronal cell death, whilst not doing 
so via IIS signalling, is unclear. One possibility is that we are missing changes in p-
ERK or pS-Akt levels with the time points we picked, as Subramaniam et al showed 
early IGF1 supplementation caused an early increase in p-ERK after 15 minutes that 
was not present at later times, accompanied by increased pS-Akt 24 hours after injury 
and IGF1 addition (Subramaniam et al., 2005). However, these experiments applied 
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high levels of IGF1 immediately at the point of injury, whereas endogenously we do 
not observe Igf1 increase until 72 hours post insult. Nonetheless it may be interesting 
to investigate earlier time points for IIS levels in our cultures.   
 
It is also a possibility that Igf1 is not signalling via the IIS cascade. Our focus on the 
IIS cascade as the mediator of IGF1’s effect on cells comes from the assumption that 
it signals via IGF1R. Hybrid IGF1R/insulin receptors exist, composed of a 
heterodimer of one IGF1R subunit and one insulin receptor subunit, and some are 
preferentially activated by IGF1 (Slaaby, 2015), however the formation of these in the 
brain and their physiological function is unknown. Furthermore IGF1 has also been 
shown to signal via other non-IIS means such as via Janus kinases (Gual et al., 1998), 
and c-Abl kinase (Genua et al., 2009). This furthers the possibility that IGF1 induced 
neuronal cell death is through non-IIS based mechanisms, making its exploitation as a 
neuroprotective options more difficult.  
 
Furthermore whilst astrocyte Igf1 seems to signal only weakly through the IIS 
cascade to neurons and astrocytes, this may not be the case in the brain where far 
more cell types exist. With Igf1 being a proliferative factor, and microglial 
proliferating in cases of brain injury (Perry and Holmes, 2014), Igf1 increase could 
drive the proliferation of microglia. This would not explain the neurotoxic effects of 
Igf1 increase in our model, but suggests that raised Igf1 may have more physiological 
roles in neurodegeneration than was possible to observe in our in vitro model.  
 
It is also very likely that Igf1 is not the only factor released from astrocytes in 
response to neuronal cell damage, but is a single factor in a whole milieu of 
chemokines and cytokines released in response to stress. It therefore seems that whilst 
we are modulating only one of these factors, that others may be responsible for or 
contribute to the neuronal cell loss observed, and that Igf1 in some way compounds 
this effect via non-IIS based means. Similarly we have been considering Igf1 change 
solely from its influence on p-ERK levels and its effect on neuronal cell death. Igf1 is 
implicated in many other neuronal functions, including synaptic function and 
plasticity in the adult brain (Llorens-Martin et al., 2009). Various studies have 
identified its effects of modifying neuronal excitation and synaptic transmission (Cao 
et al., 2011; Gazit et al., 2016), so whilst we were interested in Igf1’s role in 
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neurodegeneration, it is clear that its physiological function in the brain is more 
complex than this.  
 
Therefore it seems that increased IGF1 in acute neurodegenerative diseases could be 
contributing to neuronal cell death, but is not doing so via p-ERK dependant 
mechanisms. Further research is required to elucidate this observed phenomenon 
further before any firm conclusions can be made.  
 
 
 
Trametinib as a repurposable IIS inhibitor for acute neurodegeneration 
 
 
 
Despite increased IIS induced neuronal cell death seeming not to be present in our in 
vitro model of acute neuronal degeneration, abundant evidence exists that reducing 
IIS is neuroprotective in neurodegeneration. In particular, pharmacological 
application of IIS inhibitors to animal models of disease has been neuroprotective 
(Ashabi et al., 2013; Echeverria et al., 2009; Gladbach et al., 2014), yet the 
progression of these results to clinical trials has not yet taken place. We therefore 
investigated the neuroprotective effects of the already clinically approved drugs 
Trametinib and Dabrafenib, and the efficacy of using these drugs to inhibit the IIS 
cascade in the mammalian brain.  
 
Identifying a suitable IIS inhibitor 
 
 
Previous studies had indicated that Dabrafenib treatment to cells containing wild type 
as opposed to cells with a V600E B-raf mutation, might paradoxically lead to an 
increase in signalling through the Ras-Raf-ERK pathway (Anforth et al., 2012; 
Hatzivassiliou et al., 2010; Poulikakos et al., 2010). When testing Dabrafenib in 
primary astrocyte cultures, we found that ERK2 levels were in fact increased when 
Dabrafenib was repeatedly applied every 2 days for a week. With our aim being to 
investigate IIS inhibition this made Dabrafenib unsuitable for further investigation of 
our hypothesis. Trametinib on the other hand, proved effective at potently reducing p-
ERK levels in primary neurons and astrocytes, and also had no toxic effects on ex 
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vivo organotypic brain slices when applied for 2 weeks. Trametinib was therefore 
used for testing our hypothesis.  
 
Trametinib as a neuroprotective drug 
 
 
When applied to our in vitro model of acute neurodegeneration, Trametinib reduced 
neuronal cell death following a hypoxic insult, indicating that inhibiting IIS with 
Trametinib is neuroprotective. Furthermore levels of apoptosis measured by CC3 
were also reduced with Trametinib administration, indicating it is protective against 
apoptosis. This is interesting, as the neuronal cell death in our in vitro model was not 
accompanied by increased p-ERK levels, and therefore very unlikely to be p-ERK 
dependant. This is similarly shown in lifespan extension experiments, where reduced 
IIS leads to longer lifespans in a variety of organisms. The cause of death in these 
animals is not due to increased IIS, but rather it seems reducing IIS conveys a pro-
health effect. It is highly likely therefore that this is also the case with Trametinib 
administration, where the neuroprotection is not by blocking p-ERK dependant 
neuronal cell death, but by a pro-health effect as a consequence of reduced p-ERK.  
 
Based on this evidence of neuroprotection in vitro, we investigated the ability of 
Trametinib to inhibit IIS in the mammalian brain, for the eventual testing of 
neuroprotection in mouse models of neurodegeneration.  
 
 
Trametinib use in the mammalian brain 
 
 
Trametinib applied intracerebroventricularly (ICV) to the brain of wild type mice did 
not result in p-ERK reduction. Previous studies suggest that the efflux transporter P-
glycoprotein (P-gp) limits the brain bioavailability of Trametinib (Vaidhyanathan et 
al., 2014; Vaidhyanathan et al., 2016). We therefore co-administered the P-gp 
inhibitor Elacridar with Trametinib in wild type mice, and found that p-ERK levels 
were substantially decreased in the brain. We did also see reductions with Trametinib 
treatment alone in these experiments, albeit smaller reductions than when combined 
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with Elacridar. In this experiment we examined p-ERK levels in the brain 3 hours 
after administration, rather than 24 hours at the earliest in the ICV experiments. 
Despite this, the greater brain p-ERK reduction when Trametinib was co-administered 
with Elacridar suggests that P-gp was limiting the brain bioavailability of Trametinib, 
but that P-gp does not fully prevent Trametinib’s effect in the brain when measured a 
short duration after administration.  
 
These results suggest that Trametinib has the potential to potently inhibit the IIS 
cascade in the brain, however it appears necessary to co-administer it with Elacridar 
to improve its brain bioavailability. As we were aiming to investigate the most 
clinically applicable use of IIS inhibitors to ameliorate neurodegeneration, we 
endeavoured to avoid co-administering a non-clinically available drug with 
Trametinib (Elacridar has been tested at phase I trial but no further (Kuppens et al., 
2007)).  
 
 
Mechanisms of IIS related cell death in acute neurodegeneration 
 
 
 
Our findings have indicated that both reducing p-ERK levels and the astrocyte Igf1 
increase are neuroprotective in a cellular model of acute neurodegeneration. Not only 
do these data indicate a role of these factors in neuronal cell death, but they allow a 
mechanistic insight into how IIS may be implicated in neuronal cell death.  
 
 
The role and interaction of phosphorylated ERK1/2 and raised Igf1 expression in 
neurodegeneration 
 
 
 
Increased p-ERK levels have been implicated in neuronal cell death (Chen et al., 
2009; Luo and DeFranco, 2006). IGF1 is a potent activator of the IIS cascade, in 
particular leading to increased p-ERK, and has been observed in acute 
neurodegeneration (Beilharz et al., 1998; Li et al., 1998; Madathil et al., 2010; Nieto-
Sampedro et al., 1982). To investigate the trio of neuronal p-ERK increase, astrocytic 
Igf1 increase, and neurodegeneration in acute neurodegenerative diseases, and the 
impact these factors have on one another, we manipulated the Igf1 and p-ERK levels 
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in a culture model of neurodegeneration (figure 6.1). Put simply, by altering p-ERK 
and Igf1 levels, we could address the question: does astrocyte Igf1 increase cause 
neurodegeneration by increasing p-ERK levels?  
 
Following a hypoxic insult in our culture model, Igf1 expression increased in 
astrocytes, but p-ERK levels did not significantly increase in neurons. Whilst this 
change in astrocyte Igf1 expression did correlate with neuronal p-ERK levels, the 
effect was weak; meaning only small increases in p-ERK resulted from substantial 
astrocyte Igf1 expression increase. This correlation between astrocyte Igf1 expression 
and neuronal p-ERK levels did not hold true when Igf1 was prevented from increasing 
by knocking down Igf1 using siRNA, with large increases in p-ERK levels still 
possible under low Igf1 conditions. Furthermore, changes in neuronal p-ERK levels in 
hypoxia exposed siRNA treated cultures correlated very well with the level of 
neuronal cell death, suggesting that neuronal p-ERK level is still related to neuronal 
cell death level; even when neuronal death is reduced by knocking down Igf1. This 
heavily implies that the Igf1 caused neuronal cell death is not dependant upon Igf1 
increasing p-ERK levels in neurons.  
 
When p-ERK levels were lowered by Trametinib treatment, neuronal loss was 
reduced, but there was an increase in astrocyte Igf1 expression (figure 6.1). Although 
we showed astrocyte Igf1 expression levels were associated with neuronal cell death, 
this increased Igf1 expression in Trametinib treated cultures was shown to not limit 
the neuroprotective effect of Trametinib, as shown by our combination of Trametinib 
with Igf1 knockdown showing comparable levels of neuroprotection.  
 
This suggests a detachment of the effects that neuronal p-ERK levels and astrocyte 
Igf1 levels have on neuronal cell death, whereby decreased Igf1 may lead to 
neuroprotection, but does not do so by lowering p-ERK levels. Increased neuronal p-
ERK levels due to increased Igf1 expression cannot therefore be the mechanism of 
action of the Igf1 knockdown neuroprotective effect, meaning that other mechanisms 
must be responsible. This does show though, that reducing Igf1 expression levels is 
not a sensible way of modulating neuronal p-ERK levels in an attempt to prevent p-
ERK dependant neurodegeneration, meaning if p-ERK reduction is to be investigated  
 
Neuronal 
cell death 
Neuronal 
p-ERK 
Astrocyte 
Igf1 
Neuronal 
cell death 
Neuronal 
p-ERK Astrocyte 
Igf1 
Neuronal 
cell death 
Neuronal 
p-ERK Astrocyte 
Igf1 
Neuronal 
cell death 
Neuronal 
p-ERK 
Astrocyte 
Igf1 
HYPOXIA 
HYPOXIA
+Igf1 knock 
down 
HYPOXIA
+Trametinib 
Normoxic 
conditions 
Figure 6.1. The relationship between astrocyte Igf1 expression, neuronal p-ERK 
level, and neuronal cell death, under our experimental conditions. By modulating 
astrocyte Igf1 increase and p-ERK levels in cultures during hypoxia, we were able to 
investigate the relationship between these factors and neuronal cell death. Whilst both 
neuronal p-ERK and astrocyte Igf1 when reduced are neuroprotective, Igf1 knockdown 
is not neuroprotective via reducing p-ERK levels. (A) Levels under normoxic conditions 
(B) Hypoxia and Igf1 knock down (C) Hypoxia alone (D) Hypoxia with Trametinib 
administration. Black lines = no change, red lines = increase, blue lines = decrease. 
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as a neuroprotective mechanism, it has do done so through a more direct route, like 
Trametinib administration.  
 
The weak correlation between astrocyte Igf1 expression and neuronal p-ERK levels 
under hypoxic non-treated conditions could be a problem with our in vitro model 
however. Whilst it was possible to plate neuronal cultures at 500,000 neurons/cm3, it 
was only possible to plate astrocytes at 120,000/cm3. This imposes another difference 
between physiological conditions and our cell cultures therefore, as the proportion of 
astrocytes to neurons is higher in vivo than we could achieve in vitro. This could 
affect the relationship between the Igf1 increase we observe in astrocytes and the 
change in p-ERK levels in neurons, as the change in Igf1 level we see in astrocytes is 
relative, and therefore the actual protein amount that is released from the astrocyte 
layer is dependent upon the amount of astrocytes.  
 
 
 
The potential for IIS inhibitors to treat neurodegeneration 
 
 
 
 
IIS seems to be endogenously changed in acute and chronic neurodegenerative 
diseases, and IIS inhibition seems to be beneficial in both, indicating that the IIS 
cascade plays a key role in the neurodegenerative process. This has led us and others 
to suspect that the IIS cascade could be targeted to provide therapeutic gain to these 
diseases. Whilst the central tenant of both acute and chronic neurodegenerative 
diseases is undoubtedly the loss of neurons, the time frame that this happens over is 
very different. This time frame of neurodegeneration crucially effects how we can 
approach treatment in these diseases, as factors such as side effects of intervention, 
the endogenous IIS state of the brain, and the patient group, will differ between these 
two groups, and therefore effect the suitability of different approaches to treating 
these diseases. We must consider how our results combined with previous findings, 
affect the appropriateness of targeting the IIS cascade for therapeutic gain, and how it 
would be best to move forward with utilising this pathway in these diseases.  
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The appropriateness of our in vitro model of neurodegenerative disease 
 
 
 
Using our previously described bilaminar co-culture model we developed an in vitro 
model of acute neurodegenerative disease. Using this model we identified acute Igf1 
increase as a contributing factor to neuronal cell loss, and also established that 
Trametinib application was neuroprotective. To move forward with these promising 
findings we must consider how applicable our model of acute neurodegenerative 
disease is.  
 
The benefits of a model such as this are many, the most substantial of which is the 
ability to test our hypotheses about IIS and neurodegeneration in cell culture models 
before progressing to animal models. Our bilaminar co-cultures are also an 
improvement upon single cell cultures. In the brain neurons and astrocytes do not 
exist in isolation, but form contacts, interact, and influence each other during 
development, maturity, and in times of stress and disease. Therefore to study each cell 
type individually, whilst useful, ignored the interactions between cell types, and 
therefore limits the applicability to real life scenarios. To have both astrocytes and 
neurons in the same well therefore goes some way to replicate a more physiological 
scenario, however this model only accounts for 2 cell types of the brain, so is far from 
a complete in vitro model of the brain. Considering the involvement of microglia in 
neurodegeneration (Perry and Holmes, 2014), our bilaminar co-cultures should be 
viewed as an improved cellular model compared to single cell cultures, useful in 
particular for investigating interactions between neurons and astrocytes, but not a 
complete model of the brain.  
 
The downsides of this model however are also plentiful. Astrocytes in our bilaminar 
co-cultures are likely to be very different from mature astrocytes in the brain. Whilst 
the neurons in primary neuronal cultures share many similarities with those found in 
vivo, such as morphological similarities, their capability of firing action potentials and 
undergoing complex cellular processes such as neural plasticity, similarities of this 
nature are less apparent in primary astrocyte cultures. The morphology of astrocyte in 
primary cultures is extraordinarily different from in vivo, with cultured astrocytes 
more similar to fibroblasts in size and shape than astrocytes. Also, perhaps most 
significantly, cultured cells are between 13 and 25 days old in our culture 
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experiments, and grown in a near 2D environment without the normal developmental 
cues that neurons microglia and the vasculature would provide. This all likely 
combines to give a young astrocyte phenotype, perhaps most similar to the developing 
nervous system, making interpreting changes in astrocyte physiology and number in 
our co-culture experiments difficult in relation to mature astrocyte in vivo.  
 
These differences in astrocytes in culture does not undermine the benefit of their 
presence in our cultures however, as to begin to replicate physiological responses 
from neurons astrocytes must be present in proximity to them. This is especially 
evident in chapter 4, where to elicit the same kind of increase in Igf1 expression that 
we see in vivo in astrocytes in response to damage, neurons must be present. This 
shows the benefit of a co-culture system, but to fully determine the role of Igf1 
increase and Trametinib application on acute neurodegeneration, we must move 
towards animal models of these diseases. 
 
 
 
IGF1 in chronic vs acute neurodegenerative diseases 
 
 
 
Endogenous changes in the IIS cascade have been reported in both acute and chronic 
neurodegenerative diseases. These endogenous changes differ in different diseases, 
but with incomplete characterisation of IIS signalling levels in all neurodegenerative 
diseases, we are not in a position to conclusively say whether these differences are 
genuine or a consequence of sampling bias. Whilst some changes have been shown 
repeatedly, such as increased IGF1 levels, others such as increased p-ERK levels in 
neurons, have only been shown in a handful of diseases. Care must be taken not to 
over extrapolate these findings from one disease to many however.  
 
We have shown that in our in vitro model of acute neurodegeneration, the increase in 
astrocyte Igf1 contributes to neuronal cell death. This must not be interpreted as IGF1 
increase in all neurodegenerative diseases contributing to neuronal cell death, as we 
cannot presume that the effects of a short term increase in astrocyte IGF1 is 
comparable to that observed in AD, where increased IGF1 expression is presumably 
apparent for years. This is especially pertinent considering the well documented IIS 
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resistance in the chronic neurodegenerative disease AD (Talbot et al., 2012), 
suggesting that increased astrocyte IGF1 could have differing effects on IIS signalling 
and therefore pathology in chronic versus acute neurodegenerative diseases, despite 
its presence in both. Therefore whilst we showed in chapter 3 that Igf1 expression 
increased in both mouse models of different pathological components of AD, we 
cannot then marry this with our findings in chapter 4 that raised Igf1 expression in an 
acute model of neurodegeneration is neurotoxic. Therefore the implications of 
inhibiting Igf1 increase, as a neuroprotective therapeutic strategy must currently only 
be considered with regard to acute neurodegenerative diseases until the role of raised 
IGF1 in chronic neurodegenerative diseases has been investigated directly. 
 
With short term Igf1 increase proving neurotoxic, and with acquired IIS resistance 
being demonstrated in human AD brain tissue, it could be that acquired IIS resistance 
is a protective mechanism of preventing a neurotoxic increase in signalling through 
the IIS cascade. Therefore the raised IGF1 observed in AD could be toxic, but is 
protected against by the acquired IIS resistance.  
 
 
Inhibiting astrocyte Igf1 increase as a therapy in acute neurodegenerative disease 
 
 
 
We have identified that Igf1 increase during acute neurodegeneration may contribute 
to neuronal cell death. We established this by using siRNA to knock down Igf1 
mRNA, but this approach is not suitable for clinical application (Shim et al., 2012). 
Therefore not only should our next experiments attempt to block Igf1 induced 
neuronal cell death in an animal model of acute neurodegeneration, but we should do 
so pharmacologically. Whilst a possible candidate for the pharmacological reduction 
of IGF1 increase is the IGF1R inhibitor Linsitinib, this is making the presumption that 
the neurotoxic affect of IGF1 is through the IGF1R, which given the lack of increase 
in ERK1/2 or Akt phosphorylation in our cultures is far from a certainty. To be able to 
investigate this further a suitable next step would be to apply Linsitinib to our in vitro 
model of neurodegeneration and attempt to replicate the neuroprotection we observed 
with Igf1 knock down.  
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Given our evidence that knock down of Igf1 under normoxic conditions was 
neurotoxic, to exploit the neuroprotection of preventing astrocyte Igf1 increase whilst 
not lowering Igf1 signalling below normal levels may prove difficult. Another 
possible means of reducing this Igf1 increase response would be to identify the 
molecular signal that leads to the increase. Given the necessity of neurons sharing the 
same media as astrocytes when the noxious stimulus is given, it would seem likely 
that the signal for astrocytes to increase Igf1 expression is through a secreted factor 
from neurons. Therefore if the factor or factors responsible could be identified, this 
would provide alternative approaches to prevent the apparent Igf1 dependant 
neurotoxic effect in acute neurodegeneration.  
 
 
Repurposing Trametinib as a neuroprotective agent 
 
 
 
In our studies Trametinib has shown neuroprotective properties, and by combining its 
administration with the P-gp inhibitor Elacridar, we have shown that it has the 
capacity to reduce p-ERK levels in the brain. Whilst this means that we now have an 
approach where we can test the clinically available drug Trametinib in animal models 
of acute neurodegeneration to investigate the possibility of repurposing for these 
diseases, the use of the non-clinically approved drug Elacridar to achieve this would 
undoubtedly slow its progression to clinic if it proved efficacious.  
 
With us proposing that Trametinib may be most suited to the treatment of acute 
neurodegenerative disorders, there is evidence to suggest that perhaps the Elacridar 
dependency may not be so severe in the chronic neurodegenerative disorder AD. 
Evidence showing a reduction in P-gp in mice modelling components of AD, AD 
patients, and indeed a reduction with age (Deo et al., 2014; Hartz et al., 2010; 
Silverberg et al., 2010; van Assema et al., 2012), gives hope that perhaps the necessity 
of Elacridar co-administered with IIS inhibitors may be less in sAD patients, and that 
Trametinib administration on its own may well be brain bioavailable in these patients. 
However, as discussed below, inhibiting IIS in chronic neurodegenerative diseases is 
more challenging than inhibiting IIS for acute neurodegenerative diseases. These P-gp 
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findings therefore are unlikely to impact on the repurposing of Trametinib without 
Elacridar to acute neurodegenerative diseases.  
 
 
 
Side effects of IIS inhibition and the implications these have on repurposing 
 
 
 
When repurposing a drug the new patient group must be stringently considered in 
order to ensure the drug is suitable. Inhibitors of the IIS cascade are predominantly 
used to treat cancers, with our drug of choice Trametinib specifically being used to 
treat metastatic melanoma. The side effects of Trametinib are many, and often 
serious. Essentially all patients taking combined Trametinib and Dabrafenib, or 
Trametinib as an individual treatment, experienced one clinically relevant adverse 
event during their course of treatment (Falchook et al., 2012; Infante et al., 2012; 
Robert et al., 2015). Of these events the most common in the combined therapy are 
pyrexia (53%) nausea (35%) and diarrhoea (32%), with skin rashes and dermatitis 
acneiform (49%) diarrhoea (34%) and peripheral oedema (26%) some of the most 
common events in solo drug treatment. Whilst these are undoubtedly unpleasant for 
the patients taking this medication, the high incidence of more serious events such as 
decreased heart ejection fraction (8%) and cutaneous squamous cell-carcinoma (1%) 
are far more concerning. Therefore the eventual repurposing of Trametinib in context 
of these side effects must be considered. 
 
Symptoms such as these are far more acceptable as clinical outcomes in patients with 
terminal disorders such as metastatic melanoma, where the median survival from 
diagnosis is less than 1 year (Tsao et al., 2004). In chronic neurodegenerative disease 
patients where neuronal cell loss occurs over years, to elicit long-term 
neuroprotection Trametinib may be required to be administered for years to a patient. 
The side effects experienced from Trametinib would therefore be highly unlikely to 
be tolerable when administered for this duration, especially given the advanced age of 
the patient group. Unless a treatment regime could be devised to mitigate the majority 
of these side effects whilst maintaining the benefits, it seems unlikely that it would 
progress far as a neuroprotective agent for the long-term administration to chronic 
neurodegenerative disease patients. This is a problem experienced with many 
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discussions of life span extending therapies that target proliferative pathways such as 
IIS. Possible ways of maximising benefit whilst reducing harm would be by titrating 
the dose so that Trametinib proved efficacious at a suitably low dose to provide 
benefit with less side effects. Others would be regimes where Trametinib is 
administered at full dose for a short period of time before being withdrawn, with cycle 
repeated over a long period of time. This approach would be similar to an intermittent 
fasting paradigm that has conveyed many of the benefits of full fasting, but mitigated 
many of the side effects.  
 
In acute neurodegenerative diseases however, the shorter duration of neuronal cell 
loss, and therefore shorter duration of required neuroprotection, would likely decrease 
the experienced side effects. This indicates that Trametinib administration would be 
suitable for repurposing to treat acute neurodegenerative diseases in humans. Stroke 
and TBI would therefore seem particularly well suited for the repurposing of 
Trametinib.  
 
 
Alternative targets in the IIS cascade 
 
 
 
Another possible way of avoiding the side effects of pharmacologically inhibiting the 
Ras-Raf-ERK cascade is to investigate the possibility of members of this pathway 
being more abundantly expressed, or exclusive expressed, in the brain as opposed to 
other tissues. This would allow the inhibition of these pathways to target 
neurodegeneration, whilst mitigating the substantial side effects of inhibiting this 
cascade elsewhere in the body. Identifying brain specific members of the cascade 
would therefore make therapeutic targeting of this pathway in neurodegenerative 
disease easier. 
 
Using the Human Protein Atlas database to compile a list of genes that are expressed 
at a significantly higher level in brain tissue than other tissues (Uhlen et al., 2015), 
381 genes were expressed at a level at least 5 times greater in the brain than all other 
tissues measured. Comparing this with a list of genes of proteins involved in MAPK 
signalling, identified 8 genes involved in MAPK signalling that were relatively 
overexpressed in the brain (figure 6.2). 7 of the 8 genes identified were too far  
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Figure 6.2. PTPN5 as a possible brain specific modulator of p-ERK levels. (A) Identification 
of brain enriched genes implicated in Ras-Raf-ERK signaling (B) PTPN5 is expressed in 
multiple cell types in the brain, including neurons and astrocytes (C) Staining of brain 
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upstream to specifically inhibit the Ras-Raf-ERK pathway without affecting multiple 
other cascades. The remaining gene Protein tyrosine phosphatase non-receptor type 5 
(PTPN5; previously know as STEP) is a brain specific protein phosphatase, originally 
purified from striatum, but present at a high level of expression in all brain regions 
(Lombroso et al., 1991) (figure 6.2). Amongst its many substrates are p38, Fyn, 
PyK2, GluN2B, GluA2, and ERK1/2 (Moult et al., 2006; Munoz et al., 2003; Paul et 
al., 2003; Xu et al., 2012; Xu et al., 2009).  
 
As this protein is a phosphatase, we would want to increase its effect, to reduce p-
ERK levels. Activators of phosphatases are very difficult to design however, and 
currently none are known to exist. Furthermore previous work aiming to reduce 
PTPN5 using small molecular inhibitors have shown a positive effect on cognitive 
function in a triple transgenic mouse model of AD, thereby implying that decreasing 
PTPN5 action is beneficial in AD (Yang et al., 2012). Other evidence however 
suggests that decreasing the activity of PTPN5 has a detrimental effect on cell 
survival following focal cerebral ischemia in rats, and delays recovery from stressful 
stimuli (Deb et al., 2013). Therefore the potential role of PTPN5 in neurodegeneration 
is far from clear, but given its brain specificity, it seems worthy of further 
investigation.  
 
 
Approaches to treating chronic neurodegeneration – the Alzheimer’s disease problem 
 
In this thesis we have identified that the use of a single IIS inhibitor may show 
efficacy in reducing neuronal cell death in neurodegenerative diseases, and have 
suggested that its use as a solo agent would be most appropriate for the treatment of 
acute neurodegenerative diseases where its long term side effects may be mitigated by 
the duration of its administration in these diseases. It brings us to a particularly 
pertinent question with regards to treating chronic neurodegenerative diseases 
however; are the methods and approaches currently used to approach chronic 
neurodegenerative disease treatment appropriate? AD has overwhelmingly received 
the greatest attention and man-hours in the attempt to devise improved therapeutic 
strategies for its treatment, and yet these have overwhelmingly failed to succeed, and 
is a perfect example of the problems encountered when attempting to treat chronic 
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neurodegenerative diseases. If biomedicine is to succeed in combatting AD and other 
chronic neurodegenerative diseases, then we must consider how we approach these 
diseases; this will be discussed here by considering AD. 
 
Why some people develop sAD whilst others do not, especially in light of the 
possibility of high plaque brain load in cognitively functional patients (Braak et al., 
2011), is unclear. Similarly the neuropathological features of dementia and sAD 
patients are extremely varied (Lam et al., 2013), and yet sAD patients in clinical trials 
are considered and crucially treated as one homogenous patient group. Risk factors 
associated with sAD development are extremely numerous and varied as well, making 
it seem highly likely that the reason different patients develop sAD varies, but can 
give rise to a similar clinical phenotype. With great patient heterogeneity why are we 
attempting to treat the patient group with a single treatment for all? It seems highly 
likely that different patients would be variably susceptible to different treatments, 
with it being possible that many of the recent failed phase III trials would prove 
efficacious for a particular AD patient group. Furthermore, recent evidence had cast 
doubt on even the disease pathogenesis is certain fAD patient populations, where the 
pathogenesis of disease has appeared far more straightforward than in sAD patients. 
With some patients with presenelin-1 mutations showing intact presenelin-1 activity, 
whilst others show a complete loss (Ben-Gedalya et al., 2015; Szaruga et al., 2015; 
Xia et al., 2015), evidence for heterogeneity in disease pathogenesis even amongst far 
simpler patient groups, would suggest that the mechanisms that give rise to the 
phenotype of AD are not consistent within patient groups, stressing that different 
treatments may work better for different patients. 
 
With all this considered, it seems highly likely that for therapeutic developments to 
succeed in such a large variable patient group, and greater understanding of the 
pathological, genetic, and environmental heterogeneity of sAD patients is required. 
This would allow more targeted therapeutic approaches, which could open up 
possibilities for patients and lead to a vast improvement in AD patient care.  
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Conclusion 
 
 
 
The IIS cascade seems critically implicated in neuronal cell death. In this thesis we 
have investigated how this implication could be exploited for therapeutic gain in 
treating neurodegenerative diseases by preventing neuronal cell death. 
Neurodegenerative diseases are a broad set of diseases however, split roughly into 
chronic and acute, with neuronal cell loss taking place over years or weeks 
respectively. The length of time that neuronal loss occurs over and therefore the 
length of time that clinical intervention would have to take place over, and the effect 
of inhibiting the IIS cascade systemically, mean that chronic and acute 
neurodegenerative diseases have to be considered separately in terms of disease 
intervention via the IIS cascade. 
 
Chronic neurodegenerative diseases would be unlikely to be suitably treated by the 
application of IIS inhibitors over the duration of the neuronal loss. We therefore 
investigated times in the pathological development of AD that IIS changes are 
endogenously changes, and identified that there is an early strong increase in IIS 
signalling in response to rising amyloid pathology. How this early increase is 
implicated in disease progression is unknown, but investigating early inhibition of this 
rise would be an interesting way of modulating the earliest changes in relation to AD 
pathology. Otherwise, IIS based interventions in the chronic neurodegenerative 
disease pathogenesis may come down to titrating the dose of IIS inhibition to provide 
neuroprotection whilst mitigating peripheral side effects, or identifying brain specific 
means of intervening in the IIS cascade. 
 
Acute neurodegenerative diseases seem the most susceptible to therapeutic IIS 
intervention, as the short duration of neuronal cell loss would reduce the duration of 
IIS inhibitor intervention, and therefore reduce the side effects as a consequence. 
Trametinib seems a potential option, having shown neuroprotective properties in 
vitro. However, the dependence of its brain IIS inhibition on the co-administration of 
Elacridar, means that the effect of P-gp inhibition on acute neurodegeneration would 
need to be investigated further to ensure that functional P-gp is not protective 
following an acute neurodegenerative insult. 
	 159	
 
 Igf1 increase in acute neurodegenerative disease is another possible novel 
intervention strategy, with the prevention of this increase being neuroprotective. 
However, much work in in vitro models would be required with IGF1R inhibitors 
before this possible endogenous alteration could be therapeutically exploited.  
 
Overall therefore, Trametinib seems an exciting novel treatment option for acute 
neurodegenerative diseases such as stroke and TBI, with potential promise to be had 
in modulating the endogenous increase in astrocyte Igf1 increase observed during 
acute neuronal cell loss. Targeting chronic neurodegenerative diseases via the IIS 
cascade seems far more complex and fraught with complications.  
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